Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock)
Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Orbimed Advisors Llc. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at Orbimed Advisors Llc har rapporteret besiddelser eller handler i følgende virksomheder:
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Orbimed Advisors Llc. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb AFIB / Acutus Medical, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg AFIB / Acutus Medical, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ALEC / Alector, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ALEC / Alector, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb AMRN / Amarin Corporation plc - Depositary Receipt (Common Stock) – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg AMRN / Amarin Corporation plc - Depositary Receipt (Common Stock) – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ANTH / Anthera Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ANTH / Anthera Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ARQT / Arcutis Biotherapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ARQT / Arcutis Biotherapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb AVBP / ArriVent BioPharma, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg AVBP / ArriVent BioPharma, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb BOLD / Boundless Bio, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2016-07-25 | BOLD | ORBIMED ADVISORS LLC | 33.334 | 15,0000 | 33.334 | 15,0000 | 500.010 | 730 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg BOLD / Boundless Bio, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb CALC / CalciMedica, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-09-25 | GRAY | ORBIMED ADVISORS LLC | 562.500 | 16,0000 | 40.179 | 224,0000 | 9.000.000 | 119 | 490 | 10.687.220 | 118,75 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg CALC / CalciMedica, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb CMPX / Compass Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg CMPX / Compass Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-09 | CMPX | ORBIMED ADVISORS LLC | 3.571.428 | 1,5900 | 3.571.428 | 1,5900 | 5.678.571 | 1 | 1.6500 | 214.286 | 3,77 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb CRVS / Corvus Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg CRVS / Corvus Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ETNB / 89bio, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ETNB / 89bio, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb EWTX / Edgewise Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg EWTX / Edgewise Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb GH / Guardant Health, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg GH / Guardant Health, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb GKOS / Glaukos Corporation – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg GKOS / Glaukos Corporation – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb GLTO / Galecto, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg GLTO / Galecto, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb INSP / Inspire Medical Systems, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018-05-07 | INSP | ORBIMED ADVISORS LLC | 312.500 | 16,0000 | 312.500 | 16,0000 | 5.000.000 | 297 | 62 | 14.375.000 | 287,50 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg INSP / Inspire Medical Systems, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb JANX / Janux Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg JANX / Janux Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb KALA / KALA BIO, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg KALA / KALA BIO, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb KROS / Keros Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-04-13 | KROS | ORBIMED ADVISORS LLC | 375.200 | 16,0000 | 375.200 | 16,0000 | 6.003.200 | 248 | 82.74 | 25.040.848 | 417,12 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg KROS / Keros Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb NBRVF / Nabriva Therapeutics plc – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg NBRVF / Nabriva Therapeutics plc – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb NPCE / NeuroPace, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-04-21 | NPCE | ORBIMED ADVISORS LLC | 235.000 | 17,0000 | 235.000 | 17,0000 | 3.995.000 | 6 | 26.5 | 2.232.500 | 55,88 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg NPCE / NeuroPace, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb NTLA / Intellia Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg NTLA / Intellia Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb NXTC / NextCure, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019-05-13 | NXTC | ORBIMED ADVISORS LLC | 350.000 | 15,0000 | 29.167 | 180,0000 | 5.250.000 | 176 | 92.22 | -2.560.311 | -48,77 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg NXTC / NextCure, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb ORIC / ORIC Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-04-24 | ORIC | ORBIMED ADVISORS LLC | 281.250 | 16,0000 | 281.250 | 16,0000 | 4.500.000 | 244 | 39.8 | 6.693.750 | 148,75 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ORIC / ORIC Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb PASG / Passage Bio, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg PASG / Passage Bio, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb PCRX / Pacira BioSciences, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg PCRX / Pacira BioSciences, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb PMVP / PMV Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg PMVP / PMV Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb PRLD / Prelude Therapeutics Incorporated – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg PRLD / Prelude Therapeutics Incorporated – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb QTTB / Q32 Bio Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg QTTB / Q32 Bio Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb RNAC / Cartesian Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg RNAC / Cartesian Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb RPTX / Repare Therapeutics Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg RPTX / Repare Therapeutics Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb RYTM / Rhythm Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017-10-10 | RYTM | ORBIMED ADVISORS LLC | 355.000 | 17,0000 | 355.000 | 17,0000 | 6.035.000 | 268 | 35.85 | 6.691.750 | 110,88 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg RYTM / Rhythm Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SCPH / scPharmaceuticals Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SCPH / scPharmaceuticals Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SIBN / SI-BONE, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018-10-19 | SIBN | ORBIMED ADVISORS LLC | 200.000 | 15,0000 | 200.000 | 15,0000 | 3.000.000 | 90 | 22.35 | 1.470.000 | 49,00 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SIBN / SI-BONE, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SPRY / ARS Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SPRY / ARS Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb STTK / Shattuck Labs, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg STTK / Shattuck Labs, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SUPN / Supernus Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SUPN / Supernus Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SYBX / Synlogic, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SYBX / Synlogic, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SYRE / Spyre Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SYRE / Spyre Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb TELA / TELA Bio, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019-11-08 | TELA | ORBIMED ADVISORS LLC | 384.615 | 13,0000 | 384.615 | 13,0000 | 4.999.995 | 224 | 22.61 | 3.696.150 | 73,92 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg TELA / TELA Bio, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb TERN / Terns Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg TERN / Terns Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb TRAW / Traws Pharma, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg TRAW / Traws Pharma, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb VRAYQ / ViewRay, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg VRAYQ / ViewRay, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb VRNA / Verona Pharma plc - Depositary Receipt (Common Stock) – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
|---|---|---|---|---|---|---|---|
| Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg VRNA / Verona Pharma plc - Depositary Receipt (Common Stock) – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb WHWK / Whitehawk Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg WHWK / Whitehawk Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
| Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-12-08 | ARPO | ORBIMED ADVISORS LLC | 21.400 | 1,9600 | 1.427 | 29,4000 | 41.944 | 21 |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb XTNT / Xtant Medical Holdings, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg XTNT / Xtant Medical Holdings, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock). Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af Orbimed Advisors Llc som oplyst til Securities Exchange Commission (SEC).
| Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-12 |
|
4 | PMVP |
PMV Pharmaceuticals, Inc.
Common Stock |
S - Sale | -500.000 | 5.975.291 | -7,72 | 1,80 | -900.000 | 10.755.524 | |
| 2025-09-02 |
|
4 | STTK |
Shattuck Labs, Inc.
Common Stock |
P - Purchase | 1.051.021 | 1.051.021 | 0,87 | 911.971 | 911.971 | ||
| 2025-09-02 |
|
4 | STTK |
Shattuck Labs, Inc.
Common Stock |
P - Purchase | 5.255.106 | 5.255.106 | 0,87 | 4.559.855 | 4.559.855 | ||
| 2025-08-12 |
|
4 | TSBX |
Turnstone Biologics Corp.
Common Stock |
U - Other | -3.099.265 | 0 | -100,00 | ||||
| 2025-07-30 |
|
4 | IKNA |
ImageneBio, Inc.
Common Stock |
A - Award | 83.611 | 287.885 | 40,93 | 2,49 | 208.191 | 716.834 | |
| 2025-07-01 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock |
S - Sale | -1.176.332 | 7.165.006 | -14,10 | 4,16 | -4.891.894 | 29.796.394 | |
| 2025-07-01 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock |
X - Other | 1.397.684 | 8.341.338 | 20,13 | 3,50 | 4.891.894 | 29.194.683 | |
| 2025-06-26 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -213.257 | 6.066.343 | -3,40 | 0,33 | -70.375 | 2.001.893 | |
| 2025-06-26 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -138.800 | 6.279.600 | -2,16 | 0,33 | -45.804 | 2.072.268 | |
| 2025-06-26 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -231.600 | 6.418.400 | -3,48 | 0,35 | -81.060 | 2.246.440 | |
| 2025-05-16 |
|
4 | NPCE |
NeuroPace Inc
Common Stock |
S - Sale | -34.000 | 3.238.199 | -1,04 | 15,94 | -541.960 | 51.616.892 | |
| 2025-05-16 |
|
4 | NPCE |
NeuroPace Inc
Common Stock |
S - Sale | -134.136 | 3.272.199 | -3,94 | 15,83 | -2.123.373 | 51.798.910 | |
| 2025-04-24 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -68.195 | 6.650.000 | -1,02 | 0,32 | -21.822 | 2.128.000 | |
| 2025-04-24 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -89.328 | 6.718.195 | -1,31 | 0,34 | -30.372 | 2.284.186 | |
| 2025-04-24 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -78.049 | 6.807.523 | -1,13 | 0,34 | -26.537 | 2.314.558 | |
| 2025-04-17 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -77.090 | 6.885.572 | -1,11 | 0,33 | -25.440 | 2.272.239 | |
| 2025-04-17 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -61.638 | 6.962.662 | -0,88 | 0,33 | -20.341 | 2.297.678 | |
| 2025-04-17 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -10.326 | 7.024.300 | -0,15 | 0,38 | -3.924 | 2.669.234 | |
| 2025-04-14 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
S - Sale | -17.109.618 | 0 | -100,00 | 0,42 | -7.186.040 | ||
| 2025-04-14 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
S - Sale | -56.004.974 | 0 | -100,00 | 0,42 | -23.522.089 | ||
| 2025-04-11 |
|
4 | CMPX |
Compass Therapeutics, Inc.
Common Stock |
S - Sale | -3.571.428 | 0 | -100,00 | 1,59 | -5.678.571 | ||
| 2025-04-04 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Common Stock |
P - Purchase | 124.193 | 443.792 | 38,86 | 20,13 | 2.500.005 | 8.933.533 | |
| 2025-04-04 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Common Stock |
P - Purchase | 372.578 | 14.809.075 | 2,58 | 20,13 | 7.499.995 | 298.106.680 | |
| 2025-03-26 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -756 | 186.541 | -0,40 | 54,11 | -40.907 | 10.093.734 | |
| 2025-03-26 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -3.026 | 746.171 | -0,40 | 54,11 | -163.737 | 40.375.313 | |
| 2025-03-26 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -1.956 | 482.308 | -0,40 | 54,11 | -105.839 | 26.097.686 | |
| 2025-03-21 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -1.320 | 187.297 | -0,70 | 54,00 | -71.280 | 10.114.038 | |
| 2025-03-21 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -5.279 | 749.197 | -0,70 | 54,00 | -285.066 | 40.456.638 | |
| 2025-03-21 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -3.412 | 484.264 | -0,70 | 54,00 | -184.248 | 26.150.256 | |
| 2025-03-21 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -364 | 188.617 | -0,19 | 54,01 | -19.660 | 10.187.204 | |
| 2025-03-21 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -1.457 | 754.476 | -0,19 | 54,01 | -78.693 | 40.749.249 | |
| 2025-03-21 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -941 | 487.676 | -0,19 | 54,01 | -50.823 | 26.339.381 | |
| 2025-03-21 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -5.228 | 188.981 | -2,69 | 54,02 | -282.417 | 10.208.754 | |
| 2025-03-21 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -20.911 | 755.933 | -2,69 | 54,02 | -1.129.612 | 40.835.501 | |
| 2025-03-21 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -13.517 | 488.617 | -2,69 | 54,02 | -730.188 | 26.395.090 | |
| 2025-03-12 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -10.733 | 194.209 | -5,24 | 54,44 | -584.305 | 10.572.738 | |
| 2025-03-12 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -42.930 | 776.844 | -5,24 | 54,44 | -2.337.109 | 42.291.387 | |
| 2025-03-12 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -27.750 | 502.134 | -5,24 | 54,44 | -1.510.710 | 27.336.175 | |
| 2025-03-12 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -233 | 204.942 | -0,11 | 55,05 | -12.827 | 11.282.057 | |
| 2025-03-12 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -933 | 819.774 | -0,11 | 55,05 | -51.362 | 45.128.559 | |
| 2025-03-12 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -603 | 529.884 | -0,11 | 55,05 | -33.195 | 29.170.114 | |
| 2025-03-12 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -3.567 | 205.175 | -1,71 | 54,01 | -192.654 | 11.081.502 | |
| 2025-03-12 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -14.267 | 820.707 | -1,71 | 54,01 | -770.561 | 44.326.385 | |
| 2025-03-12 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -9.222 | 530.487 | -1,71 | 54,01 | -498.080 | 28.651.603 | |
| 2025-03-12 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -53 | 208.742 | -0,03 | 55,01 | -2.916 | 11.482.897 | |
| 2025-03-12 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -211 | 834.974 | -0,03 | 55,01 | -11.607 | 45.931.920 | |
| 2025-03-12 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -136 | 539.709 | -0,03 | 55,01 | -7.481 | 29.689.392 | |
| 2025-03-12 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -26.596 | 208.795 | -11,30 | 54,29 | -1.443.897 | 11.335.481 | |
| 2025-03-12 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -106.384 | 835.185 | -11,30 | 54,29 | -5.775.587 | 45.342.194 | |
| 2025-03-12 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -68.766 | 539.845 | -11,30 | 54,29 | -3.733.306 | 29.308.185 | |
| 2025-02-19 |
|
4 | MBX |
MBX Biosciences, Inc.
Common Stock |
P - Purchase | 94.100 | 747.887 | 14,39 | 10,84 | 1.020.044 | 8.107.095 | |
| 2025-02-19 |
|
4 | MBX |
MBX Biosciences, Inc.
Common Stock |
P - Purchase | 49.070 | 3.255.000 | 1,53 | 10,84 | 531.919 | 35.284.200 | |
| 2025-02-19 |
|
4 | MBX |
MBX Biosciences, Inc.
Common Stock |
P - Purchase | 29.540 | 3.205.930 | 0,93 | 9,85 | 290.969 | 31.578.410 | |
| 2025-02-19 |
|
4 | MBX |
MBX Biosciences, Inc.
Common Stock |
P - Purchase | 17.962 | 3.176.390 | 0,57 | 9,90 | 177.824 | 31.446.261 | |
| 2025-02-10 |
|
4 | SION |
Sionna Therapeutics, Inc.
Common Stock |
P - Purchase | 550.000 | 3.704.959 | 17,43 | 18,00 | 9.900.000 | 66.689.262 | |
| 2025-02-10 |
|
4 | SION |
Sionna Therapeutics, Inc.
Common Stock |
C - Conversion | 3.154.959 | 3.154.959 | |||||
| 2025-01-14 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -79.024 | 7.034.626 | -1,11 | 0,60 | -47.414 | 4.220.776 | |
| 2025-01-14 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -17.986 | 7.113.650 | -0,25 | 0,64 | -11.511 | 4.552.736 | |
| 2025-01-14 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -126.209 | 7.131.636 | -1,74 | 0,66 | -83.298 | 4.706.880 | |
| 2025-01-08 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -75.007 | 7.257.845 | -1,02 | 0,68 | -51.005 | 4.935.335 | |
| 2025-01-08 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -52.536 | 7.332.852 | -0,71 | 0,71 | -37.301 | 5.206.325 | |
| 2025-01-08 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -19.481 | 7.385.388 | -0,26 | 0,77 | -15.000 | 5.686.749 | |
| 2024-12-26 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -230.321 | 7.404.869 | -3,02 | 0,60 | -138.193 | 4.442.921 | |
| 2024-12-11 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -80 | 7.635.190 | 0,00 | 0,80 | -64 | 6.108.152 | |
| 2024-12-11 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -8.015 | 7.635.270 | -0,10 | 0,80 | -6.412 | 6.108.216 | |
| 2024-12-11 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -54.181 | 7.643.285 | -0,70 | 0,84 | -45.512 | 6.420.359 | |
| 2024-12-06 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -20.903 | 7.697.466 | -0,27 | 0,82 | -17.140 | 6.311.922 | |
| 2024-12-06 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -76.200 | 7.718.369 | -0,98 | 0,79 | -60.198 | 6.097.512 | |
| 2024-11-05 |
|
4 | NONE |
Lomond Therapeutics Holdings, Inc.
Common Stock |
A - Award | 155.120 | 2.677.256 | 6,15 | 4,00 | 620.480 | 10.709.024 | |
| 2024-11-05 |
|
4 | NONE |
Lomond Therapeutics Holdings, Inc.
Common Stock |
A - Award | 479.736 | 2.522.136 | 23,49 | 4,00 | 1.918.944 | 10.088.544 | |
| 2024-11-05 |
|
4 | NONE |
Lomond Therapeutics Holdings, Inc.
Common Stock |
A - Award | 808.894 | 2.042.400 | 65,58 | 4,00 | 3.235.576 | 8.169.600 | |
| 2024-11-05 |
|
4 | NONE |
Lomond Therapeutics Holdings, Inc.
Common Stock |
C - Conversion | 74.613 | 1.233.506 | 6,44 | 3,60 | 268.607 | 4.440.622 | |
| 2024-11-05 |
|
4 | NONE |
Lomond Therapeutics Holdings, Inc.
Common Stock |
C - Conversion | 230.753 | 1.158.893 | 24,86 | 3,60 | 830.711 | 4.172.015 | |
| 2024-11-05 |
|
4 | NONE |
Lomond Therapeutics Holdings, Inc.
Common Stock |
C - Conversion | 389.078 | 928.140 | 72,18 | 3,60 | 1.400.681 | 3.341.304 | |
| 2024-11-05 |
|
4 | NONE |
Lomond Therapeutics Holdings, Inc.
Common Stock |
C - Conversion | 215.146 | 539.062 | 66,42 | 3,20 | 688.467 | 1.724.998 | |
| 2024-11-05 |
|
4 | NONE |
Lomond Therapeutics Holdings, Inc.
Common Stock |
C - Conversion | 323.916 | 323.916 | 3,20 | 1.036.531 | 1.036.531 | ||
| 2024-10-17 |
|
4 | UPB |
Upstream Bio, Inc.
Common Stock |
P - Purchase | 660.000 | 4.554.873 | 16,95 | 17,00 | 11.220.000 | 77.432.841 | |
| 2024-10-17 |
|
4 | UPB |
Upstream Bio, Inc.
Common Stock |
C - Conversion | 2.887.833 | 3.894.873 | 286,76 | ||||
| 2024-10-17 |
|
4 | UPB |
Upstream Bio, Inc.
Common Stock |
P - Purchase | 165.000 | 1.138.716 | 16,95 | 17,00 | 2.805.000 | 19.358.172 | |
| 2024-10-17 |
|
4 | UPB |
Upstream Bio, Inc.
Common Stock |
C - Conversion | 721.956 | 973.716 | 286,76 | ||||
| 2024-10-10 | 3 | UPB |
Upstream Bio, Inc.
Common Stock |
251.760 | ||||||||
| 2024-10-10 | 3 | UPB |
Upstream Bio, Inc.
Common Stock |
1.007.040 | ||||||||
| 2024-09-23 | 3 | TRAW |
Traws Pharma, Inc.
Common Stock |
602.000 | ||||||||
| 2024-09-23 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -39.300 | 7.794.569 | -0,50 | 0,71 | -27.903 | 5.534.144 | |
| 2024-09-18 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -25.631 | 7.833.869 | -0,33 | 0,73 | -18.711 | 5.718.724 | |
| 2024-09-18 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -111.400 | 7.859.500 | -1,40 | 0,73 | -81.322 | 5.737.435 | |
| 2024-09-18 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
S - Sale | -63.100 | 7.970.900 | -0,79 | 0,74 | -46.694 | 5.898.466 | |
| 2024-09-17 |
|
4 | MBX |
MBX Biosciences, Inc.
Common Stock |
P - Purchase | 250.000 | 653.787 | 61,91 | 16,00 | 4.000.000 | 10.460.592 | |
| 2024-09-17 |
|
4 | MBX |
MBX Biosciences, Inc.
Common Stock |
P - Purchase | 500.000 | 3.158.428 | 18,81 | 16,00 | 8.000.000 | 50.534.848 | |
| 2024-09-17 |
|
4 | MBX |
MBX Biosciences, Inc.
Common Stock |
C - Conversion | 403.787 | 403.787 | |||||
| 2024-09-17 |
|
4 | MBX |
MBX Biosciences, Inc.
Common Stock |
C - Conversion | 2.658.428 | 2.658.428 | |||||
| 2024-08-28 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Common Stock |
S - Sale | -83.695 | 0 | -100,00 | 13,00 | -1.088.035 | ||
| 2024-08-23 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Common Stock |
S - Sale | -69.500 | 83.695 | -45,37 | 13,03 | -905.585 | 1.090.546 | |
| 2024-08-23 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Common Stock |
S - Sale | -391.482 | 153.195 | -71,87 | 12,94 | -5.065.777 | 1.982.343 | |
| 2024-08-23 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Common Stock |
S - Sale | -13.300 | 544.677 | -2,38 | 14,61 | -194.313 | 7.957.731 | |
| 2024-08-23 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Common Stock |
S - Sale | -394.400 | 557.977 | -41,41 | 13,52 | -5.332.288 | 7.543.849 | |
| 2024-08-15 |
|
4 | SCPH |
scPharmaceuticals Inc.
Common Stock |
P - Purchase | 21.658 | 252.858 | 9,37 | 4,00 | 86.632 | 1.011.432 | |
| 2024-08-15 |
|
4 | SCPH |
scPharmaceuticals Inc.
Common Stock |
P - Purchase | 478.342 | 5.806.670 | 8,98 | 4,00 | 1.913.368 | 23.226.680 | |
| 2024-08-15 |
|
4 | KROS |
Keros Therapeutics, Inc.
Common Stock |
S - Sale | -29.400 | 119.522 | -19,74 | 44,01 | -1.293.894 | 5.260.163 | |
| 2024-08-15 |
|
4 | KROS |
Keros Therapeutics, Inc.
Common Stock |
S - Sale | -220.600 | 899.212 | -19,70 | 44,01 | -9.708.606 | 39.574.320 | |
| 2024-07-17 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Common Stock |
S - Sale | -623 | 755.635 | -0,08 | 10,00 | -6.230 | 7.556.350 | |
| 2024-07-17 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Common Stock |
S - Sale | -556 | 1.967.924 | -0,03 | 10,00 | -5.560 | 19.679.240 | |
| 2024-07-17 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Common Stock |
S - Sale | -4.009 | 4.839.412 | -0,08 | 10,00 | -40.090 | 48.394.120 | |
| 2024-07-17 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Common Stock |
S - Sale | -6.142 | 756.258 | -0,81 | 10,00 | -61.420 | 7.562.580 | |
| 2024-07-17 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Common Stock |
S - Sale | -5.401 | 1.968.480 | -0,27 | 10,00 | -54.010 | 19.684.800 | |
| 2024-07-17 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Common Stock |
S - Sale | -39.433 | 4.843.421 | -0,81 | 10,00 | -394.330 | 48.434.210 | |
| 2024-07-02 |
|
4 | TELA |
TELA Bio, Inc.
Common Stock |
S - Sale | -36.600 | 2.407.242 | -1,50 | 4,54 | -166.164 | 10.928.879 | |
| 2024-07-02 |
|
4 | TELA |
TELA Bio, Inc.
Common Stock |
S - Sale | -13.700 | 2.443.842 | -0,56 | 4,68 | -64.116 | 11.437.181 | |
| 2024-07-02 |
|
4 | TELA |
TELA Bio, Inc.
Common Stock |
S - Sale | -378.000 | 2.457.542 | -13,33 | 4,74 | -1.791.720 | 11.648.749 | |
| 2024-06-20 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
P - Purchase | 10.986 | 235.391 | 4,90 | 36,00 | 395.496 | 8.474.076 | |
| 2024-06-20 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
P - Purchase | 43.944 | 941.569 | 4,90 | 36,00 | 1.581.984 | 33.896.484 | |
| 2024-06-20 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
P - Purchase | 28.404 | 608.611 | 4,90 | 36,00 | 1.022.544 | 21.909.996 | |
| 2024-05-20 |
|
4 | ELVN |
Enliven Therapeutics, Inc.
Common Stock |
S - Sale | -1.000.000 | 7.663.349 | -11,54 | 22,14 | -22.140.000 | 169.666.547 | |
| 2024-05-20 |
|
4 | ELVN |
Enliven Therapeutics, Inc.
Common Stock |
S - Sale | -33.300 | 254.814 | -11,56 | 22,14 | -737.262 | 5.641.582 | |
| 2024-05-20 |
|
4 | ALPN |
ALPINE IMMUNE SCIENCES, INC.
Common Stock |
U - Other | -264.315 | 0 | -100,00 | ||||
| 2024-05-20 |
|
4 | ALPN |
ALPINE IMMUNE SCIENCES, INC.
Common Stock |
U - Other | -2.416.181 | 0 | -100,00 | ||||
| 2024-05-03 |
|
4 | NPCE |
NeuroPace Inc
Common Stock |
S - Sale | -4.674 | 3.406.335 | -0,14 | 14,03 | -65.576 | 47.790.880 | |
| 2024-05-03 |
|
4 | NPCE |
NeuroPace Inc
Common Stock |
S - Sale | -8.842 | 3.411.009 | -0,26 | 14,01 | -123.876 | 47.788.236 | |
| 2024-05-03 |
|
4 | NPCE |
NeuroPace Inc
Common Stock |
S - Sale | -15.690 | 3.419.851 | -0,46 | 14,02 | -219.974 | 47.946.311 | |
| 2024-04-26 |
|
4 | NPCE |
NeuroPace Inc
Common Stock |
S - Sale | -1.781 | 3.435.541 | -0,05 | 14,06 | -25.041 | 48.303.706 | |
| 2024-04-23 |
|
4 | NPCE |
NeuroPace Inc
Common Stock |
S - Sale | -21.791 | 3.437.322 | -0,63 | 14,29 | -311.393 | 49.119.331 | |
| 2024-04-23 |
|
4 | NPCE |
NeuroPace Inc
Common Stock |
S - Sale | -24.609 | 3.459.113 | -0,71 | 14,05 | -345.756 | 48.600.538 | |
| 2024-04-23 |
|
4 | NPCE |
NeuroPace Inc
Common Stock |
S - Sale | -18.253 | 3.483.722 | -0,52 | 14,02 | -255.907 | 48.841.782 | |
| 2024-04-18 |
|
4 | NPCE |
NeuroPace Inc
Common Stock |
S - Sale | -2.623 | 3.501.975 | -0,07 | 14,06 | -36.879 | 49.237.768 | |
| 2024-04-18 |
|
4 | NPCE |
NeuroPace Inc
Common Stock |
S - Sale | -300 | 3.504.598 | -0,01 | 14,15 | -4.245 | 49.590.062 | |
| 2024-04-18 |
|
4 | NPCE |
NeuroPace Inc
Common Stock |
S - Sale | -14.069 | 3.504.898 | -0,40 | 14,01 | -197.107 | 49.103.621 | |
| 2024-04-15 |
|
4 | NPCE |
NeuroPace Inc
Common Stock |
S - Sale | -23.101 | 3.518.967 | -0,65 | 14,42 | -333.116 | 50.743.504 | |
| 2024-04-15 |
|
4 | NPCE |
NeuroPace Inc
Common Stock |
S - Sale | -461.899 | 3.542.068 | -11,54 | 14,49 | -6.692.917 | 51.324.565 | |
| 2024-04-12 | 3/A | TRAW |
Traws Pharma, Inc.
Common Stock |
1.045.261 | ||||||||
| 2024-04-05 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
D - Sale to Issuer | -450.000 | 0 | -100,00 | ||||
| 2024-04-05 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
D - Sale to Issuer | -84.599 | 0 | -100,00 | ||||
| 2024-04-05 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
D - Sale to Issuer | -1.368.338 | 0 | -100,00 | ||||
| 2024-04-05 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
D - Sale to Issuer | -4.738.453 | 0 | -100,00 | ||||
| 2024-04-05 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
D - Sale to Issuer | -1.368.339 | 0 | -100,00 | ||||
| 2024-04-03 | 3 | TRAW |
Traws Pharma, Inc.
Common Stock |
885.532 | ||||||||
| 2024-03-27 | 3 | QTTB |
Q32 Bio Inc.
Common Stock |
2.252.987 | ||||||||
| 2024-02-14 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Common Stock |
U - Other | -650.600 | 0 | -100,00 | ||||
| 2024-02-14 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Common Stock |
U - Other | -17.063.000 | 0 | -100,00 | ||||
| 2024-01-31 |
|
4 | AVBP |
ArriVent Biopharma, Inc.
Common Stock |
P - Purchase | 222.222 | 1.513.664 | 17,21 | 18,00 | 3.999.996 | 27.245.952 | |
| 2024-01-31 |
|
4 | AVBP |
ArriVent Biopharma, Inc.
Common Stock |
P - Purchase | 222.222 | 1.513.664 | 17,21 | 18,00 | 3.999.996 | 27.245.952 | |
| 2024-01-31 |
|
4 | AVBP |
ArriVent Biopharma, Inc.
Common Stock |
C - Conversion | 469.615 | 1.291.442 | 57,14 | ||||
| 2024-01-31 |
|
4 | AVBP |
ArriVent Biopharma, Inc.
Common Stock |
C - Conversion | 469.615 | 1.291.442 | 57,14 | ||||
| 2024-01-31 |
|
4 | AVBP |
ArriVent Biopharma, Inc.
Common Stock |
C - Conversion | 821.827 | 821.827 | |||||
| 2024-01-31 |
|
4 | AVBP |
ArriVent Biopharma, Inc.
Common Stock |
C - Conversion | 821.827 | 821.827 | |||||
| 2024-01-26 |
|
4 | ACET |
Adicet Bio, Inc.
Common Stock |
P - Purchase | 1.041.700 | 1.255.985 | 486,13 | 2,40 | 2.500.080 | 3.014.364 | |
| 2024-01-26 |
|
4 | ACET |
Adicet Bio, Inc.
Common Stock |
P - Purchase | 242.200 | 990.254 | 32,38 | 2,40 | 581.280 | 2.376.610 | |
| 2024-01-26 |
|
4 | ACET |
Adicet Bio, Inc.
Common Stock |
P - Purchase | 1.841.100 | 7.526.359 | 32,38 | 2,40 | 4.418.640 | 18.063.262 | |
| 2024-01-25 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Common Stock |
P - Purchase | 454.545 | 14.436.497 | 3,25 | 11,00 | 4.999.995 | 158.801.467 | |
| 2024-01-16 |
|
4 | ALPN |
ALPINE IMMUNE SCIENCES, INC.
Common Stock |
X - Other | 145.251 | 2.416.181 | 6,40 | 12,74 | 1.850.498 | 30.782.146 | |
| 2023-12-29 |
|
4 | ALPN |
ALPINE IMMUNE SCIENCES, INC.
Common Stock |
S - Sale | -139.166 | 264.315 | -34,49 | 18,32 | -2.549.521 | 4.842.251 | |
| 2023-12-29 |
|
4 | ALPN |
ALPINE IMMUNE SCIENCES, INC.
Common Stock |
S - Sale | -1.195.683 | 2.270.930 | -34,49 | 18,32 | -21.904.913 | 41.603.438 | |
| 2023-12-29 |
|
4 | ALPN |
ALPINE IMMUNE SCIENCES, INC.
Common Stock |
S - Sale | -3.128 | 403.481 | -0,77 | 19,82 | -61.997 | 7.996.993 | |
| 2023-12-29 |
|
4 | ALPN |
ALPINE IMMUNE SCIENCES, INC.
Common Stock |
S - Sale | -26.872 | 3.466.613 | -0,77 | 19,82 | -532.603 | 68.708.270 | |
| 2023-12-29 |
|
4 | ALPN |
ALPINE IMMUNE SCIENCES, INC.
Common Stock |
S - Sale | -18.922 | 406.609 | -4,45 | 19,96 | -377.683 | 8.115.916 | |
| 2023-12-29 |
|
4 | ALPN |
ALPINE IMMUNE SCIENCES, INC.
Common Stock |
S - Sale | -162.576 | 3.493.485 | -4,45 | 19,96 | -3.245.017 | 69.729.961 | |
| 2023-12-20 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -1.724 | 0 | -100,00 | 59,24 | -102.130 | ||
| 2023-12-20 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
M - Exercise | 1.724 | 1.724 | 38,00 | 65.512 | 65.512 | ||
| 2023-12-15 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -57.100 | 224.405 | -20,28 | 56,75 | -3.240.425 | 12.734.984 | |
| 2023-12-15 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -147.600 | 580.207 | -20,28 | 56,75 | -8.376.300 | 32.926.747 | |
| 2023-12-15 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -228.500 | 897.625 | -20,29 | 56,75 | -12.967.375 | 50.940.219 | |
| 2023-12-14 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -100 | 727.807 | -0,01 | 57,73 | -5.773 | 42.016.298 | |
| 2023-12-14 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -100 | 727.807 | -0,01 | 57,73 | -5.773 | 42.016.298 | |
| 2023-12-14 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -14.100 | 281.505 | -4,77 | 58,56 | -825.696 | 16.484.933 | |
| 2023-12-14 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -36.400 | 727.907 | -4,76 | 58,56 | -2.131.584 | 42.626.234 | |
| 2023-12-14 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -56.200 | 1.126.225 | -4,75 | 58,56 | -3.291.072 | 65.951.736 | |
| 2023-12-14 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -3.600 | 295.605 | -1,20 | 60,16 | -216.576 | 17.783.597 | |
| 2023-12-14 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -9.300 | 764.307 | -1,20 | 60,16 | -559.488 | 45.980.709 | |
| 2023-12-14 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
S - Sale | -14.400 | 1.182.425 | -1,20 | 60,16 | -866.304 | 71.134.688 | |
| 2023-11-24 |
|
4 | PMVP |
PMV Pharmaceuticals, Inc.
Common Stock |
S - Sale | -87.786 | 0 | -100,00 | 2,23 | -195.763 | ||
| 2023-10-04 |
|
4 | NPCE |
NeuroPace Inc
Common Stock |
S - Sale | -700 | 4.003.967 | -0,02 | 9,02 | -6.314 | 36.115.782 | |
| 2023-10-04 |
|
4 | NPCE |
NeuroPace Inc
Common Stock |
S - Sale | -7.614 | 4.004.667 | -0,19 | 9,08 | -69.135 | 36.362.376 | |
| 2023-09-21 |
|
4/A | IKNA |
Ikena Oncology, Inc.
Non-Voting Common Stock |
A - Award | 153.121 | 5.582.144 | 2,82 | ||||
| 2023-09-14 |
|
4 | IKNA |
Ikena Oncology, Inc.
Common Stock |
A - Award | 153.121 | 2.251.218 | 7,30 | ||||
| 2023-08-31 |
|
4 | SPRY |
ARS Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 500.000 | 8.019.187 | 6,65 | 6,20 | 3.100.000 | 49.718.959 | |
| 2023-08-17 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -535.534 | 1.510.375 | -26,18 | 0,75 | -401.650 | 1.132.781 | |
| 2023-08-17 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -248.819 | 631.048 | -28,28 | 0,75 | -186.614 | 473.286 | |
| 2023-08-17 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -38.327 | 97.204 | -28,28 | 0,75 | -28.745 | 72.903 | |
| 2023-08-02 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -153.078 | 2.105.909 | -6,78 | 3,00 | -459.234 | 6.317.727 | |
| 2023-08-02 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -29.700 | 879.867 | -3,27 | 3,00 | -89.100 | 2.639.601 | |
| 2023-08-02 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -26.622 | 135.531 | -16,42 | 3,00 | -79.866 | 406.593 | |
| 2023-07-27 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -26.700 | 2.258.987 | -1,17 | 2,92 | -77.964 | 6.596.242 | |
| 2023-07-27 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -4.700 | 909.567 | -0,51 | 2,92 | -13.724 | 2.655.936 | |
| 2023-07-27 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -7.800 | 162.153 | -4,59 | 2,92 | -22.776 | 473.487 | |
| 2023-07-24 |
|
4 | TSBX |
Turnstone Biologics Corp.
Common Stock |
P - Purchase | 416.666 | 3.099.265 | 15,53 | 12,00 | 4.999.992 | 37.191.180 | |
| 2023-07-24 |
|
4 | TSBX |
Turnstone Biologics Corp.
Common Stock |
C - Conversion | 2.682.599 | 2.682.599 | |||||
| 2023-07-19 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 151.450 | 650.600 | 30,34 | 3,05 | 461.922 | 1.984.330 | |
| 2023-07-19 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 328.482 | 17.063.000 | 1,96 | 3,05 | 1.001.870 | 52.042.150 | |
| 2023-07-17 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -132.100 | 2.285.687 | -5,46 | 2,40 | -317.040 | 5.485.649 | |
| 2023-07-17 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -52.800 | 914.267 | -5,46 | 2,40 | -126.720 | 2.194.241 | |
| 2023-07-17 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -9.800 | 169.953 | -5,45 | 2,40 | -23.520 | 407.887 | |
| 2023-06-29 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
P - Purchase | 575.195 | 8.034.000 | 7,71 | 0,84 | 483.164 | 6.748.560 | |
| 2023-06-29 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
P - Purchase | 617.382 | 7.458.805 | 9,02 | 0,84 | 518.601 | 6.265.396 | |
| 2023-06-29 |
|
4 | ACET |
Adicet Bio, Inc.
Common Stock |
P - Purchase | 58.000 | 748.054 | 8,41 | 2,09 | 121.220 | 1.563.433 | |
| 2023-06-29 |
|
4 | ACET |
Adicet Bio, Inc.
Common Stock |
P - Purchase | 442.000 | 5.685.259 | 8,43 | 2,09 | 923.780 | 11.882.191 | |
| 2023-06-29 |
|
4 | ACET |
Adicet Bio, Inc.
Common Stock |
P - Purchase | 250.000 | 646.657 | 63,03 | 2,09 | 522.500 | 1.351.513 | |
| 2023-06-29 |
|
4 | ACET |
Adicet Bio, Inc.
Common Stock |
P - Purchase | 125.000 | 1.027.885 | 13,84 | 2,09 | 261.250 | 2.148.280 | |
| 2023-05-24 |
|
4 | PRLD |
Prelude Therapeutics Inc
Common Stock |
P - Purchase | 869.565 | 10.119.756 | 9,40 | 5,75 | 4.999.999 | 58.188.597 | |
| 2023-05-19 |
|
4 | ELVN |
Enliven Therapeutics, Inc.
Common Stock |
M - Exercise | 2.125 | 8.663.349 | 0,02 | 4,28 | 9.095 | 37.079.134 | |
| 2023-05-15 |
|
4 | VRNA |
Verona Pharma plc
Ordinary Shares |
S - Sale | -345.313 | 3.777.778 | -8,38 | 20,00 | -6.906.260 | 75.555.560 | |
| 2023-05-15 |
|
4 | VRNA |
Verona Pharma plc
Ordinary Shares |
S - Sale | -14.400 | 4.123.091 | -0,35 | 21,96 | -316.224 | 90.543.078 | |
| 2023-05-15 |
|
4 | VRNA |
Verona Pharma plc
Ordinary Shares |
S - Sale | -43.200 | 4.137.491 | -1,03 | 21,64 | -934.848 | 89.535.305 | |
| 2023-05-15 |
|
4 | VRNA |
Verona Pharma plc
Ordinary Shares |
S - Sale | -80.000 | 4.180.691 | -1,88 | 22,26 | -1.780.800 | 93.062.182 | |
| 2023-05-08 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 490.511 | 1.368.338 | 55,88 | 2,82 | 1.383.241 | 3.858.713 | |
| 2023-05-08 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 490.512 | 1.368.339 | 55,88 | 2,82 | 1.383.244 | 3.858.716 | |
| 2023-05-08 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 83.459 | 877.827 | 10,51 | 2,75 | 229.512 | 2.414.024 | |
| 2023-05-08 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 83.459 | 877.827 | 10,51 | 2,75 | 229.512 | 2.414.024 | |
| 2023-05-08 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 312.991 | 4.738.453 | 7,07 | 2,75 | 860.725 | 13.030.746 | |
| 2023-05-02 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 58.826 | 794.368 | 8,00 | 2,67 | 157.065 | 2.120.963 | |
| 2023-05-02 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 58.826 | 794.368 | 8,00 | 2,67 | 157.065 | 2.120.963 | |
| 2023-05-02 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 220.610 | 4.425.462 | 5,25 | 2,67 | 589.029 | 11.815.984 | |
| 2023-05-02 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 124.545 | 735.542 | 20,38 | 2,62 | 326.308 | 1.927.120 | |
| 2023-05-02 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 467.068 | 4.204.852 | 12,50 | 2,62 | 1.223.718 | 11.016.712 | |
| 2023-05-02 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 124.544 | 735.542 | 20,38 | 2,62 | 326.305 | 1.927.120 | |
| 2023-05-02 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 60.997 | 610.997 | 11,09 | 2,55 | 155.542 | 1.558.042 | |
| 2023-05-02 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 228.754 | 3.737.784 | 6,52 | 2,55 | 583.323 | 9.531.349 | |
| 2023-05-02 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 60.998 | 610.998 | 11,09 | 2,55 | 155.545 | 1.558.045 | |
| 2023-04-21 |
|
4 | TELA |
TELA Bio, Inc.
Common Stock |
S - Sale | -27.700 | 2.835.542 | -0,97 | 9,41 | -260.657 | 26.682.450 | |
| 2023-04-21 |
|
4 | TELA |
TELA Bio, Inc.
Common Stock |
S - Sale | -28.300 | 2.863.242 | -0,98 | 9,43 | -266.869 | 27.000.372 | |
| 2023-04-21 |
|
4 | TELA |
TELA Bio, Inc.
Common Stock |
S - Sale | -136.000 | 2.891.542 | -4,49 | 9,30 | -1.264.800 | 26.891.341 | |
| 2023-04-17 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -8.878 | 2.417.787 | -0,37 | 1,97 | -17.490 | 4.763.040 | |
| 2023-04-17 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -3.551 | 967.067 | -0,37 | 1,97 | -6.995 | 1.905.122 | |
| 2023-04-17 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -660 | 179.753 | -0,37 | 1,97 | -1.300 | 354.113 | |
| 2023-04-17 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -28.110 | 2.426.665 | -1,15 | 1,86 | -52.285 | 4.513.597 | |
| 2023-04-17 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -11.245 | 970.618 | -1,15 | 1,86 | -20.916 | 1.805.349 | |
| 2023-04-17 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -2.091 | 180.413 | -1,15 | 1,86 | -3.889 | 335.568 | |
| 2023-04-17 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -9.459 | 2.454.775 | -0,38 | 1,82 | -17.215 | 4.467.690 | |
| 2023-04-17 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -3.784 | 981.863 | -0,38 | 1,82 | -6.887 | 1.786.991 | |
| 2023-04-17 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -703 | 182.504 | -0,38 | 1,82 | -1.279 | 332.157 | |
| 2023-04-12 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -1.603 | 2.464.234 | -0,07 | 1,81 | -2.901 | 4.460.264 | |
| 2023-04-12 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -641 | 985.647 | -0,06 | 1,81 | -1.160 | 1.784.021 | |
| 2023-04-12 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -119 | 183.207 | -0,06 | 1,81 | -215 | 331.605 | |
| 2023-04-12 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -9.459 | 2.465.837 | -0,38 | 1,82 | -17.215 | 4.487.823 | |
| 2023-04-12 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -3.784 | 986.288 | -0,38 | 1,82 | -6.887 | 1.795.044 | |
| 2023-04-12 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -703 | 183.326 | -0,38 | 1,82 | -1.279 | 333.653 | |
| 2023-04-12 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -34.745 | 2.500.582 | -1,37 | 1,79 | -62.194 | 4.476.042 | |
| 2023-04-12 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -13.899 | 1.000.187 | -1,37 | 1,79 | -24.879 | 1.790.335 | |
| 2023-04-12 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -2.584 | 185.910 | -1,37 | 1,79 | -4.625 | 332.779 | |
| 2023-04-07 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -6.558 | 2.510.041 | -0,26 | 2,00 | -13.116 | 5.020.082 | |
| 2023-04-07 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -2.620 | 1.003.971 | -0,26 | 2,00 | -5.240 | 2.007.942 | |
| 2023-04-07 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -487 | 186.613 | -0,26 | 2,00 | -974 | 373.226 | |
| 2023-04-07 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -63.058 | 2.516.599 | -2,44 | 2,18 | -137.466 | 5.486.186 | |
| 2023-04-07 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -25.220 | 1.006.591 | -2,44 | 2,18 | -54.980 | 2.194.368 | |
| 2023-04-07 |
|
4 | GLTO |
Galecto, Inc.
Common Stock |
S - Sale | -4.687 | 187.100 | -2,44 | 2,18 | -10.218 | 407.878 | |
| 2023-02-27 |
|
4 | ELVN |
Enliven Therapeutics, Inc.
Common Stock |
A - Award | 288.114 | 288.114 | |||||
| 2023-02-27 |
|
4 | ELVN |
Enliven Therapeutics, Inc.
Common Stock |
A - Award | 7.611.458 | 8.661.225 | 725,06 | ||||
| 2023-02-23 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
A - Award | 550.000 | 550.000 | |||||
| 2023-02-23 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
A - Award | 550.000 | 550.000 | |||||
| 2023-02-17 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
P - Purchase | 14.329 | 299.205 | 5,03 | 23,00 | 329.567 | 6.881.715 | |
| 2023-02-17 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
P - Purchase | 37.049 | 773.607 | 5,03 | 23,00 | 852.127 | 17.792.961 | |
| 2023-02-17 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
P - Purchase | 57.318 | 1.196.825 | 5,03 | 23,00 | 1.318.314 | 27.526.975 | |
| 2023-01-03 | 3 | IRON |
Disc Medicine, Inc.
Common Stock |
284.876 | ||||||||
| 2023-01-03 | 3 | IRON |
Disc Medicine, Inc.
Common Stock |
1.139.507 | ||||||||
| 2023-01-03 | 3 | IRON |
Disc Medicine, Inc.
Common Stock |
153.936 | ||||||||
| 2023-01-03 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
J - Other | 1.139.507 | 1.139.507 | |||||
| 2023-01-03 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
J - Other | 153.936 | 736.558 | 26,42 | ||||
| 2023-01-03 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
J - Other | 582.622 | 582.622 | |||||
| 2023-01-03 |
|
4 | IRON |
Disc Medicine, Inc.
Common Stock |
J - Other | 284.876 | 284.876 | |||||
| 2022-12-28 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 137.931 | 4.882.854 | 2,91 | 7,25 | 1.000.000 | 35.400.692 | |
| 2022-12-27 |
|
4 | VRNA |
Verona Pharma plc
Ordinary Shares |
S - Sale | -92.992 | 34.085.528 | -0,27 | 24,11 | -2.242.037 | 821.802.080 | |
| 2022-12-27 |
|
4 | VRNA |
Verona Pharma plc
Ordinary Shares |
S - Sale | -1.116.048 | 34.178.520 | -3,16 | 23,23 | -25.925.795 | 793.967.020 | |
| 2022-12-27 |
|
4 | VRNA |
Verona Pharma plc
Ordinary Shares |
S - Sale | -961.328 | 35.294.568 | -2,65 | 22,27 | -21.408.775 | 786.010.029 | |
| 2022-12-27 |
|
4 | VRNA |
Verona Pharma plc
Ordinary Shares |
S - Sale | -684.696 | 36.255.896 | -1,85 | 22,07 | -15.111.241 | 800.167.625 | |
| 2022-12-27 |
|
4 | VRNA |
Verona Pharma plc
Ordinary Shares |
S - Sale | -3.284.800 | 36.940.592 | -8,17 | 21,71 | -71.313.008 | 801.980.252 | |
| 2022-11-29 |
|
4 | SCPH |
scPharmaceuticals Inc.
Common Stock |
P - Purchase | 762.380 | 5.328.328 | 16,70 | 5,25 | 4.002.495 | 27.973.722 | |
| 2022-11-25 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | -3.629.226 | 0 | -100,00 | 0,22 | -798.430 | ||
| 2022-11-25 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | -5.617.300 | 3.629.226 | -60,75 | 0,21 | -1.179.633 | 762.137 | |
| 2022-11-25 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | -1.034.421 | 9.246.526 | -10,06 | 0,22 | -227.573 | 2.034.236 | |
| 2022-11-10 |
|
4 | CMPX |
Compass Therapeutics, Inc.
Common Stock |
P - Purchase | 402.000 | 15.219.994 | 2,71 | 3,21 | 1.290.420 | 48.856.181 | |
| 2022-11-09 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 192.000 | 16.734.518 | 1,16 | 5,21 | 1.000.320 | 87.186.839 | |
| 2022-09-21 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
P - Purchase | 300.000 | 5.779.071 | 5,48 | 17,00 | 5.100.000 | 98.244.207 | |
| 2022-09-21 |
|
4 | THRD |
Third Harmonic Bio, Inc.
Common Stock |
C - Conversion | 5.479.071 | 5.479.071 | |||||
| 2022-09-16 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Common Stock |
P - Purchase | 484.496 | 13.981.952 | 3,59 | 10,32 | 4.999.999 | 144.293.745 | |
| 2022-09-14 |
|
4 | SWTX |
SpringWorks Therapeutics, Inc.
Common Stock |
S - Sale | -30.000 | 5.599.842 | -0,53 | 31,98 | -959.400 | 179.082.947 | |
| 2022-09-14 |
|
4 | SWTX |
SpringWorks Therapeutics, Inc.
Common Stock |
S - Sale | -123.897 | 5.629.842 | -2,15 | 31,96 | -3.959.748 | 179.929.750 | |
| 2022-08-18 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 762.400 | 762.400 | 2,42 | 1.845.008 | 1.845.008 | ||
| 2022-08-18 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 457.400 | 1.973.881 | 30,16 | 2,42 | 1.106.908 | 4.776.792 | |
| 2022-08-18 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 2.470.200 | 4.744.923 | 108,59 | 2,42 | 5.977.884 | 11.482.714 | |
| 2022-08-17 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock, $0.000001 par value |
J - Other | 215.415 | 215.415 | |||||
| 2022-08-17 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock, $0.000001 par value |
J - Other | 215.415 | 215.415 | |||||
| 2022-08-10 |
|
4 | SWTX |
SpringWorks Therapeutics, Inc.
Common Stock |
S - Sale | -69.568 | 5.753.739 | -1,19 | 37,47 | -2.606.713 | 215.592.600 | |
| 2022-08-10 |
|
4 | SWTX |
SpringWorks Therapeutics, Inc.
Common Stock |
S - Sale | -205.000 | 5.823.307 | -3,40 | 38,33 | -7.857.650 | 223.207.357 | |
| 2022-07-01 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
D - Sale to Issuer | -226.704 | 0 | -100,00 | 55,00 | -12.468.720 | ||
| 2022-07-01 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
D - Sale to Issuer | -226.704 | 0 | -100,00 | 55,00 | -12.468.720 | ||
| 2022-07-01 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
D - Sale to Issuer | -1.511.362 | 0 | -100,00 | 55,00 | -83.124.910 | ||
| 2022-06-28 |
|
4 | ARQT |
Arcutis Biotherapeutics, Inc.
Common Stock |
S - Sale | -35.944 | 415.142 | -7,97 | 21,31 | -765.967 | 8.846.676 | |
| 2022-06-28 |
|
4 | ARQT |
Arcutis Biotherapeutics, Inc.
Common Stock |
S - Sale | -306.027 | 3.534.537 | -7,97 | 21,31 | -6.521.435 | 75.320.983 | |
| 2022-06-24 |
|
4 | IKNA |
Ikena Oncology, Inc.
Common Stock |
P - Purchase | -96.035 | 2.098.097 | -4,38 | 5,37 | -515.708 | 11.266.781 | |
| 2022-06-24 |
|
4 | IKNA |
Ikena Oncology, Inc.
Common Stock |
P - Purchase | -65.965 | 2.002.062 | -3,19 | 4,37 | -288.267 | 8.749.011 | |
| 2022-06-24 |
|
4 | IKNA |
Ikena Oncology, Inc.
Common Stock |
P - Purchase | -23.419 | 1.936.097 | -1,20 | 3,71 | -86.884 | 7.182.920 | |
| 2022-06-24 |
|
4 | IKNA |
Ikena Oncology, Inc.
Common Stock |
P - Purchase | -66.806 | 1.912.678 | -3,37 | 3,55 | -237.161 | 6.790.007 | |
| 2022-05-31 |
|
4 | PMVP |
PMV Pharmaceuticals, Inc.
Common Stock |
S - Sale | -26.253 | 87.786 | -23,02 | 15,93 | -418.210 | 1.398.431 | |
| 2022-05-20 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Common Stock |
P - Purchase | 138.000 | 13.497.456 | 1,03 | 7,21 | 994.980 | 97.316.658 | |
| 2022-05-13 |
|
4 | CMPX |
Compass Therapeutics, Inc.
Common Stock |
P - Purchase | 30.722 | 14.817.994 | 0,21 | 2,49 | 76.498 | 36.896.805 | |
| 2022-05-13 |
|
4 | CMPX |
Compass Therapeutics, Inc.
Common Stock |
P - Purchase | 97.094 | 14.787.272 | 0,66 | 2,35 | 228.171 | 34.750.089 | |
| 2022-05-13 |
|
4 | CMPX |
Compass Therapeutics, Inc.
Common Stock |
P - Purchase | 64.700 | 14.690.178 | 0,44 | 1,79 | 115.813 | 26.295.419 | |
| 2022-05-10 |
|
4 | CMPX |
Compass Therapeutics, Inc.
Common Stock |
P - Purchase | 24.447 | 14.625.478 | 0,17 | 1,60 | 39.115 | 23.400.765 | |
| 2022-05-10 |
|
4 | CMPX |
Compass Therapeutics, Inc.
Common Stock |
P - Purchase | 90.712 | 14.601.031 | 0,63 | 1,56 | 141.511 | 22.777.608 | |
| 2022-05-10 |
|
4 | CMPX |
Compass Therapeutics, Inc.
Common Stock |
P - Purchase | 10.200 | 14.510.319 | 0,07 | 1,63 | 16.626 | 23.651.820 | |
| 2022-05-05 |
|
4/A | PASG |
Passage BIO, Inc.
Common Stock |
P - Purchase | 50.800 | 6.316.423 | 0,81 | 5,00 | 254.000 | 31.582.115 | |
| 2022-05-05 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
P - Purchase | 303.500 | 6.841.423 | 4,64 | 1,94 | 588.790 | 13.272.361 | |
| 2022-05-05 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
P - Purchase | 221.500 | 6.537.923 | 3,51 | 1,93 | 427.495 | 12.618.191 | |
| 2022-04-08 |
|
4 | ARQT |
Arcutis Biotherapeutics, Inc.
Common Stock |
S - Sale | -102.800 | 451.086 | -18,56 | 20,71 | -2.128.988 | 9.341.991 | |
| 2022-04-08 |
|
4 | ARQT |
Arcutis Biotherapeutics, Inc.
Common Stock |
S - Sale | -97.200 | 3.840.564 | -2,47 | 20,71 | -2.013.012 | 79.538.080 | |
| 2022-04-08 |
|
4 | ARQT |
Arcutis Biotherapeutics, Inc.
Common Stock |
S - Sale | -177.196 | 553.886 | -24,24 | 20,66 | -3.660.869 | 11.443.285 | |
| 2022-04-08 |
|
4 | ARQT |
Arcutis Biotherapeutics, Inc.
Common Stock |
S - Sale | -167.800 | 3.937.764 | -4,09 | 20,66 | -3.466.748 | 81.354.204 | |
| 2022-04-08 |
|
4 | ARQT |
Arcutis Biotherapeutics, Inc.
Common Stock |
S - Sale | -171.204 | 731.082 | -18,97 | 20,69 | -3.542.211 | 15.126.087 | |
| 2022-04-08 |
|
4 | ARQT |
Arcutis Biotherapeutics, Inc.
Common Stock |
S - Sale | -162.000 | 4.105.564 | -3,80 | 20,69 | -3.351.780 | 84.944.119 | |
| 2022-03-31 |
|
4 | PMVP |
PMV Pharmaceuticals, Inc.
Common Stock |
S - Sale | -34.500 | 0 | -100,00 | 21,17 | -730.365 | ||
| 2022-03-31 |
|
4 | PMVP |
PMV Pharmaceuticals, Inc.
Common Stock |
S - Sale | -75.000 | 34.500 | -68,49 | 22,39 | -1.679.250 | 772.455 | |
| 2022-03-31 |
|
4 | PMVP |
PMV Pharmaceuticals, Inc.
Common Stock |
S - Sale | -365.000 | 109.500 | -76,92 | 21,52 | -7.854.800 | 2.356.440 | |
| 2022-02-15 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 9.000 | 3.509.030 | 0,26 | 9,96 | 89.640 | 34.949.939 | |
| 2022-02-15 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 10.000 | 3.500.030 | 0,29 | 9,89 | 98.900 | 34.615.297 | |
| 2022-02-15 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 20.700 | 3.490.030 | 0,60 | 9,98 | 206.586 | 34.830.499 | |
| 2022-02-15 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 156.000 | 3.469.330 | 4,71 | 10,22 | 1.594.320 | 35.456.553 | |
| 2022-01-28 |
|
4 | SRRA |
Sierra Oncology, Inc.
Series B Warrants |
X - Other | -56.244 | 0 | -100,00 | ||||
| 2022-01-28 |
|
4 | SRRA |
Sierra Oncology, Inc.
Series B Warrants |
X - Other | -56.244 | 0 | -100,00 | ||||
| 2022-01-28 |
|
4 | SRRA |
Sierra Oncology, Inc.
Series B Warrants |
X - Other | -374.962 | 0 | -100,00 | ||||
| 2022-01-28 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
X - Other | 56.244 | 226.704 | 33,00 | 13,20 | 742.421 | 2.992.493 | |
| 2022-01-28 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
X - Other | 56.244 | 226.704 | 33,00 | 13,20 | 742.421 | 2.992.493 | |
| 2022-01-28 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
X - Other | 374.962 | 1.511.362 | 33,00 | 13,20 | 4.949.498 | 19.949.978 | |
| 2022-01-27 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
S - Sale | -10.740 | 1.829.436 | -0,58 | 8,38 | -90.001 | 15.330.674 | |
| 2022-01-27 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
S - Sale | -10.742 | 1.829.433 | -0,58 | 8,38 | -90.018 | 15.330.649 | |
| 2022-01-27 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
S - Sale | -24.545 | 1.840.176 | -1,32 | 8,40 | -206.178 | 15.457.478 | |
| 2022-01-27 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
S - Sale | -24.546 | 1.840.175 | -1,32 | 8,40 | -206.186 | 15.457.470 | |
| 2022-01-24 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
P - Purchase | 369.100 | 6.634.723 | 5,89 | 5,42 | 2.000.522 | 35.960.199 | |
| 2022-01-21 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 111.896 | 16.542.652 | 0,68 | 9,97 | 1.115.603 | 164.930.240 | |
| 2022-01-21 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 35.000 | 16.430.756 | 0,21 | 9,95 | 348.250 | 163.486.022 | |
| 2022-01-21 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 11.521 | 16.395.756 | 0,07 | 9,97 | 114.864 | 163.465.687 | |
| 2022-01-20 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
P - Purchase | 43.300 | 6.265.623 | 0,70 | 5,11 | 221.263 | 32.017.334 | |
| 2022-01-20 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
P - Purchase | 114.700 | 6.222.323 | 1,88 | 5,46 | 626.262 | 33.973.884 | |
| 2022-01-20 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
P - Purchase | 10.300 | 6.107.623 | 0,17 | 5,60 | 57.680 | 34.202.689 | |
| 2022-01-13 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 17.320 | 16.384.235 | 0,11 | 9,43 | 163.328 | 154.503.336 | |
| 2022-01-13 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 18.897 | 16.366.915 | 0,12 | 10,06 | 190.104 | 164.651.165 | |
| 2022-01-13 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 6.900 | 16.348.018 | 0,04 | 10,67 | 73.623 | 174.433.352 | |
| 2022-01-13 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 1.600 | 16.341.118 | 0,01 | 9,81 | 15.696 | 160.306.368 | |
| 2022-01-13 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
P - Purchase | 41.800 | 6.097.323 | 0,69 | 5,52 | 230.736 | 33.657.223 | |
| 2022-01-13 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
P - Purchase | 100.000 | 6.055.523 | 1,68 | 5,65 | 565.000 | 34.213.705 | |
| 2022-01-13 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
P - Purchase | 8.200 | 5.955.523 | 0,14 | 5,53 | 45.346 | 32.934.042 | |
| 2021-12-30 |
|
4 | JANX |
Janux Therapeutics, Inc.
Common Stock |
S - Sale | -3.700 | 231.098 | -1,58 | 20,30 | -75.110 | 4.691.289 | |
| 2021-12-30 |
|
4 | JANX |
Janux Therapeutics, Inc.
Common Stock |
S - Sale | -36.700 | 2.258.566 | -1,60 | 20,30 | -745.010 | 45.848.890 | |
| 2021-12-23 |
|
4 | JANX |
Janux Therapeutics, Inc.
Common Stock |
S - Sale | -11.100 | 234.798 | -4,51 | 19,00 | -210.900 | 4.461.162 | |
| 2021-12-23 |
|
4 | JANX |
Janux Therapeutics, Inc.
Common Stock |
S - Sale | -108.300 | 2.295.266 | -4,51 | 19,00 | -2.057.700 | 43.610.054 | |
| 2021-12-17 |
|
4 | JANX |
Janux Therapeutics, Inc.
Common Stock |
S - Sale | -36.500 | 245.898 | -12,93 | 19,07 | -696.055 | 4.689.275 | |
| 2021-12-17 |
|
4 | JANX |
Janux Therapeutics, Inc.
Common Stock |
S - Sale | -356.800 | 2.403.566 | -12,93 | 19,07 | -6.804.176 | 45.836.004 | |
| 2021-12-14 |
|
4 | ACET |
Adicet Bio, Inc.
Common Stock |
A - Award | 214.285 | 242.285 | 765,30 | 14,00 | 2.999.990 | 3.391.990 | |
| 2021-11-17 |
|
4 | TCDA |
Tricida, Inc.
Comm on Warrants to Purchase Common Stock |
A - Award | 666.667 | 666.667 | |||||
| 2021-11-17 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
A - Award | 666.667 | 10.280.947 | 6,93 | 6,00 | 4.000.002 | 61.685.682 | |
| 2021-11-08 |
|
4 | CMPX |
Compass Therapeutics, Inc.
Common Stock |
P - Purchase | 3.571.428 | 3.571.428 | 3,50 | 12.499.998 | 12.499.998 | ||
| 2021-11-08 |
|
4 | CMPX |
Compass Therapeutics, Inc.
Common Stock |
P - Purchase | 1.785.715 | 14.500.119 | 14,04 | 3,50 | 6.250.002 | 50.750.416 | |
| 2021-10-14 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -436.650 | 0 | -100,00 | ||||
| 2021-10-14 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -873.300 | 0 | -100,00 | ||||
| 2021-10-14 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -14.903.718 | 0 | -100,00 | ||||
| 2021-10-14 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 62.500 | 499.150 | 14,31 | 16,00 | 1.000.000 | 7.986.400 | |
| 2021-10-14 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 562.500 | 16.339.518 | 3,57 | 16,00 | 9.000.000 | 261.432.288 | |
| 2021-10-14 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 436.650 | 436.650 | |||||
| 2021-10-14 |
|
4 | THRX |
Theseus Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 15.777.018 | 15.777.018 | |||||
| 2021-09-22 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
S - Sale | -1.109.644 | 6.943.654 | -13,78 | 6,09 | -6.757.732 | 42.286.853 | |
| 2021-09-21 |
|
4 | ALPN |
ALPINE IMMUNE SCIENCES, INC.
Common Stock |
P - Purchase | 425.531 | 425.531 | 9,40 | 3.999.991 | 3.999.991 | ||
| 2021-09-21 |
|
4 | ALPN |
ALPINE IMMUNE SCIENCES, INC.
Common Stock |
P - Purchase | 585.106 | 3.656.061 | 19,05 | 9,40 | 5.499.996 | 34.366.973 | |
| 2021-09-08 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -26 | 96.190 | -0,03 | 33,93 | -882 | 3.263.727 |
| 2021-09-08 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -861 | 3.177.041 | -0,03 | 33,93 | -29.214 | 107.797.001 |
| 2021-09-08 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -212 | 96.216 | -0,22 | 34,00 | -7.208 | 3.271.344 |
| 2021-09-08 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -6.985 | 3.177.902 | -0,22 | 34,00 | -237.490 | 108.048.668 |
| 2021-09-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -483 | 96.428 | -0,50 | 34,24 | -16.538 | 3.301.695 |
| 2021-09-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -15.941 | 3.184.887 | -0,50 | 34,24 | -545.820 | 109.050.531 |
| 2021-09-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -382 | 96.911 | -0,39 | 33,98 | -12.980 | 3.293.036 |
| 2021-09-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -12.586 | 3.200.828 | -0,39 | 33,98 | -427.672 | 108.764.135 |
| 2021-09-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -249 | 97.293 | -0,26 | 33,94 | -8.451 | 3.302.124 |
| 2021-09-02 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -8.223 | 3.213.414 | -0,26 | 33,94 | -279.089 | 109.063.271 |
| 2021-08-30 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -197 | 97.542 | -0,20 | 33,92 | -6.682 | 3.308.625 |
| 2021-08-30 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -6.500 | 3.221.637 | -0,20 | 33,92 | -220.480 | 109.277.927 |
| 2021-08-30 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -209 | 97.739 | -0,21 | 33,94 | -7.093 | 3.317.262 |
| 2021-08-30 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -6.884 | 3.228.137 | -0,21 | 33,94 | -233.643 | 109.562.970 |
| 2021-08-30 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -126 | 97.948 | -0,13 | 34,52 | -4.350 | 3.381.165 |
| 2021-08-30 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -4.157 | 3.235.021 | -0,13 | 34,52 | -143.500 | 111.672.925 |
| 2021-08-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -208 | 98.074 | -0,21 | 34,34 | -7.143 | 3.367.861 |
| 2021-08-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -6.874 | 3.239.178 | -0,21 | 34,34 | -236.053 | 111.233.373 |
| 2021-08-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -119 | 98.282 | -0,12 | 34,07 | -4.054 | 3.348.468 |
| 2021-08-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -3.920 | 3.246.052 | -0,12 | 34,07 | -133.554 | 110.592.992 |
| 2021-08-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -209 | 98.401 | -0,21 | 34,06 | -7.119 | 3.351.538 |
| 2021-08-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -6.885 | 3.249.972 | -0,21 | 34,06 | -234.503 | 110.694.046 |
| 2021-08-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -78 | 98.610 | -0,08 | 33,99 | -2.651 | 3.351.754 |
| 2021-08-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -2.852 | 3.256.857 | -0,09 | 33,99 | -96.939 | 110.700.569 |
| 2021-08-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -512 | 98.688 | -0,52 | 34,12 | -17.469 | 3.367.235 |
| 2021-08-19 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
S - Sale | X | -16.886 | 3.259.439 | -0,52 | 34,12 | -576.150 | 111.212.059 |
| 2021-08-17 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
J - Other | 85.337 | 120.549 | 242,35 | ||||
| 2021-08-17 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
J - Other | 85.337 | 120.549 | 242,35 | ||||
| 2021-07-23 |
|
4/A | IMRA |
IMARA Inc.
Common Stock |
P - Purchase | 1.666.666 | 4.199.068 | 65,81 | 6,00 | 9.999.996 | 25.194.408 | |
| 2021-07-21 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
P - Purchase | 357.143 | 1.677.361 | 27,05 | 14,00 | 5.000.002 | 23.483.054 | |
| 2021-07-21 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
P - Purchase | 714.285 | 4.872.025 | 17,18 | 14,00 | 9.999.990 | 68.208.350 | |
| 2021-07-16 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
P - Purchase | 1.666.666 | 1.666.666 | 6,00 | 9.999.996 | 9.999.996 | ||
| 2021-07-06 |
|
4 | SWTX |
SpringWorks Therapeutics, Inc.
Common Stock |
S - Sale | X | -15.959 | 6.028.307 | -0,26 | 85,01 | -1.356.675 | 512.466.378 |
| 2021-06-30 |
|
4 | SWTX |
SpringWorks Therapeutics, Inc.
Common Stock |
S - Sale | X | -6.502 | 6.044.266 | -0,11 | 85,17 | -553.775 | 514.790.135 |
| 2021-06-25 |
|
4 | SWTX |
SpringWorks Therapeutics, Inc.
Common Stock |
S - Sale | X | -22.334 | 6.050.768 | -0,37 | 85,14 | -1.901.517 | 515.162.388 |
| 2021-06-25 |
|
4 | SWTX |
SpringWorks Therapeutics, Inc.
Common Stock |
S - Sale | X | -34.200 | 6.073.102 | -0,56 | 85,22 | -2.914.524 | 517.549.752 |
| 2021-06-25 |
|
4 | SWTX |
SpringWorks Therapeutics, Inc.
Common Stock |
S - Sale | X | -100 | 6.107.302 | 0,00 | 85,00 | -8.500 | 519.120.670 |
| 2021-06-16 |
|
4 | JANX |
Janux Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -128.609 | 0 | -100,00 | ||||
| 2021-06-16 |
|
4 | JANX |
Janux Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -643.046 | 0 | -100,00 | ||||
| 2021-06-16 |
|
4 | JANX |
Janux Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -1.052.632 | 0 | -100,00 | ||||
| 2021-06-16 |
|
4 | JANX |
Janux Therapeutics, Inc.
Common Stock |
P - Purchase | 117.650 | 282.398 | 71,41 | 17,00 | 2.000.050 | 4.800.766 | |
| 2021-06-16 |
|
4 | JANX |
Janux Therapeutics, Inc.
Common Stock |
C - Conversion | 164.748 | 164.748 | |||||
| 2021-06-16 |
|
4 | JANX |
Janux Therapeutics, Inc.
Common Stock |
P - Purchase | 588.203 | 2.760.366 | 27,08 | 17,00 | 9.999.451 | 46.926.222 | |
| 2021-06-16 |
|
4 | JANX |
Janux Therapeutics, Inc.
Common Stock |
C - Conversion | 823.742 | 2.172.163 | 61,09 | ||||
| 2021-06-16 |
|
4 | JANX |
Janux Therapeutics, Inc.
Common Stock |
C - Conversion | 1.348.421 | 1.348.421 | |||||
| 2021-06-14 |
|
4 | SWTX |
SpringWorks Therapeutics, Inc.
Common Stock |
S - Sale | X | -30.852 | 6.107.402 | -0,50 | 85,09 | -2.625.197 | 519.678.836 |
| 2021-06-09 |
|
4 | SWTX |
SpringWorks Therapeutics, Inc.
Common Stock |
S - Sale | X | -5.049 | 6.138.254 | -0,08 | 85,33 | -430.831 | 523.777.214 |
| 2021-06-09 |
|
4 | SWTX |
SpringWorks Therapeutics, Inc.
Common Stock |
S - Sale | X | -42.633 | 6.143.303 | -0,69 | 85,37 | -3.639.579 | 524.453.777 |
| 2021-06-09 |
|
4 | SWTX |
SpringWorks Therapeutics, Inc.
Common Stock |
S - Sale | X | -371 | 6.185.936 | -0,01 | 84,90 | -31.498 | 525.185.966 |
| 2021-04-26 |
|
4 | NPCE |
NeuroPace Inc
Series B' Preferred Stock |
C - Conversion | -3.605.386 | 0 | -100,00 | ||||
| 2021-04-26 |
|
4 | NPCE |
NeuroPace Inc
Series A' Preferred Stock |
C - Conversion | -171.895 | 0 | -100,00 | ||||
| 2021-04-26 |
|
4 | NPCE |
NeuroPace Inc
Common Stock |
C - Conversion | 3.777.281 | 4.012.281 | 1.607,35 | ||||
| 2021-04-23 |
|
4 | NPCE |
NeuroPace Inc
Common Stock |
P - Purchase | 235.000 | 235.000 | 17,00 | 3.995.000 | 3.995.000 | ||
| 2021-04-22 |
|
4 | SYBX |
SYNLOGIC, INC.
Common Stock, $0.001 par value |
A - Award | 1.666.666 | 3.696.662 | 82,10 | 3,00 | 4.999.998 | 11.089.986 | |
| 2021-04-13 |
|
4/A | IKNA |
Ikena Oncology, Inc.
Series B Preferred Stock |
C - Conversion | -42.614 | 0 | -100,00 | ||||
| 2021-04-13 |
|
4/A | IKNA |
Ikena Oncology, Inc.
Series B Preferred Stock |
C - Conversion | -157.288 | 0 | -100,00 | ||||
| 2021-04-13 |
|
4/A | IKNA |
Ikena Oncology, Inc.
Series B Preferred Stock |
C - Conversion | -266.336 | 0 | -100,00 | ||||
| 2021-04-13 |
|
4/A | IKNA |
Ikena Oncology, Inc.
Series B Preferred Stock |
C - Conversion | -983.055 | 0 | -100,00 | ||||
| 2021-04-13 |
|
4/A | IKNA |
Ikena Oncology, Inc.
Series A-1 Preferred Stock |
C - Conversion | -653.277 | 0 | -100,00 | ||||
| 2021-04-13 |
|
4/A | IKNA |
Ikena Oncology, Inc.
Series A-1 Preferred Stock |
C - Conversion | -2.411.260 | 0 | -100,00 | ||||
| 2021-04-13 |
|
4/A | IKNA |
Ikena Oncology, Inc.
Series A Preferred Stock |
C - Conversion | -551.259 | 0 | -100,00 | ||||
| 2021-04-13 |
|
4/A | IKNA |
Ikena Oncology, Inc.
Series A Preferred Stock |
C - Conversion | -2.034.708 | 0 | -100,00 | ||||
| 2021-04-13 |
|
4/A | IKNA |
Ikena Oncology, Inc.
Non-Voting Common Stock |
C - Conversion | 157.288 | 157.288 | |||||
| 2021-04-13 |
|
4/A | IKNA |
Ikena Oncology, Inc.
Non-Voting Common Stock |
C - Conversion | 5.429.023 | 5.429.023 | |||||
| 2021-04-13 |
|
4/A | IKNA |
Ikena Oncology, Inc.
Common Stock |
P - Purchase | 48.400 | 91.014 | 113,58 | 16,00 | 774.400 | 1.456.224 | |
| 2021-04-13 |
|
4/A | IKNA |
Ikena Oncology, Inc.
Common Stock |
P - Purchase | 375.000 | 1.845.872 | 25,50 | 16,00 | 6.000.000 | 29.533.952 | |
| 2021-04-13 |
|
4/A | IKNA |
Ikena Oncology, Inc.
Common Stock |
C - Conversion | 42.614 | 42.614 | |||||
| 2021-04-13 |
|
4/A | IKNA |
Ikena Oncology, Inc.
Common Stock |
C - Conversion | 1.470.872 | 1.470.872 | |||||
| 2021-04-13 |
|
4/A | IKNA |
Ikena Oncology, Inc.
Series B Preferred Stock |
A - Award | 1.430.103 | 1.430.103 | 1,40 | 1.999.999 | 1.999.999 | ||
| 2021-04-13 |
|
4/A | IKNA |
Ikena Oncology, Inc.
Series B Preferred Stock |
A - Award | 8.938.148 | 8.938.148 | 1,40 | 12.500.000 | 12.500.000 | ||
| 2021-04-01 |
|
4 | IKNA |
Ikena Oncology, Inc.
Series B Preferred Stock |
C - Conversion | -68.978 | 0 | -100,00 | ||||
| 2021-04-01 |
|
4 | IKNA |
Ikena Oncology, Inc.
Series B Preferred Stock |
C - Conversion | -130.924 | 0 | -100,00 | ||||
| 2021-04-01 |
|
4 | IKNA |
Ikena Oncology, Inc.
Series B Preferred Stock |
C - Conversion | -328.907 | 0 | -100,00 | ||||
| 2021-04-01 |
|
4 | IKNA |
Ikena Oncology, Inc.
Series B Preferred Stock |
C - Conversion | -920.484 | 0 | -100,00 | ||||
| 2021-04-01 |
|
4 | IKNA |
Ikena Oncology, Inc.
Series A-1 Preferred Stock |
C - Conversion | -806.752 | 0 | -100,00 | ||||
| 2021-04-01 |
|
4 | IKNA |
Ikena Oncology, Inc.
Series A-1 Preferred Stock |
C - Conversion | -2.257.785 | 0 | -100,00 | ||||
| 2021-04-01 |
|
4 | IKNA |
Ikena Oncology, Inc.
Series A Preferred Stock |
C - Conversion | -680.766 | 0 | -100,00 | ||||
| 2021-04-01 |
|
4 | IKNA |
Ikena Oncology, Inc.
Series A Preferred Stock |
C - Conversion | -1.905.201 | 0 | -100,00 | ||||
| 2021-04-01 |
|
4 | IKNA |
Ikena Oncology, Inc.
Non-Voting Common Stock |
C - Conversion | 130.924 | 130.924 | |||||
| 2021-04-01 |
|
4 | IKNA |
Ikena Oncology, Inc.
Non-Voting Common Stock |
C - Conversion | 5.083.470 | 5.083.470 | |||||
| 2021-04-01 |
|
4 | IKNA |
Ikena Oncology, Inc.
Common Stock |
P - Purchase | 48.400 | 117.378 | 70,17 | 16,00 | 774.400 | 1.878.048 | |
| 2021-04-01 |
|
4 | IKNA |
Ikena Oncology, Inc.
Common Stock |
P - Purchase | 375.000 | 2.191.425 | 20,64 | 16,00 | 6.000.000 | 35.062.800 | |
| 2021-04-01 |
|
4 | IKNA |
Ikena Oncology, Inc.
Common Stock |
C - Conversion | 68.978 | 68.978 | |||||
| 2021-04-01 |
|
4 | IKNA |
Ikena Oncology, Inc.
Common Stock |
C - Conversion | 1.816.425 | 1.816.425 | |||||
| 2021-04-01 |
|
4 | IKNA |
Ikena Oncology, Inc.
Series B Preferred Stock |
A - Award | 1.430.103 | 1.430.103 | 1,40 | 1.999.999 | 1.999.999 | ||
| 2021-04-01 |
|
4 | IKNA |
Ikena Oncology, Inc.
Series B Preferred Stock |
A - Award | 8.938.148 | 8.938.148 | 1,40 | 12.500.000 | 12.500.000 | ||
| 2021-03-31 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -27.869 | 2.212.571 | -1,24 | 23,93 | -666.905 | 52.946.824 |
| 2021-03-31 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -75.555 | 2.240.440 | -3,26 | 23,31 | -1.761.187 | 52.224.656 |
| 2021-03-31 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -272.724 | 0 | -100,00 | ||||
| 2021-03-31 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -1.668.350 | 0 | -100,00 | ||||
| 2021-03-31 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Series B-2 Preferred Stock |
C - Conversion | -1.301.626 | 0 | -100,00 | ||||
| 2021-03-31 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Series B-1 Preferred Stock |
C - Conversion | -1.572.960 | 0 | -100,00 | ||||
| 2021-03-31 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -8.187.100 | 0 | -100,00 | ||||
| 2021-03-31 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Common Stock |
P - Purchase | 312.500 | 13.359.456 | 2,40 | 16,00 | 5.000.000 | 213.751.296 | |
| 2021-03-31 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Common Stock |
P - Purchase | 46.875 | 319.599 | 17,19 | 16,00 | 750.000 | 5.113.584 | |
| 2021-03-31 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Common Stock |
C - Conversion | 272.724 | 272.724 | |||||
| 2021-03-31 |
|
4 | EWTX |
Edgewise Therapeutics, Inc.
Common Stock |
C - Conversion | 12.730.036 | 13.046.956 | 4.016,80 | ||||
| 2021-03-26 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -27.816 | 2.315.995 | -1,19 | 23,88 | -664.246 | 55.305.961 |
| 2021-03-26 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -51.523 | 2.343.811 | -2,15 | 24,70 | -1.272.618 | 57.892.132 |
| 2021-03-26 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -32.959 | 2.395.334 | -1,36 | 24,80 | -817.383 | 59.404.283 |
| 2021-03-25 | 3 | EWTX |
Edgewise Therapeutics, Inc.
Common Stock |
316.920 | ||||||||
| 2021-03-23 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -3.992 | 2.428.293 | -0,16 | 24,32 | -97.085 | 59.056.086 |
| 2021-03-23 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -7.673 | 2.432.285 | -0,31 | 26,47 | -203.104 | 64.382.584 |
| 2021-03-23 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -21.275 | 2.439.958 | -0,86 | 26,47 | -563.149 | 64.585.688 |
| 2021-03-18 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -6.059 | 2.461.233 | -0,25 | 28,03 | -169.834 | 68.988.361 |
| 2021-03-18 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -18.790 | 2.467.292 | -0,76 | 28,43 | -534.200 | 70.145.112 |
| 2021-03-18 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -41.353 | 2.486.082 | -1,64 | 27,72 | -1.146.305 | 68.914.193 |
| 2021-03-15 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -89.210 | 2.527.435 | -3,41 | 29,14 | -2.599.579 | 73.649.456 |
| 2021-03-15 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -90.521 | 2.616.645 | -3,34 | 30,29 | -2.741.881 | 79.258.177 |
| 2021-03-15 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
S - Sale | X | -58.551 | 2.707.166 | -2,12 | 33,04 | -1.934.525 | 89.444.765 |
| 2021-03-03 |
|
4 | SWTX |
SpringWorks Therapeutics, Inc.
Common Stock |
S - Sale | -1.220.000 | 6.186.307 | -16,47 | 83,19 | -101.491.800 | 514.638.879 | |
| 2021-02-19 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 1.285.714 | 8.053.298 | 19,00 | 3,50 | 4.499.999 | 28.186.543 | |
| 2021-02-19 |
|
4 | DBTX |
Decibel Therapeutics, Inc.
Series D Preferred Stock |
C - Conversion | -1.158.412 | 0 | -100,00 | ||||
| 2021-02-19 |
|
4 | DBTX |
Decibel Therapeutics, Inc.
Series D Preferred Stock |
C - Conversion | -1.737.619 | 0 | -100,00 | ||||
| 2021-02-19 |
|
4 | DBTX |
Decibel Therapeutics, Inc.
Series D Preferred Stock |
C - Conversion | -14.480.162 | 0 | -100,00 | ||||
| 2021-02-19 |
|
4 | DBTX |
Decibel Therapeutics, Inc.
Common Stock |
P - Purchase | 555.566 | 883.418 | 169,46 | 18,00 | 10.000.188 | 15.901.524 | |
| 2021-02-19 |
|
4 | DBTX |
Decibel Therapeutics, Inc.
Common Stock |
P - Purchase | 1.111.100 | 3.843.206 | 40,67 | 18,00 | 19.999.800 | 69.177.708 | |
| 2021-02-19 |
|
4 | DBTX |
Decibel Therapeutics, Inc.
Common Stock |
C - Conversion | 218.568 | 218.568 | |||||
| 2021-02-19 |
|
4 | DBTX |
Decibel Therapeutics, Inc.
Common Stock |
C - Conversion | 327.852 | 327.852 | |||||
| 2021-02-19 |
|
4 | DBTX |
Decibel Therapeutics, Inc.
Common Stock |
C - Conversion | 2.732.106 | 2.732.106 | |||||
| 2021-02-18 |
|
4 | ACET |
Adicet Bio, Inc.
Common Stock |
A - Award | 104.050 | 396.657 | 35,56 | 13,00 | 1.352.650 | 5.156.541 | |
| 2021-02-18 |
|
4 | ACET |
Adicet Bio, Inc.
Common Stock |
A - Award | 420.299 | 5.243.259 | 8,71 | 13,00 | 5.463.887 | 68.162.367 | |
| 2021-02-10 | 3 | GMTX |
Gemini Therapeutics, Inc. /DE
Common Stock |
5.316.224 | ||||||||
| 2021-02-10 | 3 | GMTX |
Gemini Therapeutics, Inc. /DE
Common Stock |
510.000 | ||||||||
| 2021-02-09 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Series C Preferred Stock |
C - Conversion | -918.295 | 0 | -100,00 | ||||
| 2021-02-09 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Series C Preferred Stock |
C - Conversion | -612.196 | 0 | -100,00 | ||||
| 2021-02-09 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -1.071.428 | 0 | -100,00 | ||||
| 2021-02-09 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -714.285 | 0 | -100,00 | ||||
| 2021-02-09 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 285.000 | 2.274.723 | 14,32 | 17,00 | 4.845.000 | 38.670.291 | |
| 2021-02-09 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 190.000 | 1.516.481 | 14,32 | 17,00 | 3.230.000 | 25.780.177 | |
| 2021-02-09 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.989.723 | 1.989.723 | |||||
| 2021-02-09 |
|
4 | TERN |
Terns Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.326.481 | 1.326.481 | |||||
| 2021-01-26 |
|
4 | PRVL |
Prevail Therapeutics Inc.
Common Stock |
U - Other | -13.822.463 | 0 | -100,00 | ||||
| 2021-01-12 |
|
4 | PRLD |
Prelude Therapeutics Inc
Non-Voting Common Stock |
P - Purchase | 41.700 | 5.596.886 | 0,75 | 60,00 | 2.502.000 | 335.813.160 | |
| 2021-01-11 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock |
S - Sale | -2.000.000 | 7.520.600 | -21,01 | 3,50 | -7.000.000 | 26.322.100 | |
| 2021-01-05 | 3 | VRNA |
Verona Pharma plc
Ordinary Shares |
40.225.392 | ||||||||
| 2020-12-30 |
|
4 | ALPN |
ALPINE IMMUNE SCIENCES, INC.
Common Stock |
S - Sale | -600.000 | 3.070.955 | -16,34 | 14,25 | -8.550.000 | 43.761.109 | |
| 2020-12-10 |
|
4 | ARPO |
Aerpio Pharmaceuticals, Inc.
Stock Option (Right to Buy) |
X - Other | -21.400 | 0 | -100,00 | ||||
| 2020-12-10 |
|
4 | ARPO |
Aerpio Pharmaceuticals, Inc.
Common Stock |
S - Sale | -21.400 | 0 | -100,00 | 1,96 | -41.944 | ||
| 2020-12-10 |
|
4 | ARPO |
Aerpio Pharmaceuticals, Inc.
Common Stock |
X - Other | 21.400 | 21.400 | 0,96 | 20.544 | 20.544 | ||
| 2020-12-09 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Series C Preferred Stock |
C - Conversion | -24.555 | 0 | -100,00 | ||||
| 2020-12-09 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Series B Preferred Stock |
C - Conversion | -9.461 | 0 | -100,00 | ||||
| 2020-12-09 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Series A Preferred Stock |
C - Conversion | -50.501 | 0 | -100,00 | ||||
| 2020-12-09 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Series C Preferred Stock |
C - Conversion | -118.398 | 0 | -100,00 | ||||
| 2020-12-09 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Series B Preferred Stock |
C - Conversion | -2.651.042 | 0 | -100,00 | ||||
| 2020-12-09 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Series A Preferred Stock |
C - Conversion | -243.494 | 0 | -100,00 | ||||
| 2020-12-09 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
C - Conversion | 24.637 | 84.599 | 41,09 | ||||
| 2020-12-09 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
C - Conversion | 9.461 | 59.962 | 18,73 | ||||
| 2020-12-09 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
C - Conversion | 50.501 | 50.501 | |||||
| 2020-12-09 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
C - Conversion | 118.794 | 3.313.330 | 3,72 | ||||
| 2020-12-09 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
C - Conversion | 2.651.042 | 3.194.536 | 487,78 | ||||
| 2020-12-09 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
C - Conversion | 243.494 | 543.494 | 81,16 | ||||
| 2020-12-08 |
|
4 | SBTX |
Silverback Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -3.918.279 | 0 | -100,00 | ||||
| 2020-12-08 |
|
4 | SBTX |
Silverback Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -9.259.259 | 0 | -100,00 | ||||
| 2020-12-08 |
|
4 | SBTX |
Silverback Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -12.857.142 | 0 | -100,00 | ||||
| 2020-12-08 |
|
4 | SBTX |
Silverback Therapeutics, Inc.
Common Stock |
P - Purchase | 952.377 | 952.377 | 21,00 | 19.999.917 | 19.999.917 | ||
| 2020-12-08 |
|
4 | SBTX |
Silverback Therapeutics, Inc.
Common Stock |
C - Conversion | 1.055.287 | 7.519.188 | 16,33 | ||||
| 2020-12-08 |
|
4 | SBTX |
Silverback Therapeutics, Inc.
Common Stock |
C - Conversion | 2.493.741 | 6.463.901 | 62,81 | ||||
| 2020-12-08 |
|
4 | SBTX |
Silverback Therapeutics, Inc.
Common Stock |
C - Conversion | 3.462.737 | 3.970.160 | 682,42 | ||||
| 2020-12-08 |
|
4 | SBTX |
Silverback Therapeutics, Inc.
Common Stock |
P - Purchase | 238.100 | 507.423 | 88,41 | 21,00 | 5.000.100 | 10.655.883 | |
| 2020-12-04 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 450.000 | 450.000 | 20,00 | 9.000.000 | 9.000.000 | ||
| 2020-12-04 |
|
4 | KNTE |
Kinnate Biopharma Inc.
Common Stock |
P - Purchase | 300.000 | 300.000 | 20,00 | 6.000.000 | 6.000.000 | ||
| 2020-12-03 | 3 | SBTX |
Silverback Therapeutics, Inc.
Common Stock |
269.323 | ||||||||
| 2020-12-03 | 3 | SBTX |
Silverback Therapeutics, Inc.
Common Stock |
269.323 | ||||||||
| 2020-11-19 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Warrant (right to buy) |
X - Other | -868.016 | 0 | -100,00 | ||||
| 2020-11-19 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Warrant (right to buy) |
X - Other | -1.531.984 | 0 | -100,00 | ||||
| 2020-11-19 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Warrant (right to buy) |
X - Other | -434.008 | 0 | -100,00 | ||||
| 2020-11-19 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Warrant (right to buy) |
X - Other | -434.008 | 0 | -100,00 | ||||
| 2020-11-19 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Warrant (right to buy) |
X - Other | -765.992 | 0 | -100,00 | ||||
| 2020-11-19 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Warrant (right to buy) |
X - Other | -765.992 | 0 | -100,00 | ||||
| 2020-11-19 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
X - Other | 868.016 | 17.036.720 | 5,37 | 0,01 | 8.680 | 170.367 | |
| 2020-11-19 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
X - Other | 434.008 | 16.168.704 | 2,76 | 0,01 | 4.340 | 161.687 | |
| 2020-11-19 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
X - Other | 434.008 | 16.168.704 | 2,76 | 0,01 | 4.340 | 161.687 | |
| 2020-11-19 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
X - Other | 1.531.984 | 55.766.352 | 2,82 | 0,01 | 15.320 | 557.664 | |
| 2020-11-19 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
X - Other | 765.992 | 54.234.368 | 1,43 | 0,01 | 7.660 | 542.344 | |
| 2020-11-19 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
X - Other | 765.992 | 54.234.368 | 1,43 | 0,01 | 7.660 | 542.344 | |
| 2020-11-04 |
|
4 | GLTO |
Galecto, Inc.
Series D Preferred Stock |
C - Conversion | -73.773 | 0 | -100,00 | ||||
| 2020-11-04 |
|
4 | GLTO |
Galecto, Inc.
Series D Preferred Stock |
C - Conversion | -59.350 | 0 | -100,00 | ||||
| 2020-11-04 |
|
4 | GLTO |
Galecto, Inc.
Series D Preferred Stock |
C - Conversion | -148.395 | 0 | -100,00 | ||||
| 2020-11-04 |
|
4 | GLTO |
Galecto, Inc.
Series C-5 Preferred Stock |
C - Conversion | -31.147 | 0 | -100,00 | ||||
| 2020-11-04 |
|
4 | GLTO |
Galecto, Inc.
Series C-5 Preferred Stock |
C - Conversion | -77.866 | 0 | -100,00 | ||||
| 2020-11-04 |
|
4 | GLTO |
Galecto, Inc.
Series C-4 Preferred Stock |
C - Conversion | -109.013 | 0 | -100,00 | ||||
| 2020-11-04 |
|
4 | GLTO |
Galecto, Inc.
Series C-4 Preferred Stock |
C - Conversion | -272.533 | 0 | -100,00 | ||||
| 2020-11-04 |
|
4 | GLTO |
Galecto, Inc.
Series C-2 Preferred Stock |
C - Conversion | -116.800 | 0 | -100,00 | ||||
| 2020-11-04 |
|
4 | GLTO |
Galecto, Inc.
Series C-2 Preferred Stock |
C - Conversion | -291.999 | 0 | -100,00 | ||||
| 2020-11-04 |
|
4 | GLTO |
Galecto, Inc.
Common Shares |
P - Purchase | 209.500 | 1.031.811 | 25,48 | 15,00 | 3.142.500 | 15.477.165 | |
| 2020-11-04 |
|
4 | GLTO |
Galecto, Inc.
Common Shares |
P - Purchase | 523.833 | 2.579.657 | 25,48 | 15,00 | 7.857.495 | 38.694.855 | |
| 2020-11-04 |
|
4 | GLTO |
Galecto, Inc.
Common Shares |
C - Conversion | 191.787 | 191.787 | |||||
| 2020-11-04 |
|
4 | GLTO |
Galecto, Inc.
Common Shares |
C - Conversion | 822.311 | 822.311 | |||||
| 2020-11-04 |
|
4 | GLTO |
Galecto, Inc.
Common Shares |
C - Conversion | 2.055.824 | 2.055.824 | |||||
| 2020-11-04 |
|
4 | GLTO |
Galecto, Inc.
Series D Preferred Stock |
A - Award | -73.773 | 73.773 | -50,00 | 27,11 | -1.999.986 | 1.999.986 | |
| 2020-11-04 |
|
4 | GLTO |
Galecto, Inc.
Series D Preferred Stock |
A - Award | -59.350 | 59.350 | -50,00 | 27,11 | -1.608.978 | 1.608.978 | |
| 2020-11-04 |
|
4 | GLTO |
Galecto, Inc.
Series D Preferred Stock |
A - Award | -148.395 | 148.395 | -50,00 | 27,11 | -4.022.988 | 4.022.988 | |
| 2020-10-06 |
|
4 | ARQT |
Arcutis Biotherapeutics, Inc.
Common Stock |
P - Purchase | 296.000 | 902.286 | 48,82 | 25,00 | 7.400.000 | 22.557.150 | |
| 2020-10-06 |
|
4 | ARQT |
Arcutis Biotherapeutics, Inc.
Common Stock |
P - Purchase | 200.000 | 4.267.564 | 4,92 | 25,00 | 5.000.000 | 106.689.100 | |
| 2020-10-05 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
A - Award | 11.969.619 | 15.300.688 | 359,33 | 1,07 | 12.807.492 | 16.371.736 | |
| 2020-10-05 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
A - Award | 46.784.775 | 52.702.384 | 790,60 | 1,07 | 50.059.709 | 56.391.551 | |
| 2020-10-05 |
|
4 | LOGC |
LogicBio Therapeutics, Inc.
Common Stock |
P - Purchase | 296.296 | 296.296 | 6,00 | 1.777.776 | 1.777.776 | ||
| 2020-10-05 |
|
4 | LOGC |
LogicBio Therapeutics, Inc.
Common Stock |
P - Purchase | 639.212 | 4.126.972 | 18,33 | 6,00 | 3.835.272 | 24.761.832 | |
| 2020-10-05 |
|
4 | LOGC |
LogicBio Therapeutics, Inc.
Common Stock |
P - Purchase | 545.974 | 3.524.997 | 18,33 | 6,00 | 3.275.844 | 21.149.982 | |
| 2020-09-30 |
|
4/A | PRLD |
Prelude Therapeutics Inc
Series C Preferred Stock |
P - Purchase | 1.033.084 | 1.033.084 | |||||
| 2020-09-30 |
|
4/A | PRLD |
Prelude Therapeutics Inc
Series B Preferred Stock |
P - Purchase | 3.681.822 | 7.363.644 | 100,00 | ||||
| 2020-09-29 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Series C Preferred Stock |
C - Conversion | -846.574 | 0 | -100,00 | ||||
| 2020-09-29 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Series B Preferred Stock |
C - Conversion | -2.754.273 | 0 | -100,00 | ||||
| 2020-09-29 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Common Stock |
C - Conversion | 3.600.847 | 4.163.347 | 640,15 | ||||
| 2020-09-29 |
|
4 | GRAY |
GRAYBUG VISION, INC.
Common Stock |
P - Purchase | 562.500 | 562.500 | 16,00 | 9.000.000 | 9.000.000 | ||
| 2020-09-29 |
|
4 | PMVP |
PMV Pharmaceuticals, Inc.
Series D Preferred Stock |
C - Conversion | -114.039 | 0 | -100,00 | ||||
| 2020-09-29 |
|
4 | PMVP |
PMV Pharmaceuticals, Inc.
Series D Preferred Stock |
C - Conversion | -380.133 | 0 | -100,00 | ||||
| 2020-09-29 |
|
4 | PMVP |
PMV Pharmaceuticals, Inc.
Series C Preferred Stock |
C - Conversion | -518.191 | 0 | -100,00 | ||||
| 2020-09-29 |
|
4 | PMVP |
PMV Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -1.076.891 | 0 | -100,00 | ||||
| 2020-09-29 |
|
4 | PMVP |
PMV Pharmaceuticals, Inc.
Series A Preferred Stock |
C - Conversion | -4.025.076 | 0 | -100,00 | ||||
| 2020-09-29 |
|
4 | PMVP |
PMV Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 114.039 | 114.039 | |||||
| 2020-09-29 |
|
4 | PMVP |
PMV Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 380.133 | 6.475.291 | 6,24 | ||||
| 2020-09-29 |
|
4 | PMVP |
PMV Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 518.191 | 6.095.158 | 9,29 | ||||
| 2020-09-29 |
|
4 | PMVP |
PMV Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.076.891 | 5.576.967 | 23,93 | ||||
| 2020-09-29 |
|
4 | PMVP |
PMV Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 4.025.076 | 4.500.076 | 847,38 | ||||
| 2020-09-29 |
|
4 | PMVP |
PMV Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 475.000 | 475.000 | 18,00 | 8.550.000 | 8.550.000 | ||
| 2020-09-29 |
|
4 | PMVP |
PMV Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 475.000 | 475.000 | 18,00 | 8.550.000 | 8.550.000 | ||
| 2020-09-29 |
|
4 | PRLD |
Prelude Therapeutics Inc
Non-Voting Common Stock |
C - Conversion | 5.555.186 | 5.555.186 | |||||
| 2020-09-29 |
|
4 | PRLD |
Prelude Therapeutics Inc
Series C Preferred Stock |
C - Conversion | -413.234 | 0 | -100,00 | ||||
| 2020-09-29 |
|
4 | PRLD |
Prelude Therapeutics Inc
Series C Preferred Stock |
C - Conversion | -619.850 | 0 | -100,00 | ||||
| 2020-09-29 |
|
4 | PRLD |
Prelude Therapeutics Inc
Series B Preferred Stock |
C - Conversion | -2.945.458 | 0 | -100,00 | ||||
| 2020-09-29 |
|
4 | PRLD |
Prelude Therapeutics Inc
Series B Preferred Stock |
C - Conversion | -4.418.186 | 0 | -100,00 | ||||
| 2020-09-29 |
|
4 | PRLD |
Prelude Therapeutics Inc
Series A Prefered Stock |
C - Conversion | -2.196.494 | 0 | -100,00 | ||||
| 2020-09-29 |
|
4 | PRLD |
Prelude Therapeutics Inc
Series A Preferred Stock |
C - Conversion | -3.294.743 | 0 | -100,00 | ||||
| 2020-09-29 |
|
4 | PRLD |
Prelude Therapeutics Inc
Common Stock |
C - Conversion | 8.332.779 | 9.250.191 | 908,29 | ||||
| 2020-09-29 |
|
4 | PRLD |
Prelude Therapeutics Inc
Common Stock |
P - Purchase | 710.500 | 917.412 | 343,38 | 19,00 | 13.499.500 | 17.430.828 | |
| 2020-09-29 |
|
4 | PRLD |
Prelude Therapeutics Inc
Common Stock |
P - Purchase | 526.300 | 526.300 | 19,00 | 9.999.700 | 9.999.700 | ||
| 2020-09-24 | 3 | PRLD |
Prelude Therapeutics Inc
Common Stock |
206.912 | ||||||||
| 2020-09-23 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
S - Sale | -137.500 | 1.864.721 | -6,87 | 28,00 | -3.850.000 | 52.212.188 | |
| 2020-09-23 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
S - Sale | -137.500 | 1.864.721 | -6,87 | 28,00 | -3.850.000 | 52.212.188 | |
| 2020-09-17 |
|
4 | ACET |
Adicet Bio, Inc.
Stock Option (Right to Buy) |
A - Award | 30.000 | 30.000 | |||||
| 2020-09-17 |
|
4 | ACET |
Adicet Bio, Inc.
Stock Option (Right to Buy) |
A - Award | 30.000 | 30.000 | |||||
| 2020-09-17 |
|
4 | ACET |
Adicet Bio, Inc.
Common Stock |
A - Award | 292.607 | 292.607 | |||||
| 2020-09-17 |
|
4 | ACET |
Adicet Bio, Inc.
Common Stock |
A - Award | 902.885 | 902.855 | -3.009.616,67 | ||||
| 2020-09-17 |
|
4 | ACET |
Adicet Bio, Inc.
Common Stock |
A - Award | 4.822.960 | 4.822.960 | |||||
| 2020-08-19 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock, $0.001 par value |
S - Sale | -43.543 | 0 | -100,00 | 108,54 | -4.726.157 | ||
| 2020-08-19 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock, $0.001 par value |
S - Sale | -94.900 | 43.543 | -68,55 | 107,49 | -10.200.801 | 4.680.437 | |
| 2020-08-14 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock, $0.001 par value |
S - Sale | -20.257 | 138.443 | -12,76 | 109,03 | -2.208.621 | 15.094.440 | |
| 2020-08-14 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock, $0.001 par value |
S - Sale | -29.251 | 158.500 | -15,58 | 109,93 | -3.215.562 | 17.423.905 | |
| 2020-08-14 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock, $0.001 par value |
S - Sale | -42.679 | 187.751 | -18,52 | 107,45 | -4.585.859 | 20.173.845 | |
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -378.733 | 0 | -100,00 | ||||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -1.202.117 | 0 | -100,00 | ||||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -389.116 | 0 | -100,00 | ||||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -899.985 | 0 | -100,00 | ||||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -647.582 | 0 | -100,00 | ||||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -673.123 | 0 | -100,00 | ||||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -872.302 | 0 | -100,00 | ||||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
C - Conversion | 1.278.718 | 1.320.218 | 3.081,25 | ||||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
C - Conversion | 3.784.240 | 4.157.740 | 1.013,18 | ||||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
P - Purchase | 41.500 | 41.500 | 18,00 | 747.000 | 747.000 | ||
| 2020-08-12 |
|
4 | AFIB |
Acutus Medical, Inc.
Common Stock |
P - Purchase | 373.500 | 373.500 | 18,00 | 6.723.000 | 6.723.000 | ||
| 2020-08-11 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock, $0.001 par value |
S - Sale | -39.877 | 230.430 | -14,75 | 105,78 | -4.218.189 | 24.374.885 | |
| 2020-08-11 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock, $0.001 par value |
S - Sale | -47.700 | 270.307 | -15,00 | 105,23 | -5.019.471 | 28.444.406 | |
| 2020-08-11 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock, $0.001 par value |
S - Sale | -28.993 | 318.007 | -8,36 | 106,18 | -3.078.477 | 33.765.983 | |
| 2020-07-02 |
|
4 | FUSN |
Fusion Pharmaceuticals Inc.
Class B Preferred Shares |
C - Conversion | -11.878.051 | 0 | -100,00 | ||||
| 2020-07-02 |
|
4 | FUSN |
Fusion Pharmaceuticals Inc.
Common Shares |
P - Purchase | 192.100 | 192.100 | 17,00 | 3.265.700 | 3.265.700 | ||
| 2020-07-02 |
|
4 | FUSN |
Fusion Pharmaceuticals Inc.
Common Shares |
P - Purchase | 705.900 | 2.930.670 | 31,73 | 17,00 | 12.000.300 | 49.821.390 | |
| 2020-07-02 |
|
4 | FUSN |
Fusion Pharmaceuticals Inc.
Common Shares |
C - Conversion | 2.224.770 | 2.224.770 | |||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Class B Preferred Shares |
C - Conversion | -2.601.325 | 0 | -100,00 | ||||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
P - Purchase | 99.200 | 99.200 | 20,00 | 1.984.000 | 1.984.000 | ||
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
P - Purchase | 675.000 | 3.276.325 | 25,95 | 20,00 | 13.500.000 | 65.526.500 | |
| 2020-06-25 |
|
4 | RPTX |
Repare Therapeutics Inc.
Common Stock |
C - Conversion | 2.601.325 | 2.601.325 | |||||
| 2020-06-23 | 3 | NONE |
Compass Therapeutics, Inc.
Common Stock |
22.518.544 | ||||||||
| 2020-06-23 | 3 | NONE |
Compass Therapeutics, Inc.
Common Stock |
22.518.544 | ||||||||
| 2020-06-23 | 3 | NONE |
Compass Therapeutics, Inc.
Common Stock |
22.518.544 | ||||||||
| 2020-06-23 | 3 | NONE |
Compass Therapeutics, Inc.
Common Stock |
22.518.544 | ||||||||
| 2020-06-23 |
|
4 | NONE |
Compass Therapeutics, Inc.
Common Stock |
P - Purchase | 1.455.132 | 12.714.404 | 12,92 | 5,00 | 7.275.660 | 63.572.020 | |
| 2020-05-26 |
|
4 | SCPH |
scPharmaceuticals Inc.
Common Stock |
P - Purchase | 231.200 | 231.200 | 8,65 | 1.999.880 | 1.999.880 | ||
| 2020-05-26 |
|
4 | SCPH |
scPharmaceuticals Inc.
Common Stock |
P - Purchase | 1.156.083 | 4.565.948 | 33,90 | 8,65 | 10.000.118 | 39.495.450 | |
| 2020-05-20 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Warrant (right to buy) |
A - Award | 868.016 | 868.016 | |||||
| 2020-05-20 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Warrant (right to buy) |
A - Award | 1.531.984 | 1.531.984 | |||||
| 2020-04-28 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Series D Preferred Stock |
C - Conversion | -236.111 | 0 | -100,00 | ||||
| 2020-04-28 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Series C Preferred Stock |
C - Conversion | -373.356 | 0 | -100,00 | ||||
| 2020-04-28 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Series B Preferred Stock |
C - Conversion | -1.875.000 | 0 | -100,00 | ||||
| 2020-04-28 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 236.111 | 2.765.717 | 9,33 | ||||
| 2020-04-28 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 373.356 | 2.529.606 | 17,32 | ||||
| 2020-04-28 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 1.875.000 | 2.156.250 | 666,67 | ||||
| 2020-04-28 |
|
4 | ORIC |
Oric Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 281.250 | 281.250 | 16,00 | 4.500.000 | 4.500.000 | ||
| 2020-04-16 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -15.086 | 1.906.718 | -0,78 | 23,53 | -354.974 | 44.865.075 | |
| 2020-04-16 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -47.097 | 5.955.674 | -0,78 | 23,53 | -1.108.192 | 140.137.009 | |
| 2020-04-16 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -5.636 | 1.921.804 | -0,29 | 23,52 | -132.559 | 45.200.830 | |
| 2020-04-16 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -17.595 | 6.002.771 | -0,29 | 23,52 | -413.834 | 141.185.174 | |
| 2020-04-13 |
|
4 | KROS |
Keros Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -148.922 | 0 | -100,00 | ||||
| 2020-04-13 |
|
4 | KROS |
Keros Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -744.612 | 0 | -100,00 | ||||
| 2020-04-13 |
|
4 | KROS |
Keros Therapeutics, Inc.
Common Stock |
P - Purchase | 375.200 | 1.119.812 | 50,39 | 16,00 | 6.003.200 | 17.916.992 | |
| 2020-04-13 |
|
4 | KROS |
Keros Therapeutics, Inc.
Common Stock |
C - Conversion | 148.922 | 148.922 | |||||
| 2020-04-13 |
|
4 | KROS |
Keros Therapeutics, Inc.
Common Stock |
C - Conversion | 744.612 | 744.612 | |||||
| 2020-04-09 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -69.893 | 1.927.440 | -3,50 | 23,79 | -1.662.754 | 45.853.798 | |
| 2020-04-09 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -218.208 | 6.020.366 | -3,50 | 23,79 | -5.191.168 | 143.224.507 | |
| 2020-04-09 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -20.041 | 1.997.333 | -0,99 | 23,65 | -473.970 | 47.236.925 | |
| 2020-04-09 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -62.573 | 6.238.574 | -0,99 | 23,65 | -1.479.851 | 147.542.275 | |
| 2020-04-09 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -2.224 | 2.017.374 | -0,11 | 23,10 | -51.374 | 46.601.339 | |
| 2020-04-09 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -6.946 | 6.301.147 | -0,11 | 23,10 | -160.453 | 145.556.496 | |
| 2020-04-02 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -60.645 | 2.019.598 | -2,92 | 24,50 | -1.485.802 | 49.480.151 | |
| 2020-04-02 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -189.355 | 6.308.093 | -2,91 | 24,50 | -4.639.198 | 154.548.278 | |
| 2020-03-25 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -13.684 | 2.080.243 | -0,65 | 24,66 | -337.447 | 51.298.792 | |
| 2020-03-25 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -42.727 | 6.497.448 | -0,65 | 24,66 | -1.053.648 | 160.227.068 | |
| 2020-03-25 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -16.409 | 2.093.927 | -0,78 | 24,45 | -401.200 | 51.196.515 | |
| 2020-03-25 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -51.235 | 6.540.175 | -0,78 | 24,45 | -1.252.696 | 159.907.279 | |
| 2020-03-25 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -3.541 | 2.110.336 | -0,17 | 26,05 | -92.243 | 54.974.253 | |
| 2020-03-25 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -11.057 | 6.591.410 | -0,17 | 26,05 | -288.035 | 171.706.230 | |
| 2020-03-16 |
|
4 | IMRA |
IMARA Inc.
Series B Preferred Stock |
C - Conversion | -10.046.294 | 0 | -100,00 | ||||
| 2020-03-16 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
C - Conversion | 1.594.902 | 2.532.402 | 170,12 | ||||
| 2020-03-16 |
|
4 | IMRA |
IMARA Inc.
Common Stock |
P - Purchase | 937.500 | 937.500 | 16,00 | 15.000.000 | 15.000.000 | ||
| 2020-03-10 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock |
19.040.000 | ||||||||
| 2020-03-10 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock |
19.040.000 | ||||||||
| 2020-03-10 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock |
19.040.000 | ||||||||
| 2020-03-10 | 3 | CTIC |
CTI BIOPHARMA CORP
Common Stock |
19.040.000 | ||||||||
| 2020-03-10 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock, $0.001 par value |
S - Sale | -500.000 | 347.000 | -59,03 | 83,52 | -41.760.000 | 28.981.440 | |
| 2020-03-05 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock, $0.001 par value |
S - Sale | -400.000 | 847.000 | -32,08 | 84,42 | -33.768.000 | 71.503.740 | |
| 2020-03-05 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock, $0.001 par value |
S - Sale | -25.000 | 1.247.000 | -1,97 | 84,55 | -2.113.750 | 105.433.850 | |
| 2020-03-05 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock, $0.001 par value |
S - Sale | -75.000 | 1.272.000 | -5,57 | 83,21 | -6.240.750 | 105.843.120 | |
| 2020-03-04 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -38.808 | 0 | -100,00 | 26,00 | -1.009.008 | ||
| 2020-03-04 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -445.086 | 2.113.877 | -17,39 | 26,00 | -11.572.236 | 54.960.802 | |
| 2020-03-04 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -1.390.309 | 6.602.467 | -17,39 | 26,00 | -36.148.034 | 171.664.142 | |
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Series B Preferred Stock |
C - Conversion | -541.002 | 0 | -100,00 | ||||
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Series A-2 Preferred Stock |
C - Conversion | -1.311.469 | 0 | -100,00 | ||||
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Series A-1 Preferred Stock |
C - Conversion | -3.721.552 | 0 | -100,00 | ||||
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
C - Conversion | 541.002 | 5.947.323 | 10,01 | ||||
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
C - Conversion | 1.311.469 | 5.406.321 | 32,03 | ||||
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
C - Conversion | 3.721.552 | 4.094.852 | 996,93 | ||||
| 2020-03-03 |
|
4 | PASG |
Passage BIO, Inc.
Common Stock |
P - Purchase | 373.300 | 373.300 | 18,00 | 6.719.400 | 6.719.400 | ||
| 2020-02-07 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock, $0.000001 par value |
J - Other | 70.423 | 91.256 | 338,04 | ||||
| 2020-02-07 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock, $0.000001 par value |
J - Other | 70.423 | 91.256 | 338,04 | ||||
| 2020-02-04 |
|
4 | ARQT |
Arcutis Biotherapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -429.786 | 0 | -100,00 | ||||
| 2020-02-04 |
|
4 | ARQT |
Arcutis Biotherapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -859.573 | 0 | -100,00 | ||||
| 2020-02-04 |
|
4 | ARQT |
Arcutis Biotherapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -2.825.603 | 0 | -100,00 | ||||
| 2020-02-04 |
|
4 | ARQT |
Arcutis Biotherapeutics, Inc.
Common Stock |
C - Conversion | 429.786 | 606.286 | 243,50 | ||||
| 2020-02-04 |
|
4 | ARQT |
Arcutis Biotherapeutics, Inc.
Common Stock |
C - Conversion | 859.573 | 4.067.564 | 26,79 | ||||
| 2020-02-04 |
|
4 | ARQT |
Arcutis Biotherapeutics, Inc.
Common Stock |
C - Conversion | 2.825.603 | 3.207.991 | 738,94 | ||||
| 2020-02-04 |
|
4 | ARQT |
Arcutis Biotherapeutics, Inc.
Common Stock |
P - Purchase | 176.500 | 176.500 | 17,00 | 3.000.500 | 3.000.500 | ||
| 2020-02-04 |
|
4 | ARQT |
Arcutis Biotherapeutics, Inc.
Common Stock |
P - Purchase | 382.388 | 382.388 | 17,00 | 6.500.596 | 6.500.596 | ||
| 2020-01-31 |
|
4 | SRRA |
Sierra Oncology, Inc.
Series A Convertible Voting Preferred Stock |
C - Conversion | -19.500 | 0 | -100,00 | ||||
| 2020-01-31 |
|
4 | SRRA |
Sierra Oncology, Inc.
Common Stock |
C - Conversion | 1.477.320 | 1.477.320 | |||||
| 2020-01-13 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -1.392 | 38.808 | -3,46 | 19,50 | -27.144 | 756.756 | |
| 2020-01-13 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -91.818 | 2.558.963 | -3,46 | 19,50 | -1.790.451 | 49.899.778 | |
| 2020-01-13 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -286.787 | 7.992.776 | -3,46 | 19,50 | -5.592.346 | 155.859.132 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -1.200 | 40.200 | -2,90 | 18,60 | -22.320 | 747.720 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -2.325 | 2.650.781 | -0,09 | 18,60 | -43.245 | 49.304.527 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -7.275 | 8.279.563 | -0,09 | 18,60 | -135.315 | 153.999.872 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -8.000 | 41.400 | -16,19 | 19,59 | -156.720 | 811.026 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -15.476 | 2.653.106 | -0,58 | 19,59 | -303.175 | 51.974.347 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -48.324 | 8.286.838 | -0,58 | 19,59 | -946.667 | 162.339.156 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -10.400 | 49.400 | -17,39 | 19,82 | -206.128 | 979.108 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -20.350 | 2.668.582 | -0,76 | 19,82 | -403.337 | 52.891.295 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -63.535 | 8.335.162 | -0,76 | 19,82 | -1.259.264 | 165.202.911 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -37.900 | 59.800 | -38,79 | 19,66 | -745.114 | 1.175.668 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -73.879 | 2.688.932 | -2,67 | 19,66 | -1.452.461 | 52.864.403 | |
| 2019-12-26 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -230.721 | 8.398.697 | -2,67 | 19,66 | -4.535.975 | 165.118.383 | |
| 2019-12-19 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -105.500 | 97.700 | -51,92 | 18,52 | -1.953.860 | 1.809.404 | |
| 2019-12-19 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -205.793 | 2.762.811 | -6,93 | 18,52 | -3.811.286 | 51.167.260 | |
| 2019-12-19 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -642.807 | 8.629.418 | -6,93 | 18,52 | -11.904.786 | 159.816.821 | |
| 2019-12-12 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | -1.500.000 | 9.614.280 | -13,50 | 40,00 | -60.000.000 | 384.571.200 | |
| 2019-11-29 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock, $0.001 par value |
S - Sale | X | -2.306 | 1.348.326 | -0,17 | 72,13 | -166.332 | 97.254.754 |
| 2019-11-29 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock, $0.001 par value |
S - Sale | X | -47.981 | 1.350.632 | -3,43 | 71,67 | -3.438.798 | 96.799.795 |
| 2019-11-29 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock, $0.001 par value |
S - Sale | X | -3.100 | 1.398.613 | -0,22 | 70,60 | -218.860 | 98.742.078 |
| 2019-11-29 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock, $0.001 par value |
S - Sale | X | -50.478 | 1.401.713 | -3,48 | 70,16 | -3.541.536 | 98.344.184 |
| 2019-11-29 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock, $0.001 par value |
S - Sale | X | -20.135 | 1.452.191 | -1,37 | 69,55 | -1.400.389 | 100.999.884 |
| 2019-11-13 |
|
4 | ETNB |
89bio, Inc.
Series A Preferred Stock |
C - Conversion | -7.944.444 | 0 | -100,00 | ||||
| 2019-11-13 |
|
4 | ETNB |
89bio, Inc.
Series A Preferred Stock |
C - Conversion | -7.944.444 | 0 | -100,00 | ||||
| 2019-11-13 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
C - Conversion | 1.277.858 | 2.002.221 | 176,41 | ||||
| 2019-11-13 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
C - Conversion | 1.277.858 | 2.002.221 | 176,41 | ||||
| 2019-11-13 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
P - Purchase | 418.750 | 724.363 | 137,02 | 16,00 | 6.700.000 | 11.589.808 | |
| 2019-11-13 |
|
4 | ETNB |
89bio, Inc.
Common Stock |
P - Purchase | 418.750 | 724.363 | 137,02 | 16,00 | 6.700.000 | 11.589.808 | |
| 2019-11-13 |
|
4 | TELA |
TELA Bio, Inc.
Warrant (right to buy) |
C - Conversion | 758.623 | 758.623 | |||||
| 2019-11-13 |
|
4 | TELA |
TELA Bio, Inc.
Warrant (right to buy) |
C - Conversion | -758.623 | 0 | -100,00 | ||||
| 2019-11-13 |
|
4 | TELA |
TELA Bio, Inc.
Series B Preferred Stock |
C - Conversion | -24.142.419 | 0 | -100,00 | ||||
| 2019-11-13 |
|
4 | TELA |
TELA Bio, Inc.
Series A Preferred Stock |
C - Conversion | -11.878.249 | 0 | -100,00 | ||||
| 2019-11-13 |
|
4 | TELA |
TELA Bio, Inc.
Common Stock |
C - Conversion | 977.820 | 3.027.542 | 47,71 | ||||
| 2019-11-13 |
|
4 | TELA |
TELA Bio, Inc.
Common Stock |
C - Conversion | 481.095 | 2.049.722 | 30,67 | ||||
| 2019-11-13 |
|
4 | TELA |
TELA Bio, Inc.
Common Stock |
P - Purchase | 384.615 | 1.568.627 | 32,48 | 13,00 | 4.999.995 | 20.392.151 | |
| 2019-11-08 | 3 | ETNB |
89bio, Inc.
Common Stock, par value $0.001 per share |
916.839 | ||||||||
| 2019-11-08 | 3 | ETNB |
89bio, Inc.
Common Stock, par value $0.001 per share |
916.839 | ||||||||
| 2019-11-08 | 3 | ETNB |
89bio, Inc.
Common Stock, par value $0.001 per share |
916.839 | ||||||||
| 2019-11-08 | 3 | ETNB |
89bio, Inc.
Common Stock, par value $0.001 per share |
916.839 | ||||||||
| 2019-11-08 | 3 | ETNB |
89bio, Inc.
Common Stock, par value $0.001 per share |
916.839 | ||||||||
| 2019-11-08 | 3 | ETNB |
89bio, Inc.
Common Stock, par value $0.001 per share |
916.839 | ||||||||
| 2019-11-08 | 3 | ETNB |
89bio, Inc.
Common Stock, par value $0.001 per share |
916.839 | ||||||||
| 2019-11-08 | 3 | ETNB |
89bio, Inc.
Common Stock, par value $0.001 per share |
916.839 | ||||||||
| 2019-11-08 | 3 | ETNB |
89bio, Inc.
Common Stock, par value $0.001 per share |
916.839 | ||||||||
| 2019-11-08 | 3 | ETNB |
89bio, Inc.
Common Stock, par value $0.001 per share |
916.839 | ||||||||
| 2019-11-08 | 3 | ETNB |
89bio, Inc.
Common Stock, par value $0.001 per share |
916.839 | ||||||||
| 2019-11-08 | 3 | ETNB |
89bio, Inc.
Common Stock, par value $0.001 per share |
916.839 | ||||||||
| 2019-10-31 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock, $0.000001 par value |
J - Other | 20.833 | 20.833 | |||||
| 2019-10-31 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock, $0.000001 par value |
J - Other | 20.833 | 20.833 | |||||
| 2019-09-19 |
|
4 | SWTX |
SpringWorks Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.053.204 | 0 | -100,00 | ||||
| 2019-09-19 |
|
4 | SWTX |
SpringWorks Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -6.078.103 | 0 | -100,00 | ||||
| 2019-09-19 |
|
4 | SWTX |
SpringWorks Therapeutics, Inc.
Common Stock |
P - Purchase | 275.000 | 7.406.307 | 3,86 | 18,00 | 4.950.000 | 133.313.526 | |
| 2019-09-19 |
|
4 | SWTX |
SpringWorks Therapeutics, Inc.
Common Stock |
C - Conversion | 1.053.204 | 7.131.307 | 17,33 | ||||
| 2019-09-19 |
|
4 | SWTX |
SpringWorks Therapeutics, Inc.
Common Stock |
C - Conversion | 6.078.103 | 6.078.103 | |||||
| 2019-08-09 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -157.636 | 2.968.604 | -5,04 | 17,90 | -2.821.684 | 53.138.012 | |
| 2019-08-09 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
S - Sale | -492.364 | 9.272.225 | -5,04 | 17,90 | -8.813.316 | 165.972.828 | |
| 2019-08-08 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 142.656 | 6.767.584 | 2,15 | 3,51 | 500.723 | 23.754.220 | |
| 2019-07-01 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 59.243 | 6.624.928 | 0,90 | 3,91 | 231.640 | 25.903.468 | |
| 2019-07-01 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 565.178 | 6.565.685 | 9,42 | 3,72 | 2.102.462 | 24.424.348 | |
| 2019-07-01 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 32.923 | 6.000.507 | 0,55 | 3,34 | 109.963 | 20.041.693 | |
| 2019-06-26 |
|
4 | PRVL |
Prevail Therapeutics Inc.
Series B Preferred Stock |
C - Conversion | -1.011.499 | 0 | -100,00 | ||||
| 2019-06-26 |
|
4 | PRVL |
Prevail Therapeutics Inc.
Series A Preferred Stock |
C - Conversion | -3.099.612 | 0 | -100,00 | ||||
| 2019-06-26 |
|
4 | PRVL |
Prevail Therapeutics Inc.
Series Seed Preferred Stock |
C - Conversion | -6.399.000 | 0 | -100,00 | ||||
| 2019-06-26 |
|
4 | PRVL |
Prevail Therapeutics Inc.
Common Stock |
P - Purchase | 882.352 | 13.822.463 | 6,82 | 17,00 | 14.999.984 | 234.981.871 | |
| 2019-06-26 |
|
4 | PRVL |
Prevail Therapeutics Inc.
Common Stock |
C - Conversion | 10.510.111 | 12.940.111 | 432,51 | ||||
| 2019-06-19 | 3 | PRVL |
Prevail Therapeutics Inc.
Common Stock |
4.860.000 | ||||||||
| 2019-06-19 | 3 | PRVL |
Prevail Therapeutics Inc.
Common Stock |
4.860.000 | ||||||||
| 2019-06-19 | 3 | PRVL |
Prevail Therapeutics Inc.
Common Stock |
4.860.000 | ||||||||
| 2019-06-19 | 3 | PRVL |
Prevail Therapeutics Inc.
Common Stock |
4.860.000 | ||||||||
| 2019-05-22 |
|
4 | PRNB |
Principia Biopharma Inc.
Common Stock |
S - Sale | -1.000.000 | 1.605.713 | -38,38 | 30,25 | -30.250.000 | 48.572.818 | |
| 2019-05-13 |
|
4 | NXTC |
NextCure, Inc.
Series B-1 Preferred Stock |
C - Conversion | -3.554.466 | 0 | -100,00 | ||||
| 2019-05-13 |
|
4 | NXTC |
NextCure, Inc.
Series A-3 Preferred Stock |
C - Conversion | -5.861.455 | 0 | -100,00 | ||||
| 2019-05-13 |
|
4 | NXTC |
NextCure, Inc.
Series A-2 Preferred Stock |
C - Conversion | -5.970.000 | 0 | -100,00 | ||||
| 2019-05-13 |
|
4 | NXTC |
NextCure, Inc.
Series A-1 Preferred Stock |
C - Conversion | -3.582.000 | 0 | -100,00 | ||||
| 2019-05-13 |
|
4 | NXTC |
NextCure, Inc.
Common Stock |
P - Purchase | 350.000 | 2.711.013 | 14,82 | 15,00 | 5.250.000 | 40.665.195 | |
| 2019-05-13 |
|
4 | NXTC |
NextCure, Inc.
Common Stock |
C - Conversion | 442.438 | 2.361.013 | 23,06 | ||||
| 2019-05-13 |
|
4 | NXTC |
NextCure, Inc.
Common Stock |
C - Conversion | 729.599 | 1.918.575 | 61,36 | ||||
| 2019-05-13 |
|
4 | NXTC |
NextCure, Inc.
Common Stock |
C - Conversion | 743.110 | 1.188.976 | 166,67 | ||||
| 2019-05-13 |
|
4 | NXTC |
NextCure, Inc.
Common Stock |
C - Conversion | 445.866 | 445.866 | |||||
| 2019-04-24 |
|
4 | TPTX |
Turning Point Therapeutics, Inc.
Series D Preferred Stock |
C - Conversion | -2.105.259 | 0 | -100,00 | ||||
| 2019-04-24 |
|
4 | TPTX |
Turning Point Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -4.314.809 | 0 | -100,00 | ||||
| 2019-04-24 |
|
4 | TPTX |
Turning Point Therapeutics, Inc.
Common Stock |
P - Purchase | 360.000 | 2.027.550 | 21,59 | 18,00 | 6.480.000 | 36.495.900 | |
| 2019-04-24 |
|
4 | TPTX |
Turning Point Therapeutics, Inc.
Common Stock |
C - Conversion | 546.820 | 1.667.550 | 48,79 | ||||
| 2019-04-24 |
|
4 | TPTX |
Turning Point Therapeutics, Inc.
Common Stock |
C - Conversion | 1.120.730 | 1.120.730 | |||||
| 2019-04-05 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
P - Purchase | 225.000 | 11.114.280 | 2,07 | 36,00 | 8.100.000 | 400.114.080 | |
| 2019-04-03 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Warrant (right to buy) |
A - Award | 434.008 | 434.008 | |||||
| 2019-04-03 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Warrant (right to buy) |
A - Award | 765.992 | 765.992 | |||||
| 2019-03-11 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock, $0.001 par value |
S - Sale | -290.231 | 1.471.725 | -16,47 | 57,75 | -16.760.840 | 84.992.119 | |
| 2019-03-11 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock, $0.001 par value |
S - Sale | -68.218 | 1.761.956 | -3,73 | 55,01 | -3.752.672 | 96.925.200 | |
| 2019-02-19 |
|
4 | AVDR |
AVEDRO INC
Series CC Convertible Preferred Stock |
C - Conversion | -383.746 | 0 | -100,00 | ||||
| 2019-02-19 |
|
4 | AVDR |
AVEDRO INC
Series BB Convertible Preferred Stock |
C - Conversion | -333.178 | 0 | -100,00 | ||||
| 2019-02-19 |
|
4 | AVDR |
AVEDRO INC
Series AA Convertible Preferred Stock |
C - Conversion | -3.370.786 | 0 | -100,00 | ||||
| 2019-02-19 |
|
4 | AVDR |
AVEDRO INC
Common Stock |
C - Conversion | 383.746 | 4.240.128 | 9,95 | ||||
| 2019-02-19 |
|
4 | AVDR |
AVEDRO INC
Common Stock |
C - Conversion | 333.178 | 3.856.382 | 9,46 | ||||
| 2019-02-19 |
|
4 | AVDR |
AVEDRO INC
Common Stock |
C - Conversion | 3.370.786 | 3.523.204 | 2.211,54 | ||||
| 2019-02-13 | 3 | AVDR |
AVEDRO INC
Common Stock |
304.836 | ||||||||
| 2019-02-13 | 3 | AVDR |
AVEDRO INC
Common Stock |
304.836 | ||||||||
| 2019-02-13 | 3 | AVDR |
AVEDRO INC
Common Stock |
304.836 | ||||||||
| 2019-02-13 | 3 | AVDR |
AVEDRO INC
Common Stock |
304.836 | ||||||||
| 2019-02-13 | 3 | AVDR |
AVEDRO INC
Common Stock |
304.836 | ||||||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series E Preferred Stock |
C - Conversion | -85.295 | 0 | -100,00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series E Preferred Stock |
C - Conversion | -266.437 | 0 | -100,00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series D Preferred Stock |
C - Conversion | -234.601 | 0 | -100,00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series D Preferred Stock |
C - Conversion | -1.012.282 | 0 | -100,00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series C Preferred Stock |
C - Conversion | -528.510 | 0 | -100,00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series C Preferred Stock |
C - Conversion | -2.280.479 | 0 | -100,00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series B Preferred Stock |
C - Conversion | -470.374 | 0 | -100,00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series B Preferred Stock |
C - Conversion | -2.029.626 | 0 | -100,00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series A-2 Preferred Stock |
C - Conversion | -992.437 | 0 | -100,00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series A-2 Preferred Stock |
C - Conversion | -4.282.288 | 0 | -100,00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series A-1 Preferred Stock |
C - Conversion | -94.075 | 0 | -100,00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Series A-1 Preferred Stock |
C - Conversion | -405.925 | 0 | -100,00 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
P - Purchase | 203.200 | 203.200 | 19,00 | 3.860.800 | 3.860.800 | ||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
P - Purchase | 50.561 | 2.455.853 | 2,10 | 19,00 | 960.659 | 46.661.207 | |
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 85.295 | 2.405.292 | 3,68 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 234.601 | 2.319.997 | 11,25 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 528.510 | 2.085.396 | 33,95 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 470.374 | 1.556.886 | 43,29 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 992.437 | 1.086.512 | 1.054,94 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 94.075 | 94.075 | |||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
P - Purchase | 157.939 | 10.434.976 | 1,54 | 19,00 | 3.000.841 | 198.264.544 | |
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 266.437 | 10.277.037 | 2,66 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 1.012.282 | 10.010.600 | 11,25 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 2.280.479 | 8.998.318 | 33,95 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 2.029.626 | 6.717.839 | 43,29 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 4.282.288 | 4.688.213 | 1.054,95 | ||||
| 2019-02-11 |
|
4 | ALEC |
Alector, Inc.
Common Stock |
C - Conversion | 405.925 | 405.925 | |||||
| 2019-01-23 |
|
4 | ALPN |
ALPINE IMMUNE SCIENCES, INC.
Warrants to Purchase Common Stock |
P - Purchase | 145.251 | 145.251 | |||||
| 2019-01-23 |
|
4 | ALPN |
ALPINE IMMUNE SCIENCES, INC.
Common Stock |
P - Purchase | 372.439 | 3.670.955 | 11,29 | 5,37 | 1.999.997 | 19.713.028 | |
| 2018-12-13 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock |
S - Sale | -614.772 | 0 | -100,00 | 37,60 | -23.115.427 | ||
| 2018-12-13 |
|
4 | THOR |
Synthorx, Inc.
Series C Preferred Stock |
C - Conversion | -6.333.206 | 0 | -100,00 | ||||
| 2018-12-13 |
|
4 | THOR |
Synthorx, Inc.
Common Stock |
C - Conversion | 3.952.719 | 5.316.355 | 289,87 | ||||
| 2018-12-13 |
|
4 | THOR |
Synthorx, Inc.
Common Stock |
P - Purchase | 1.363.636 | 1.363.636 | 11,00 | 14.999.996 | 14.999.996 | ||
| 2018-10-25 |
|
4 | LOGC |
LogicBio Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -4.352.775 | 0 | -100,00 | ||||
| 2018-10-25 |
|
4 | LOGC |
LogicBio Therapeutics, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -3.046.943 | 2.279.023 | -57,21 | ||||
| 2018-10-25 |
|
4 | LOGC |
LogicBio Therapeutics, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -2.678.571 | 0 | -100,00 | ||||
| 2018-10-25 |
|
4 | LOGC |
LogicBio Therapeutics, Inc.
Common Stock |
P - Purchase | 700.000 | 6.466.783 | 12,14 | 10,00 | 7.000.000 | 64.667.830 | |
| 2018-10-25 |
|
4 | LOGC |
LogicBio Therapeutics, Inc.
Common Stock |
P - Purchase | 490.000 | 5.766.783 | 9,29 | 10,00 | 4.900.000 | 57.667.830 | |
| 2018-10-25 |
|
4 | LOGC |
LogicBio Therapeutics, Inc.
Common Stock |
C - Conversion | 2.279.023 | 5.276.783 | 76,02 | ||||
| 2018-10-25 |
|
4 | LOGC |
LogicBio Therapeutics, Inc.
Common Stock |
C - Conversion | 2.997.760 | 2.997.760 | |||||
| 2018-10-19 |
|
4 | SIBN |
SI-BONE, Inc.
Series 7 Preferred Stock |
C - Conversion | -179.404 | 0 | -100,00 | ||||
| 2018-10-19 |
|
4 | SIBN |
SI-BONE, Inc.
Series 6 Preferred Stock |
C - Conversion | -572.326 | 0 | -100,00 | ||||
| 2018-10-19 |
|
4 | SIBN |
SI-BONE, Inc.
Common Stock |
P - Purchase | 200.000 | 985.368 | 25,47 | 15,00 | 3.000.000 | 14.780.520 | |
| 2018-10-19 |
|
4 | SIBN |
SI-BONE, Inc.
Common Stock |
C - Conversion | 179.404 | 785.368 | 29,61 | ||||
| 2018-10-19 |
|
4 | SIBN |
SI-BONE, Inc.
Common Stock |
C - Conversion | 605.964 | 605.964 | |||||
| 2018-10-11 |
|
4 | GH |
Guardant Health, Inc.
SERIES E PREFERRED STOCK |
C - Conversion | -8.972 | 0 | -100,00 | ||||
| 2018-10-11 |
|
4 | GH |
Guardant Health, Inc.
SERIES D PREFERRED STOCK |
C - Conversion | -1.525.492 | 0 | -100,00 | ||||
| 2018-10-11 |
|
4 | GH |
Guardant Health, Inc.
Common Stock |
C - Conversion | 8.972 | 8.972 | |||||
| 2018-10-11 |
|
4 | GH |
Guardant Health, Inc.
Common Stock |
C - Conversion | 1.525.492 | 1.525.492 | |||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Series C Convertible Preferred Stock |
C - Conversion | -167.537 | 0 | -100,00 | ||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Series B-3 Convertible Preferred Stock |
C - Conversion | -544.047 | 0 | -100,00 | ||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Series B-2 Convertible Preferred Stock |
C - Conversion | -260.617 | 0 | -100,00 | ||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Series B-1 Convertible Preferred Stock |
C - Conversion | -312.741 | 0 | -100,00 | ||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Series A Convertible Preferred Stock |
C - Conversion | -1.070.771 | 0 | -100,00 | ||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Common Stock |
P - Purchase | 250.000 | 2.605.713 | 10,61 | 17,00 | 4.250.000 | 44.297.121 | |
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Common Stock |
C - Conversion | 167.537 | 2.355.713 | 7,66 | ||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Common Stock |
C - Conversion | 544.047 | 2.188.176 | 33,09 | ||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Common Stock |
C - Conversion | 260.617 | 1.644.129 | 18,84 | ||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Common Stock |
C - Conversion | 312.741 | 1.383.512 | 29,21 | ||||
| 2018-09-20 |
|
4 | PRNB |
Principia Biopharma Inc.
Common Stock |
C - Conversion | 1.070.771 | 1.070.771 | |||||
| 2018-09-19 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Warrant (right to buy) |
A - Award | 434.008 | 434.008 | |||||
| 2018-09-19 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Warrant (right to buy) |
A - Award | 765.992 | 765.992 | |||||
| 2018-09-07 |
|
4 | STDY |
SteadyMed Ltd.
Warrants to Purchase Ordinary Shares |
S - Sale | 0 | ||||||
| 2018-09-07 |
|
4 | STDY |
SteadyMed Ltd.
Warrants to Purchase Ordinary Shares |
S - Sale | -348.500 | 0 | -100,00 | ||||
| 2018-09-07 |
|
4 | STDY |
SteadyMed Ltd.
Warrants to Purchase Ordinary Shares |
S - Sale | -348.500 | 0 | -100,00 | ||||
| 2018-09-07 |
|
4 | STDY |
SteadyMed Ltd.
Warrants to Purchase Ordinary Shares |
S - Sale | -1.536.098 | 0 | -100,00 | ||||
| 2018-09-07 |
|
4 | STDY |
SteadyMed Ltd.
Warrants to Purchase Ordinary Shares |
P - Purchase | 55.000 | 348.500 | 18,74 | 3,85 | 211.750 | 1.341.725 | |
| 2018-09-07 |
|
4 | STDY |
SteadyMed Ltd.
Warrants to Purchase Ordinary Shares |
P - Purchase | 55.000 | 348.500 | 18,74 | 3,85 | 211.750 | 1.341.725 | |
| 2018-09-07 |
|
4 | STDY |
SteadyMed Ltd.
Ordinary Shares, nominal value NIS 0.01 per share |
S - Sale | -2.123.098 | 0 | -100,00 | 4,46 | -9.469.017 | ||
| 2018-09-07 |
|
4 | STDY |
SteadyMed Ltd.
Ordinary Shares, nominal value NIS 0.01 per share |
S - Sale | -2.123.098 | 0 | -100,00 | 4,46 | -9.469.017 | ||
| 2018-08-21 |
|
4/A | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -736 | 73.819 | -0,99 | 9,93 | -7.308 | 733.023 | |
| 2018-08-21 |
|
4/A | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -77.314 | 7.751.662 | -0,99 | 9,93 | -767.728 | 76.974.004 | |
| 2018-08-21 |
|
4/A | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -198 | 74.555 | -0,26 | 9,94 | -1.968 | 741.077 | |
| 2018-08-21 |
|
4/A | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -20.777 | 7.828.976 | -0,26 | 9,94 | -206.523 | 77.820.021 | |
| 2018-08-21 |
|
4/A | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -820 | 74.753 | -1,09 | 9,98 | -8.184 | 746.035 | |
| 2018-08-21 |
|
4/A | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -86.103 | 7.849.753 | -1,08 | 9,98 | -859.308 | 78.340.535 | |
| 2018-08-21 |
|
4/A | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -153.921 | 68.898 | -69,08 | 9,98 | -1.536.132 | 687.602 | |
| 2018-08-21 |
|
4/A | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -153.921 | 7.234.976 | -2,08 | 9,98 | -1.536.132 | 72.205.060 | |
| 2018-08-21 |
|
4/A | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -3.455 | 70.364 | -4,68 | 9,94 | -34.343 | 699.418 | |
| 2018-08-21 |
|
4/A | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -362.765 | 7.388.897 | -4,68 | 9,94 | -3.605.884 | 73.445.636 | |
| 2018-08-20 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -1.466 | 69.617 | -2,06 | 9,98 | -14.631 | 694.778 | |
| 2018-08-20 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -153.921 | 7.310.457 | -2,06 | 9,98 | -1.536.132 | 72.958.361 | |
| 2018-08-20 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -3.455 | 71.083 | -4,64 | 9,94 | -34.343 | 706.565 | |
| 2018-08-20 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -362.765 | 7.464.378 | -4,63 | 9,94 | -3.605.884 | 74.195.917 | |
| 2018-08-15 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -736 | 74.538 | -0,98 | 9,93 | -7.308 | 740.162 | |
| 2018-08-15 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -77.314 | 7.827.143 | -0,98 | 9,93 | -767.728 | 77.723.530 | |
| 2018-08-15 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -198 | 75.274 | -0,26 | 9,94 | -1.968 | 748.224 | |
| 2018-08-15 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -20.777 | 7.904.457 | -0,26 | 9,94 | -206.523 | 78.570.303 | |
| 2018-08-15 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -820 | 75.472 | -1,07 | 9,98 | -8.184 | 753.211 | |
| 2018-08-15 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -86.103 | 7.925.234 | -1,07 | 9,98 | -859.308 | 79.093.835 | |
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -6.460 | 75.573 | -7,87 | 9,96 | -64.342 | 752.707 | |
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -678.333 | 7.935.856 | -7,87 | 9,96 | -6.756.197 | 79.041.126 | |
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Stock Option (right to buy) |
M - Exercise | -431 | 0 | -100,00 | ||||
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Stock Option (right to buy) |
M - Exercise | -45.203 | 0 | -100,00 | ||||
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Stock Option (right to buy) |
M - Exercise | -184 | 0 | -100,00 | ||||
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Stock Option (right to buy) |
M - Exercise | -19.372 | 0 | -100,00 | ||||
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -249 | 82.033 | -0,30 | 9,86 | -2.455 | 808.845 | |
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -26.139 | 8.614.189 | -0,30 | 9,86 | -257.731 | 84.935.904 | |
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -615 | 82.282 | -0,74 | 9,91 | -6.095 | 815.415 | |
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -64.575 | 8.640.328 | -0,74 | 9,91 | -639.938 | 85.625.650 | |
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
M - Exercise | 431 | 82.897 | 0,52 | 5,00 | 2.155 | 414.485 | |
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
M - Exercise | 45.203 | 8.704.903 | 0,52 | 5,00 | 226.015 | 43.524.515 | |
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
M - Exercise | 184 | 82.466 | 0,22 | 5,00 | 920 | 412.330 | |
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
M - Exercise | 19.372 | 8.659.700 | 0,22 | 5,00 | 96.860 | 43.298.500 | |
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -1.036 | 82.282 | -1,24 | 9,95 | -10.308 | 818.706 | |
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -108.729 | 8.640.328 | -1,24 | 9,95 | -1.081.854 | 85.971.264 | |
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -4.553 | 83.318 | -5,18 | 10,00 | -45.530 | 833.180 | |
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -478.107 | 8.749.057 | -5,18 | 10,00 | -4.781.070 | 87.490.570 | |
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Restricted Stock Unit |
M - Exercise | -249 | 0 | -100,00 | ||||
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Restricted Stock Unit |
M - Exercise | -26.139 | 0 | -100,00 | ||||
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
M - Exercise | 249 | 87.871 | 0,28 | ||||
| 2018-08-10 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
M - Exercise | 26.139 | 9.227.164 | 0,28 | ||||
| 2018-08-07 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -478 | 87.622 | -0,54 | 10,01 | -4.785 | 877.096 | |
| 2018-08-07 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -50.149 | 9.201.025 | -0,54 | 10,01 | -501.991 | 92.102.260 | |
| 2018-08-07 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -1.125 | 88.100 | -1,26 | 11,71 | -13.174 | 1.031.651 | |
| 2018-08-07 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock |
S - Sale | -118.168 | 9.251.174 | -1,26 | 11,71 | -1.383.747 | 108.331.248 | |
| 2018-07-24 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Series F Preferred Stock |
C - Conversion | -3.500.000 | 0 | -100,00 | ||||
| 2018-07-24 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Series F Preferred Stock |
C - Conversion | -3.500.000 | 0 | -100,00 | ||||
| 2018-07-24 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
P - Purchase | 100.000 | 417.921 | 31,45 | 15,00 | 1.500.000 | 6.268.815 | |
| 2018-07-24 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
P - Purchase | 100.000 | 417.921 | 31,45 | 15,00 | 1.500.000 | 6.268.815 | |
| 2018-07-24 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
C - Conversion | 317.921 | 317.921 | |||||
| 2018-07-24 |
|
4 | CNST |
CONSTELLATION PHARMACEUTICALS INC
Common Stock |
C - Conversion | 317.921 | 317.921 | |||||
| 2018-07-02 |
|
4 | ARPO |
Aerpio Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 777.500 | 5.193.946 | 17,60 | 3,85 | 2.993.375 | 19.996.692 | |
| 2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -4.255.319 | 0 | -100,00 | ||||
| 2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -14.292.958 | 0 | -100,00 | ||||
| 2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -17.117.085 | 0 | -100,00 | ||||
| 2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -6.207.674 | 0 | -100,00 | ||||
| 2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
P - Purchase | 368.421 | 10.889.280 | 3,50 | 19,00 | 6.999.999 | 206.896.320 | |
| 2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
C - Conversion | 1.069.175 | 10.520.859 | 11,31 | ||||
| 2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
C - Conversion | 3.591.194 | 9.451.684 | 61,28 | ||||
| 2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
C - Conversion | 4.300.774 | 5.860.490 | 275,74 | ||||
| 2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
C - Conversion | 1.559.716 | 1.559.716 | |||||
| 2018-06-22 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Common Stock |
U - Other | -409.547 | 409.547 | -50,00 | 50,00 | -20.477.350 | 20.477.350 | |
| 2018-06-22 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Common Stock |
U - Other | -3.709.356 | 3.709.356 | -50,00 | 50,00 | -185.467.800 | 185.467.800 | |
| 2018-06-06 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
American Depositary Shares representing Ordinary Shares |
S - Sale | -1.600 | 4.901.310 | -0,03 | 13,49 | -21.584 | 66.118.672 | |
| 2018-06-06 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
American Depositary Shares representing Ordinary Shares |
S - Sale | -17.100 | 4.902.910 | -0,35 | 13,57 | -232.047 | 66.532.489 | |
| 2018-06-01 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
American Depositary Shares representing Ordinary Shares |
S - Sale | -50.000 | 4.920.010 | -1,01 | 13,49 | -674.500 | 66.370.935 | |
| 2018-06-01 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
American Depositary Shares representing Ordinary Shares |
S - Sale | -121.000 | 4.970.010 | -2,38 | 13,52 | -1.635.920 | 67.194.535 | |
| 2018-05-24 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -1.600 | 2.750.079 | -0,06 | 30,96 | -49.536 | 85.142.446 | |
| 2018-05-24 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -17.980 | 2.751.679 | -0,65 | 30,38 | -546.232 | 83.596.008 | |
| 2018-05-21 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -62.500 | 2.769.659 | -2,21 | 31,01 | -1.938.125 | 85.887.126 | |
| 2018-05-21 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -69.136 | 2.832.159 | -2,38 | 30,77 | -2.127.315 | 87.145.532 | |
| 2018-05-16 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
American Depositary Shares representing Ordinary Shares |
S - Sale | -10.300 | 5.091.010 | -0,20 | 13,50 | -139.050 | 68.728.635 | |
| 2018-05-09 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Series F Convertible Preferred Stock |
C - Conversion | -3.649.635 | 0 | -100,00 | ||||
| 2018-05-09 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Series E Convertible Preferred Stock |
C - Conversion | -9.160.305 | 0 | -100,00 | ||||
| 2018-05-09 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock |
P - Purchase | 312.500 | 2.444.221 | 14,66 | 16,00 | 5.000.000 | 39.107.536 | |
| 2018-05-09 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock |
C - Conversion | 548.817 | 2.131.721 | 34,67 | ||||
| 2018-05-09 |
|
4 | INSP |
Inspire Medical Systems, Inc.
Common Stock |
C - Conversion | 1.582.904 | 1.582.904 | |||||
| 2018-05-02 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -10.400 | 38.870 | -21,11 | 6,35 | -66.040 | 246.824 | |
| 2018-05-02 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -989.600 | 4.511.130 | -17,99 | 6,35 | -6.283.960 | 28.645.676 | |
| 2018-03-29 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
American Depositary Shares representing Ordinary Shares |
S - Sale | -31.983 | 5.101.310 | -0,62 | 11,53 | -368.764 | 58.818.104 | |
| 2018-03-29 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
American Depositary Shares representing Ordinary Shares |
S - Sale | -1.016.084 | 5.133.293 | -16,52 | 11,50 | -11.684.966 | 59.032.870 | |
| 2018-03-14 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 588.235 | 5.967.584 | 10,94 | 8,50 | 4.999.998 | 50.724.464 | |
| 2018-03-12 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -16.937 | 3.539.997 | -0,48 | 34,92 | -591.440 | 123.616.695 | |
| 2018-03-12 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -1.066 | 3.556.934 | -0,03 | 36,04 | -38.419 | 128.191.901 | |
| 2018-03-12 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -11.305 | 3.558.000 | -0,32 | 36,44 | -411.954 | 129.653.520 | |
| 2018-03-12 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -47.395 | 3.569.305 | -1,31 | 35,86 | -1.699.585 | 127.995.277 | |
| 2018-03-12 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -21.300 | 3.616.700 | -0,59 | 34,67 | -738.471 | 125.390.989 | |
| 2018-03-12 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -58.428 | 3.638.000 | -1,58 | 34,06 | -1.990.058 | 123.910.280 | |
| 2018-03-06 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -11.372 | 3.696.428 | -0,31 | 33,03 | -375.617 | 122.093.017 | |
| 2018-03-06 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -200 | 3.707.800 | -0,01 | 36,06 | -7.212 | 133.703.268 | |
| 2018-03-06 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -35.558 | 3.708.000 | -0,95 | 36,33 | -1.291.822 | 134.711.640 | |
| 2018-03-06 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -386.080 | 3.743.558 | -9,35 | 35,06 | -13.535.965 | 131.249.143 | |
| 2018-03-06 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -445 | 0 | -100,00 | 32,06 | -14.267 | ||
| 2018-03-06 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -46.676 | 0 | -100,00 | 32,06 | -1.496.433 | ||
| 2018-03-06 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -192 | 445 | -30,14 | 30,77 | -5.908 | 13.693 | |
| 2018-03-06 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -20.114 | 46.676 | -30,12 | 30,77 | -618.908 | 1.436.221 | |
| 2018-03-06 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -886 | 637 | -58,17 | 30,01 | -26.589 | 19.116 | |
| 2018-03-06 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -93.008 | 66.790 | -58,20 | 30,01 | -2.791.170 | 2.004.368 | |
| 2018-03-06 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -768 | 1.523 | -33,52 | 33,06 | -25.390 | 50.350 | |
| 2018-03-06 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -80.516 | 159.798 | -33,50 | 33,06 | -2.661.859 | 5.282.922 | |
| 2018-03-06 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -1.220 | 2.291 | -34,75 | 32,05 | -39.101 | 73.427 | |
| 2018-03-06 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -128.092 | 240.314 | -34,77 | 32,05 | -4.105.349 | 7.702.064 | |
| 2018-03-06 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -1.851 | 3.511 | -34,52 | 32,80 | -60.713 | 115.161 | |
| 2018-03-06 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -194.433 | 368.406 | -34,55 | 32,80 | -6.377.402 | 12.083.717 | |
| 2018-03-06 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -2.533 | 5.362 | -32,08 | 31,92 | -80.853 | 171.155 | |
| 2018-03-06 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -265.766 | 562.839 | -32,07 | 31,92 | -8.483.251 | 17.965.821 | |
| 2018-02-23 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Convertible Note |
D - Sale to Issuer | 809.614 | 0 | -100,00 | 34,80 | 28.174.567 | ||
| 2018-02-23 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Convertible Note |
D - Sale to Issuer | 1.428.553 | 0 | -100,00 | 34,80 | 49.713.644 | ||
| 2018-02-23 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Convertible Note |
D - Sale to Issuer | 18.810.000 | 0 | -100,00 | 46,56 | 875.793.600 | ||
| 2018-02-23 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Convertible Note |
D - Sale to Issuer | 33.190.000 | 0 | -100,00 | 46,56 | 1.545.326.400 | ||
| 2018-02-23 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
P - Purchase | 342.132 | 3.316.128 | 11,50 | 7,20 | 2.463.350 | 23.876.122 | |
| 2018-02-23 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
P - Purchase | 603.687 | 5.890.884 | 11,42 | 7,20 | 4.346.546 | 42.414.365 | |
| 2018-02-23 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
A - Award | 2.905.396 | 2.973.996 | 4.235,27 | 7,20 | 20.918.851 | 21.412.771 | |
| 2018-02-23 |
|
4 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
A - Award | 5.126.534 | 5.287.197 | 3.190,86 | 7,20 | 36.911.045 | 38.067.818 | |
| 2018-02-15 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -17 | 0 | -100,00 | ||||
| 2018-02-15 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -1.765 | 0 | -100,00 | ||||
| 2018-02-15 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -58 | 0 | -100,00 | ||||
| 2018-02-15 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -6.057 | 0 | -100,00 | ||||
| 2018-02-15 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -75 | 49.270 | -0,15 | 8,98 | -674 | 442.445 | |
| 2018-02-15 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -7.822 | 5.500.730 | -0,14 | 8,98 | -70.242 | 49.396.555 | |
| 2018-02-15 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 17 | 49.345 | 0,03 | 5,08 | 86 | 250.673 | |
| 2018-02-15 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 1.765 | 5.508.552 | 0,03 | 5,08 | 8.966 | 27.983.444 | |
| 2018-02-15 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 58 | 49.328 | 0,12 | 4,68 | 271 | 230.855 | |
| 2018-02-15 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 6.057 | 5.506.787 | 0,11 | 4,68 | 28.347 | 25.771.763 | |
| 2018-02-12 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 25.000 | 3.447.840 | 0,73 | 12,93 | 323.250 | 44.580.571 | |
| 2018-02-06 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 37.840 | 3.422.840 | 1,12 | 14,73 | 557.383 | 50.418.433 | |
| 2018-02-02 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 22.840 | 3.385.000 | 0,68 | 14,99 | 342.372 | 50.741.150 | |
| 2018-02-02 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 339.400 | 3.362.160 | 11,23 | 15,00 | 5.091.000 | 50.432.400 | |
| 2018-01-30 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 50.000 | 3.022.760 | 1,68 | 14,99 | 749.500 | 45.311.172 | |
| 2018-01-30 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 22.760 | 2.972.760 | 0,77 | 14,93 | 339.807 | 44.383.307 | |
| 2018-01-30 |
|
4 | SYBX |
SYNLOGIC, INC.
Common Stock |
A - Award | 715.000 | 2.029.996 | 54,37 | 9,75 | 6.971.250 | 19.792.461 | |
| 2018-01-30 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Series C-1 Convertible Preferred Stock |
C - Conversion | -31.315 | 0 | -100,00 | ||||
| 2018-01-30 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -45.961 | 0 | -100,00 | ||||
| 2018-01-30 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Series B-1 Convertible Preferred Stock |
C - Conversion | -332.271 | 0 | -100,00 | ||||
| 2018-01-30 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Series C-1 Convertible Preferred Stock |
C - Conversion | -283.627 | 0 | -100,00 | ||||
| 2018-01-30 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -415.869 | 0 | -100,00 | ||||
| 2018-01-30 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -1.226.156 | 0 | -100,00 | ||||
| 2018-01-30 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -1.783.704 | 0 | -100,00 | ||||
| 2018-01-30 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Common Stock |
C - Conversion | 409.547 | 409.547 | |||||
| 2018-01-30 |
|
4 | ARMO |
ARMO BioSciences, Inc.
Common Stock |
C - Conversion | 3.709.356 | 3.709.356 | |||||
| 2018-01-30 |
|
4 | TORC |
resTORbio, Inc.
Series B Preferred Stock |
C - Conversion | -1.871.569 | 0 | -100,00 | ||||
| 2018-01-30 |
|
4 | TORC |
resTORbio, Inc.
Series A Preferred Stock |
C - Conversion | -2.425.482 | 0 | -100,00 | ||||
| 2018-01-30 |
|
4 | TORC |
resTORbio, Inc.
Common Stock |
P - Purchase | 533.333 | 4.830.387 | 12,41 | 15,00 | 7.999.995 | 72.455.805 | |
| 2018-01-30 |
|
4 | TORC |
resTORbio, Inc.
Common Stock |
C - Conversion | 1.871.569 | 4.297.054 | 77,16 | ||||
| 2018-01-30 |
|
4 | TORC |
resTORbio, Inc.
Common Stock |
C - Conversion | 2.425.485 | 2.425.485 | |||||
| 2018-01-24 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 64.637 | 2.950.000 | 2,24 | 14,91 | 963.738 | 43.984.500 | |
| 2018-01-24 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 4.363 | 2.885.363 | 0,15 | 14,99 | 65.401 | 43.251.591 | |
| 2018-01-24 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 75.000 | 2.881.000 | 2,67 | 14,98 | 1.123.500 | 43.157.380 | |
| 2018-01-24 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 74.931 | 2.806.000 | 2,74 | 14,95 | 1.120.218 | 41.949.700 | |
| 2018-01-24 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 38.354 | 2.731.069 | 1,42 | 14,50 | 556.133 | 39.600.500 | |
| 2018-01-19 | 3 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
4.679.161 | ||||||||
| 2018-01-19 | 3 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
3.574.391 | ||||||||
| 2018-01-19 | 3 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
4.679.161 | ||||||||
| 2018-01-19 | 3 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
3.574.391 | ||||||||
| 2018-01-19 | 3 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
4.679.161 | ||||||||
| 2018-01-19 | 3 | XTNT |
Xtant Medical Holdings, Inc.
Common Stock |
3.574.391 | ||||||||
| 2018-01-12 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 28.446 | 2.692.715 | 1,07 | 15,40 | 438.068 | 41.467.811 | |
| 2018-01-12 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 41.700 | 2.664.269 | 1,59 | 13,65 | 569.205 | 36.367.272 | |
| 2018-01-12 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 170.338 | 2.622.569 | 6,95 | 12,83 | 2.185.437 | 33.647.560 | |
| 2018-01-12 | 3 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
4.904.462 | ||||||||
| 2018-01-12 | 3 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
4.904.462 | ||||||||
| 2018-01-12 | 3 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
4.904.462 | ||||||||
| 2018-01-12 | 3 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
4.904.462 | ||||||||
| 2018-01-04 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -16.128 | 49.270 | -24,66 | 7,35 | -118.541 | 362.134 | |
| 2018-01-04 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -1.693.492 | 5.500.730 | -23,54 | 7,35 | -12.447.166 | 40.430.366 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -47 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -4.971 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -99 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -10.447 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -97 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -97 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -10.216 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -142 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -14.858 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -97 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -10.182 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -92 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -9.642 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -77 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -8.097 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -189 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -19.811 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -10.180 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -83 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -8.717 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -63 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -6.654 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -50 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -5.227 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -259 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | -27.241 | 0 | -100,00 | ||||
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -1.392 | 65.398 | -2,08 | 5,70 | -7.934 | 372.769 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
S - Sale | -146.243 | 7.194.222 | -1,99 | 5,70 | -833.585 | 41.007.065 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 47 | 66.790 | 0,07 | 5,64 | 265 | 376.696 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 4.971 | 7.340.465 | 0,07 | 5,64 | 28.036 | 41.400.223 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 99 | 66.743 | 0,15 | 2,32 | 230 | 154.844 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 10.447 | 7.335.494 | 0,14 | 2,32 | 24.237 | 17.018.346 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 97 | 66.644 | 0,15 | 2,01 | 195 | 133.954 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 10.216 | 7.325.047 | 0,14 | 2,01 | 20.534 | 14.723.344 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 142 | 66.547 | 0,21 | 2,01 | 285 | 133.759 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 14.858 | 7.314.831 | 0,20 | 2,01 | 29.865 | 14.702.810 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 97 | 66.405 | 0,15 | 1,64 | 159 | 108.904 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 10.182 | 7.299.973 | 0,14 | 1,64 | 16.698 | 11.971.956 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 92 | 66.308 | 0,14 | 1,73 | 159 | 114.713 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 9.642 | 7.289.791 | 0,13 | 1,73 | 16.681 | 12.611.338 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 77 | 66.216 | 0,12 | 2,05 | 158 | 135.743 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 8.097 | 7.280.149 | 0,11 | 2,05 | 16.599 | 14.924.305 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 189 | 66.139 | 0,29 | 1,59 | 301 | 105.161 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 19.811 | 7.272.052 | 0,27 | 1,59 | 31.499 | 11.562.563 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 97 | 65.950 | 0,15 | 1,62 | 157 | 106.839 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 10.180 | 7.252.241 | 0,14 | 1,62 | 16.492 | 11.748.630 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 83 | 65.853 | 0,13 | 1,94 | 161 | 127.755 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 8.717 | 7.242.061 | 0,12 | 1,94 | 16.911 | 14.049.598 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 63 | 65.770 | 0,10 | 2,62 | 165 | 172.317 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 6.654 | 7.233.344 | 0,09 | 2,62 | 17.433 | 18.951.361 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 50 | 65.707 | 0,08 | 3,00 | 150 | 197.121 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 5.227 | 7.226.690 | 0,07 | 3,00 | 15.681 | 21.680.070 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 259 | 65.657 | 0,40 | 2,00 | 518 | 131.314 | |
| 2017-12-20 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 27.241 | 7.221.463 | 0,38 | 2,00 | 54.482 | 14.442.926 | |
| 2017-12-12 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
S - Sale | -250.000 | 941.000 | -20,99 | 82,50 | -20.625.000 | 77.632.500 | |
| 2017-11-27 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
S - Sale | -267.000 | 1.191.000 | -18,31 | 75,00 | -20.025.000 | 89.325.000 | |
| 2017-11-21 |
|
4 | SCPH |
scPharmaceuticals Inc.
Series B Preferred Stock |
C - Conversion | -18.500.000 | 0 | -100,00 | ||||
| 2017-11-21 |
|
4 | SCPH |
scPharmaceuticals Inc.
Common Stock |
P - Purchase | 833.333 | 3.409.865 | 32,34 | 14,00 | 11.666.662 | 47.738.110 | |
| 2017-11-21 |
|
4 | SCPH |
scPharmaceuticals Inc.
Common Stock |
C - Conversion | 2.576.532 | 2.576.532 | |||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -2.232.014 | 0 | -100,00 | ||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -229.412 | 0 | -100,00 | ||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -736.648 | 0 | -100,00 | ||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series A-2 Convertible Preferred Stock |
C - Conversion | -704.846 | 0 | -100,00 | ||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Series A-1 Convertible Preferred Stock |
C - Conversion | -66.667 | 0 | -100,00 | ||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 500.000 | 1.868.966 | 36,52 | 10,00 | 5.000.000 | 18.689.660 | |
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 653.974 | 1.368.966 | 91,47 | ||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 114.320 | 714.992 | 19,03 | ||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 328.909 | 600.672 | 121,03 | ||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 252.230 | 271.763 | 1.291,30 | ||||
| 2017-11-20 |
|
4 | ASNS |
Arsanis, Inc.
Common Stock |
C - Conversion | 19.533 | 19.533 | |||||
| 2017-11-20 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
S - Sale | -8.377 | 1.458.000 | -0,57 | 76,23 | -638.579 | 111.143.340 | |
| 2017-11-20 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
S - Sale | -71.598 | 1.466.377 | -4,66 | 75,37 | -5.396.341 | 110.520.834 | |
| 2017-11-20 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
S - Sale | -100.045 | 1.537.975 | -6,11 | 74,49 | -7.452.352 | 114.563.758 | |
| 2017-11-20 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
S - Sale | -43.300 | 1.638.020 | -2,58 | 73,48 | -3.181.684 | 120.361.710 | |
| 2017-11-20 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
S - Sale | -46.680 | 1.681.320 | -2,70 | 72,46 | -3.382.433 | 121.828.447 | |
| 2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Series A Convertible Preferred Stock |
C - Conversion | -2.546.295 | 0 | -100,00 | ||||
| 2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 355.000 | 2.901.295 | 13,94 | 17,00 | 6.035.000 | 49.322.015 | |
| 2017-10-10 |
|
4 | RYTM |
RHYTHM PHARMACEUTICALS, INC.
Common Stock |
C - Conversion | 2.546.295 | 2.546.295 | |||||
| 2017-10-05 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -1.899 | 0 | -100,00 | 0,68 | -1.291 | ||
| 2017-10-05 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -199.718 | 0 | -100,00 | 0,68 | -135.808 | ||
| 2017-10-02 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -888 | 1.899 | -31,86 | 0,74 | -657 | 1.405 | |
| 2017-10-02 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -93.246 | 199.718 | -31,83 | 0,74 | -69.002 | 147.791 | |
| 2017-10-02 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -3.592 | 2.787 | -56,31 | 0,72 | -2.586 | 2.007 | |
| 2017-10-02 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -376.950 | 292.964 | -56,27 | 0,72 | -271.404 | 210.934 | |
| 2017-09-29 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -672.000 | 4.129.638 | -14,00 | 28,25 | -18.984.000 | 116.662.274 | |
| 2017-09-28 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -498 | 6.379 | -7,24 | 0,92 | -458 | 5.869 | |
| 2017-09-28 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -52.301 | 669.914 | -7,24 | 0,92 | -48.117 | 616.321 | |
| 2017-09-28 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -706 | 6.877 | -9,31 | 1,03 | -727 | 7.083 | |
| 2017-09-28 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -74.096 | 722.215 | -9,30 | 1,03 | -76.319 | 743.881 | |
| 2017-09-11 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Stock Option (right to buy) |
X - Other | -5.000 | 0 | -100,00 | ||||
| 2017-09-11 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
S - Sale | -5.000 | 4.801.638 | -0,10 | 22,35 | -111.750 | 107.316.609 | |
| 2017-09-11 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
X - Other | 5.000 | 4.806.638 | 0,10 | 15,03 | 75.150 | 72.243.769 | |
| 2017-09-05 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -553 | 7.895 | -6,55 | 40,77 | -22.546 | 321.879 | |
| 2017-09-05 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -58.047 | 828.605 | -6,55 | 40,77 | -2.366.576 | 33.782.226 | |
| 2017-09-05 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -1.808 | 8.448 | -17,63 | 39,63 | -71.651 | 334.794 | |
| 2017-09-05 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -189.792 | 886.652 | -17,63 | 39,63 | -7.521.457 | 35.138.019 | |
| 2017-09-05 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -1.651 | 10.256 | -13,87 | 37,94 | -62.639 | 389.113 | |
| 2017-09-05 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -173.349 | 1.076.444 | -13,87 | 37,94 | -6.576.861 | 40.840.285 | |
| 2017-09-05 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -1.038 | 11.907 | -8,02 | 37,72 | -39.153 | 449.132 | |
| 2017-09-05 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -109.040 | 1.249.793 | -8,02 | 37,72 | -4.112.989 | 47.142.192 | |
| 2017-09-05 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -424 | 12.945 | -3,17 | 37,82 | -16.036 | 489.580 | |
| 2017-09-05 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -44.498 | 1.358.833 | -3,17 | 37,82 | -1.682.914 | 51.391.064 | |
| 2017-08-30 | 3 | SYBX |
SYNLOGIC, INC.
Common Stock |
2.629.992 | ||||||||
| 2017-08-30 | 3 | SYBX |
SYNLOGIC, INC.
Common Stock |
2.629.992 | ||||||||
| 2017-08-30 | 3 | SYBX |
SYNLOGIC, INC.
Common Stock |
2.629.992 | ||||||||
| 2017-08-30 | 3 | SYBX |
SYNLOGIC, INC.
Common Stock |
2.629.992 | ||||||||
| 2017-08-25 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -125 | 7.583 | -1,62 | 1,50 | -188 | 11.374 | |
| 2017-08-25 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -13.075 | 796.311 | -1,62 | 1,50 | -19.612 | 1.194.466 | |
| 2017-08-25 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -10 | 7.708 | -0,13 | 1,50 | -15 | 11.562 | |
| 2017-08-25 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -1.090 | 809.386 | -0,13 | 1,50 | -1.635 | 1.214.079 | |
| 2017-08-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -52 | 7.718 | -0,67 | 1,52 | -79 | 11.731 | |
| 2017-08-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -5.448 | 810.476 | -0,67 | 1,52 | -8.281 | 1.231.924 | |
| 2017-08-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -28 | 7.770 | -0,36 | 1,49 | -42 | 11.577 | |
| 2017-08-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -2.952 | 815.924 | -0,36 | 1,49 | -4.398 | 1.215.727 | |
| 2017-08-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -630 | 7.798 | -7,48 | 1,52 | -958 | 11.853 | |
| 2017-08-22 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -66.166 | 818.876 | -7,48 | 1,52 | -100.572 | 1.244.692 | |
| 2017-08-17 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -2.140 | 13.369 | -13,80 | 37,85 | -80.999 | 506.017 | |
| 2017-08-17 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -224.780 | 1.403.331 | -13,81 | 37,85 | -8.507.923 | 53.116.078 | |
| 2017-08-17 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -619 | 15.509 | -3,84 | 38,01 | -23.528 | 589.497 | |
| 2017-08-17 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -64.961 | 1.628.111 | -3,84 | 38,01 | -2.469.168 | 61.884.499 | |
| 2017-08-17 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -307 | 16.128 | -1,87 | 38,29 | -11.755 | 617.541 | |
| 2017-08-17 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -32.193 | 1.693.072 | -1,87 | 38,29 | -1.232.670 | 64.827.727 | |
| 2017-07-27 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Series C Preferred Stock |
C - Conversion | -10.707.985 | 0 | -100,00 | ||||
| 2017-07-27 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 319.333 | 2.375.279 | 15,53 | 15,00 | 4.789.995 | 35.629.185 | |
| 2017-07-27 |
|
4 | KALA |
Kala Pharmaceuticals, Inc.
Common Stock |
C - Conversion | 2.055.946 | 2.055.946 | |||||
| 2017-07-26 |
|
4 | ALPN |
ALPINE IMMUNE SCIENCES, INC.
Common Stock |
A - Award | 3.298.516 | 3.298.516 | |||||
| 2017-06-15 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Series N-3 Preferred Stock |
C - Conversion | -7.500 | 0 | -100,00 | ||||
| 2017-06-15 |
|
4 | CTIC |
CTI BIOPHARMA CORP
Common Stock |
C - Conversion | 5.000.000 | 5.000.000 | |||||
| 2017-04-27 |
|
4 | STDY |
SteadyMed Ltd.
Warrants to Purchase Ordinary Shares |
P - Purchase | 293.500 | 293.500 | 0,12 | 36.688 | 36.688 | ||
| 2017-04-27 |
|
4 | STDY |
SteadyMed Ltd.
Warrants to Purchase Ordinary Shares |
P - Purchase | 293.500 | 293.500 | 0,12 | 36.688 | 36.688 | ||
| 2017-04-27 |
|
4 | STDY |
SteadyMed Ltd.
Ordinary Shares, nominal value NIS 0.01 per share |
P - Purchase | 587.000 | 2.123.098 | 38,21 | 5,90 | 3.463.300 | 12.526.278 | |
| 2017-04-27 |
|
4 | STDY |
SteadyMed Ltd.
Ordinary Shares, nominal value NIS 0.01 per share |
P - Purchase | 587.000 | 2.123.098 | 38,21 | 5,90 | 3.463.300 | 12.526.278 | |
| 2017-03-28 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
American Depositary Shares representing Ordinary Shares |
P - Purchase | 1.190.476 | 6.149.377 | 24,01 | 4,20 | 4.999.999 | 25.827.383 | |
| 2017-03-17 |
|
4 | NONE |
Aerpio Pharmaceuticals, Inc.
Common Stock |
P - Purchase | 762.995 | 4.416.446 | 20,88 | 5,00 | 3.814.975 | 22.082.230 | |
| 2017-03-17 | 3 | NONE |
Aerpio Pharmaceuticals, Inc.
Common Stock |
7.306.902 | ||||||||
| 2017-03-17 | 3 | NONE |
Aerpio Pharmaceuticals, Inc.
Common Stock |
7.306.902 | ||||||||
| 2017-03-17 | 3 | NONE |
Aerpio Pharmaceuticals, Inc.
Common Stock |
7.306.902 | ||||||||
| 2017-03-17 | 3 | NONE |
Aerpio Pharmaceuticals, Inc.
Common Stock |
7.306.902 | ||||||||
| 2017-03-14 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -699 | 16.435 | -4,08 | 44,54 | -31.133 | 732.015 | |
| 2017-03-14 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -73.401 | 1.725.265 | -4,08 | 44,54 | -3.269.281 | 76.843.303 | |
| 2017-03-14 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -7 | 17.134 | -0,04 | 46,13 | -323 | 790.391 | |
| 2017-03-14 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -693 | 1.798.666 | -0,04 | 46,13 | -31.968 | 82.972.463 | |
| 2017-03-14 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -1.998 | 17.141 | -10,44 | 45,30 | -90.509 | 776.487 | |
| 2017-03-14 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -208.712 | 1.799.359 | -10,39 | 45,30 | -9.454.654 | 81.510.963 | |
| 2017-03-14 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -915 | 19.129 | -4,56 | 45,98 | -42.072 | 879.551 | |
| 2017-03-14 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -96.113 | 2.008.071 | -4,57 | 45,98 | -4.419.276 | 92.331.105 | |
| 2017-03-07 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -526 | 20.044 | -2,56 | 47,05 | -24.748 | 943.070 | |
| 2017-03-07 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -55.246 | 2.104.184 | -2,56 | 47,05 | -2.599.324 | 99.001.857 | |
| 2017-02-21 |
|
4 | AGLE |
Aeglea BioTherapeutics, Inc.
Common Stock |
P - Purchase | 7.000 | 1.469.524 | 0,48 | 5,36 | 37.520 | 7.876.649 | |
| 2017-02-21 |
|
4 | AGLE |
Aeglea BioTherapeutics, Inc.
Common Stock |
P - Purchase | 71.800 | 1.462.524 | 5,16 | 5,19 | 372.642 | 7.590.500 | |
| 2017-02-21 |
|
4 | AGLE |
Aeglea BioTherapeutics, Inc.
Common Stock |
P - Purchase | 30.500 | 1.390.724 | 2,24 | 5,04 | 153.720 | 7.009.249 | |
| 2017-01-20 |
|
4 | VRAY |
ViewRay, Inc.
Warrants to purchase common stock |
P - Purchase | 623 | 3.843 | 19,35 | 0,12 | 78 | 480 | |
| 2017-01-20 |
|
4 | VRAY |
ViewRay, Inc.
Warrants to purchase common stock |
P - Purchase | 65.491 | 403.692 | 19,36 | 0,12 | 8.186 | 50.462 | |
| 2017-01-20 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 3.118 | 89.225 | 3,62 | 3,00 | 9.354 | 267.675 | |
| 2017-01-20 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 327.459 | 9.369.342 | 3,62 | 3,00 | 982.377 | 28.108.026 | |
| 2016-12-30 | 3 | NBRV |
Nabriva Therapeutics AG
Common Shares |
559.754 | ||||||||
| 2016-12-30 | 3 | NBRV |
Nabriva Therapeutics AG
Common Shares |
616.126 | ||||||||
| 2016-12-30 | 3 | NBRV |
Nabriva Therapeutics AG
Common Shares |
559.754 | ||||||||
| 2016-12-30 | 3 | NBRV |
Nabriva Therapeutics AG
Common Shares |
616.126 | ||||||||
| 2016-12-30 | 3 | NBRV |
Nabriva Therapeutics AG
Common Shares |
559.754 | ||||||||
| 2016-12-30 | 3 | NBRV |
Nabriva Therapeutics AG
Common Shares |
616.126 | ||||||||
| 2016-12-30 | 3 | NBRV |
Nabriva Therapeutics AG
Common Shares |
559.754 | ||||||||
| 2016-12-30 | 3 | NBRV |
Nabriva Therapeutics AG
Common Shares |
616.126 | ||||||||
| 2016-12-01 |
|
4 | RBM |
RESPONSE BIOMEDICAL CORP
Common Stock |
J - Other | -2.149.902 | 0 | -100,00 | ||||
| 2016-12-01 |
|
4 | RBM |
RESPONSE BIOMEDICAL CORP
Common Stock |
J - Other | -34.291 | 0 | -100,00 | ||||
| 2016-12-01 |
|
4 | RBM |
RESPONSE BIOMEDICAL CORP
Common Stock |
J - Other | -3.604.266 | 0 | -100,00 | ||||
| 2016-09-23 |
|
4 | ROKA |
Roka BioScience, Inc.
Warrants |
P - Purchase | 53.909 | 53.909 | |||||
| 2016-09-23 |
|
4 | ROKA |
Roka BioScience, Inc.
Warrants |
P - Purchase | 5.660.377 | 5.660.377 | |||||
| 2016-09-23 |
|
4 | ROKA |
Roka BioScience, Inc.
Series A Convertible Preferred Stock |
P - Purchase | 38 | 38 | |||||
| 2016-09-23 |
|
4 | ROKA |
Roka BioScience, Inc.
Series A Convertible Preferred Stock |
P - Purchase | 3.962 | 3.962 | |||||
| 2016-08-24 |
|
4 | VRAY |
ViewRay, Inc.
Warrants to purchase common stock |
P - Purchase | 3.220 | 3.220 | 0,12 | 402 | 402 | ||
| 2016-08-24 |
|
4 | VRAY |
ViewRay, Inc.
Warrants to purchase common stock |
P - Purchase | 338.201 | 338.201 | 0,12 | 42.275 | 42.275 | ||
| 2016-08-24 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 10.736 | 86.107 | 14,24 | 2,95 | 31.671 | 254.016 | |
| 2016-08-24 |
|
4 | VRAY |
ViewRay, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 1.127.338 | 9.041.883 | 14,24 | 2,95 | 3.325.647 | 26.673.555 | |
| 2016-08-12 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
S - Sale | -447.857 | 1.728.000 | -20,58 | 26,96 | -12.074.225 | 46.586.880 | |
| 2016-08-12 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -133 | 20.570 | -0,64 | 33,72 | -4.485 | 693.620 | |
| 2016-08-12 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -13.967 | 2.159.430 | -0,64 | 33,72 | -470.967 | 72.815.980 | |
| 2016-08-12 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -1.518 | 20.703 | -6,83 | 33,63 | -51.050 | 696.242 | |
| 2016-08-12 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -159.382 | 2.173.397 | -6,83 | 33,63 | -5.360.017 | 73.091.341 | |
| 2016-08-12 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -1.113 | 22.221 | -4,77 | 33,77 | -37.586 | 750.403 | |
| 2016-08-12 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -116.825 | 2.332.779 | -4,77 | 33,77 | -3.945.180 | 78.777.947 | |
| 2016-08-12 | 3 | STDY |
SteadyMed Ltd.
Ordinary Shares |
4.608.294 | ||||||||
| 2016-08-12 | 3 | STDY |
SteadyMed Ltd.
Ordinary Shares |
4.608.294 | ||||||||
| 2016-08-12 | 3 | STDY |
SteadyMed Ltd.
Ordinary Shares |
4.608.294 | ||||||||
| 2016-08-12 | 3 | STDY |
SteadyMed Ltd.
Ordinary Shares |
4.608.294 | ||||||||
| 2016-08-12 | 3 | STDY |
SteadyMed Ltd.
Ordinary Shares |
4.608.294 | ||||||||
| 2016-08-12 | 3 | STDY |
SteadyMed Ltd.
Ordinary Shares |
4.608.294 | ||||||||
| 2016-08-12 | 3 | STDY |
SteadyMed Ltd.
Ordinary Shares |
4.608.294 | ||||||||
| 2016-08-12 | 3 | STDY |
SteadyMed Ltd.
Ordinary Shares |
4.608.294 | ||||||||
| 2016-08-12 | 3 | STDY |
SteadyMed Ltd.
Ordinary Shares |
4.608.294 | ||||||||
| 2016-08-12 | 3 | STDY |
SteadyMed Ltd.
Ordinary Shares |
4.608.294 | ||||||||
| 2016-08-12 | 3 | STDY |
SteadyMed Ltd.
Ordinary Shares |
4.608.294 | ||||||||
| 2016-08-12 | 3 | STDY |
SteadyMed Ltd.
Ordinary Shares |
4.608.294 | ||||||||
| 2016-08-05 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -4.010 | 23.334 | -14,67 | 30,59 | -122.666 | 713.787 | |
| 2016-08-05 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock, par value $0.01 per share |
S - Sale | -420.990 | 2.449.604 | -14,67 | 30,59 | -12.878.084 | 74.933.386 | |
| 2016-07-26 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -343.600 | 3.356.400 | -9,29 | 31,98 | -10.988.328 | 107.337.672 | |
| 2016-07-26 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -3.700.000 | 3.700.000 | -50,00 | 32,00 | -118.400.000 | 118.400.000 | |
| 2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Series C Preferred Stock |
C - Conversion | -332.766 | 0 | -100,00 | ||||
| 2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -1.071.992 | 0 | -100,00 | ||||
| 2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -2.511.441 | 0 | -100,00 | ||||
| 2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Series Seed Preferred Stock |
C - Conversion | -627.867 | 0 | -100,00 | ||||
| 2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
P - Purchase | 33.334 | 4.801.638 | 0,70 | 15,00 | 500.010 | 72.024.570 | |
| 2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
C - Conversion | 332.766 | 4.768.304 | 7,50 | ||||
| 2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
C - Conversion | 1.071.992 | 4.435.538 | 31,87 | ||||
| 2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
C - Conversion | 2.511.441 | 3.363.546 | 294,73 | ||||
| 2016-07-25 |
|
4 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
C - Conversion | 627.867 | 852.105 | 280,00 | ||||
| 2016-07-19 | 3 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
448.476 | ||||||||
| 2016-07-19 | 3 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
448.476 | ||||||||
| 2016-07-19 | 3 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
448.476 | ||||||||
| 2016-07-19 | 3 | BOLD |
Audentes Therapeutics, Inc.
Common Stock |
448.476 | ||||||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series E Convertible Preferred Stock |
C - Conversion | -456.870 | 0 | -100,00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series E Convertible Preferred Stock |
C - Conversion | -4.351 | 0 | -100,00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series D Convertible Preferred Stock |
C - Conversion | -77.697 | 0 | -100,00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series D Convertible Preferred Stock |
C - Conversion | -739 | 0 | -100,00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series C Convertible Preferred Stock |
C - Conversion | -380.986 | 0 | -100,00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series C Convertible Preferred Stock |
C - Conversion | -3.628 | 0 | -100,00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
P - Purchase | 544.811 | 1.825.415 | 42,54 | 14,00 | 7.627.354 | 25.555.810 | |
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
P - Purchase | 5.189 | 17.382 | 42,56 | 14,00 | 72.646 | 243.348 | |
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 1.166.884 | 1.280.604 | 1.026,10 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 11.111 | 12.193 | 1.026,89 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series E Convertible Preferred Stock |
C - Conversion | -456.870 | 0 | -100,00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series E Convertible Preferred Stock |
C - Conversion | -4.351 | 0 | -100,00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series D Convertible Preferred Stock |
C - Conversion | -77.697 | 0 | -100,00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series D Convertible Preferred Stock |
C - Conversion | -739 | 0 | -100,00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series C Convertible Preferred Stock |
C - Conversion | -380.986 | 0 | -100,00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Series C Convertible Preferred Stock |
C - Conversion | -3.628 | 0 | -100,00 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
P - Purchase | 544.811 | 1.825.415 | 42,54 | 14,00 | 7.627.354 | 25.555.810 | |
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
P - Purchase | 5.189 | 17.382 | 42,56 | 14,00 | 72.646 | 243.348 | |
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 1.166.884 | 1.280.604 | 1.026,10 | ||||
| 2016-06-29 |
|
4 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
C - Conversion | 11.111 | 12.193 | 1.026,89 | ||||
| 2016-06-27 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 900 | 5.379.349 | 0,02 | 12,99 | 11.691 | 69.877.744 | |
| 2016-06-27 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 100 | 5.378.449 | 0,00 | 12,92 | 1.292 | 69.489.561 | |
| 2016-06-21 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 26.083 | 5.378.349 | 0,49 | 12,87 | 335.688 | 69.219.352 | |
| 2016-06-21 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 12.300 | 5.352.266 | 0,23 | 12,48 | 153.504 | 66.796.280 | |
| 2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
115.884 | ||||||||
| 2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
228.522 | ||||||||
| 2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
115.884 | ||||||||
| 2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
228.522 | ||||||||
| 2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
115.884 | ||||||||
| 2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
228.522 | ||||||||
| 2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
115.884 | ||||||||
| 2016-06-21 | 3 | SELB |
SELECTA BIOSCIENCES INC
Common Stock |
228.522 | ||||||||
| 2016-06-20 |
|
4 | RBM |
RESPONSE BIOMEDICAL CORP
Common Stock |
P - Purchase | 331.225 | 2.149.902 | 18,21 | 0,56 | 185.486 | 1.203.945 | |
| 2016-06-20 |
|
4 | RBM |
RESPONSE BIOMEDICAL CORP
Common Stock |
P - Purchase | 5.294 | 34.291 | 18,26 | 0,56 | 2.965 | 19.203 | |
| 2016-06-20 |
|
4 | RBM |
RESPONSE BIOMEDICAL CORP
Common Stock |
P - Purchase | 556.339 | 3.604.266 | 18,25 | 0,56 | 311.550 | 2.018.389 | |
| 2016-06-16 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 5.000 | 5.339.966 | 0,09 | 12,04 | 60.200 | 64.293.191 | |
| 2016-06-16 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 5.000 | 5.334.966 | 0,09 | 11,94 | 59.700 | 63.699.494 | |
| 2016-06-16 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 10.000 | 5.329.966 | 0,19 | 12,71 | 127.100 | 67.743.868 | |
| 2016-06-13 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 20.000 | 5.319.966 | 0,38 | 12,98 | 259.600 | 69.053.159 | |
| 2016-06-13 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 30.000 | 5.299.966 | 0,57 | 12,95 | 388.500 | 68.634.560 | |
| 2016-05-25 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share |
P - Purchase | 518.400 | 29.753.404 | 1,77 | 10,48 | 5.432.832 | 311.815.674 | |
| 2016-05-25 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share |
P - Purchase | 1.191.600 | 29.235.004 | 4,25 | 10,40 | 12.392.640 | 304.044.042 | |
| 2016-05-25 |
|
4 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share |
P - Purchase | 2.400 | 28.043.404 | 0,01 | 10,04 | 24.096 | 281.555.776 | |
| 2016-05-24 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 4.716 | 5.269.966 | 0,09 | 13,09 | 61.732 | 68.983.855 | |
| 2016-05-20 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 61 | 5.265.250 | 0,00 | 12,75 | 778 | 67.131.938 | |
| 2016-05-20 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 2.539 | 5.265.189 | 0,05 | 12,11 | 30.747 | 63.761.439 | |
| 2016-05-20 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 4.200 | 5.262.650 | 0,08 | 11,55 | 48.510 | 60.783.608 | |
| 2016-05-13 |
|
4 | NTLA |
Intellia Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -873.475 | 0 | -100,00 | ||||
| 2016-05-13 |
|
4 | NTLA |
Intellia Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -2.857.143 | 0 | -100,00 | ||||
| 2016-05-13 |
|
4 | NTLA |
Intellia Therapeutics, Inc.
Common Stock |
P - Purchase | 58.534 | 2.662.180 | 2,25 | 18,00 | 1.053.612 | 47.919.240 | |
| 2016-05-13 |
|
4 | NTLA |
Intellia Therapeutics, Inc.
Common Stock |
P - Purchase | 191.466 | 2.603.646 | 7,94 | 18,00 | 3.446.388 | 46.865.628 | |
| 2016-05-13 |
|
4 | NTLA |
Intellia Therapeutics, Inc.
Common Stock |
C - Conversion | 564.780 | 2.412.180 | 30,57 | ||||
| 2016-05-13 |
|
4 | NTLA |
Intellia Therapeutics, Inc.
Common Stock |
C - Conversion | 1.847.400 | 1.847.400 | |||||
| 2016-04-19 | 3 | AGLE |
Aeglea BioTherapeutics, Inc.
Common Stock |
2.720.448 | ||||||||
| 2016-04-19 | 3 | AGLE |
Aeglea BioTherapeutics, Inc.
Common Stock |
2.720.448 | ||||||||
| 2016-04-19 | 3 | AGLE |
Aeglea BioTherapeutics, Inc.
Common Stock |
2.720.448 | ||||||||
| 2016-04-19 | 3 | AGLE |
Aeglea BioTherapeutics, Inc.
Common Stock |
2.720.448 | ||||||||
| 2016-03-30 | 3 | VRAY |
ViewRay, Inc.
Common Stock |
15.904.461 | ||||||||
| 2016-03-30 | 3 | VRAY |
ViewRay, Inc.
Common Stock |
8.065.287 | ||||||||
| 2016-03-30 | 3 | VRAY |
ViewRay, Inc.
Common Stock |
15.904.461 | ||||||||
| 2016-03-30 | 3 | VRAY |
ViewRay, Inc.
Common Stock |
8.065.287 | ||||||||
| 2016-03-30 | 3 | VRAY |
ViewRay, Inc.
Common Stock |
15.904.461 | ||||||||
| 2016-03-30 | 3 | VRAY |
ViewRay, Inc.
Common Stock |
8.065.287 | ||||||||
| 2016-03-30 | 3 | VRAY |
ViewRay, Inc.
Common Stock |
15.904.461 | ||||||||
| 2016-03-30 | 3 | VRAY |
ViewRay, Inc.
Common Stock |
8.065.287 | ||||||||
| 2016-03-29 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -713.776 | 0 | -100,00 | ||||
| 2016-03-29 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -3.994.674 | 0 | -100,00 | ||||
| 2016-03-29 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
P - Purchase | 550.000 | 5.258.450 | 11,68 | 15,00 | 8.250.000 | 78.876.750 | |
| 2016-03-29 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 713.776 | 4.708.450 | 17,87 | ||||
| 2016-03-29 |
|
4 | CRVS |
Corvus Pharmaceuticals, Inc.
Common Stock, $0.0001 par value |
C - Conversion | 3.994.674 | 3.994.674 | |||||
| 2016-01-04 | 3 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share |
53.449.304 | ||||||||
| 2016-01-04 | 3 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share |
30.673.708 | ||||||||
| 2016-01-04 | 3 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share |
53.449.304 | ||||||||
| 2016-01-04 | 3 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share |
30.673.708 | ||||||||
| 2016-01-04 | 3 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share |
53.449.304 | ||||||||
| 2016-01-04 | 3 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share |
30.673.708 | ||||||||
| 2016-01-04 | 3 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share |
53.449.304 | ||||||||
| 2016-01-04 | 3 | ADAP |
Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of GBP0.001 per share |
30.673.708 | ||||||||
| 2015-12-23 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -52.058 | 7.400.000 | -0,70 | 27,54 | -1.433.677 | 203.796.000 | |
| 2015-12-23 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -47.942 | 7.452.058 | -0,64 | 26,78 | -1.283.887 | 199.566.113 | |
| 2015-12-23 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -38.630 | 7.500.000 | -0,51 | 27,02 | -1.043.783 | 202.650.000 | |
| 2015-12-23 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -111.370 | 7.538.630 | -1,46 | 26,39 | -2.939.054 | 198.944.446 | |
| 2015-12-23 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -14.171 | 7.650.000 | -0,18 | 28,39 | -402.315 | 217.183.500 | |
| 2015-12-23 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -235.829 | 7.664.171 | -2,99 | 27,50 | -6.485.298 | 210.764.702 | |
| 2015-11-30 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -590 | 1.850.094 | -0,03 | 29,22 | -17.240 | 54.059.747 | |
| 2015-11-30 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -2.716 | 1.850.684 | -0,15 | 28,64 | -77.786 | 53.003.590 | |
| 2015-11-30 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -29.000 | 1.853.400 | -1,54 | 28,97 | -840.130 | 53.692.998 | |
| 2015-11-30 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -34.800 | 1.882.400 | -1,82 | 28,91 | -1.006.068 | 54.420.184 | |
| 2015-11-24 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -36.100 | 1.917.200 | -1,85 | 28,75 | -1.037.875 | 55.119.500 | |
| 2015-11-24 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -80.800 | 1.953.300 | -3,97 | 28,45 | -2.298.760 | 55.571.385 | |
| 2015-11-24 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -83.900 | 2.034.100 | -3,96 | 28,59 | -2.398.701 | 58.154.919 | |
| 2015-11-19 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -127.300 | 2.118.000 | -5,67 | 28,60 | -3.640.780 | 60.574.800 | |
| 2015-11-19 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -200 | 2.245.300 | -0,01 | 29,09 | -5.818 | 65.315.777 | |
| 2015-11-19 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
S - Sale | -10.898 | 2.245.500 | -0,48 | 28,80 | -313.862 | 64.670.400 | |
| 2015-10-29 |
|
4 | DMTX |
Dimension Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | -5.692.874 | 0 | -100,00 | ||||
| 2015-10-29 |
|
4 | DMTX |
Dimension Therapeutics, Inc.
Series A Preferred Stock |
C - Conversion | -9.500.000 | 0 | -100,00 | ||||
| 2015-10-29 |
|
4 | DMTX |
Dimension Therapeutics, Inc.
Common Stock |
P - Purchase | 200.000 | 5.397.698 | 3,85 | 13,00 | 2.600.000 | 70.170.074 | |
| 2015-10-29 |
|
4 | DMTX |
Dimension Therapeutics, Inc.
Common Stock |
C - Conversion | 1.947.613 | 5.197.698 | 59,92 | ||||
| 2015-10-29 |
|
4 | DMTX |
Dimension Therapeutics, Inc.
Common Stock |
C - Conversion | 3.250.085 | 3.250.085 | |||||
| 2015-10-22 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
P - Purchase | 310.700 | 7.900.000 | 4,09 | 12,92 | 4.014.244 | 102.068.000 | |
| 2015-10-22 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
P - Purchase | 189.300 | 7.589.300 | 2,56 | 11,97 | 2.265.921 | 90.843.921 | |
| 2015-10-13 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -2.785 | 17.100 | -14,01 | 5,98 | -16.654 | 102.258 | |
| 2015-10-13 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -285.106 | 1.767.902 | -13,89 | 5,98 | -1.704.934 | 10.572.054 | |
| 2015-10-09 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -2.041 | 19.885 | -9,31 | 7,03 | -14.348 | 139.792 | |
| 2015-10-09 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -210.668 | 2.053.008 | -9,31 | 7,03 | -1.480.996 | 14.432.646 | |
| 2015-10-09 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -3.837 | 21.926 | -14,89 | 7,24 | -27.780 | 158.744 | |
| 2015-10-09 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -396.163 | 2.263.676 | -14,89 | 7,24 | -2.868.220 | 16.389.014 | |
| 2015-10-09 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -454 | 25.763 | -1,73 | 7,36 | -3.341 | 189.616 | |
| 2015-10-09 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -53.446 | 2.659.839 | -1,97 | 7,36 | -393.363 | 19.576.415 | |
| 2015-10-06 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -59 | 26.217 | -0,22 | 7,80 | -460 | 204.493 | |
| 2015-10-06 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -6.941 | 2.713.285 | -0,26 | 7,80 | -54.140 | 21.163.623 | |
| 2015-10-06 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -1.163 | 26.276 | -4,24 | 8,19 | -9.525 | 215.200 | |
| 2015-10-06 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -136.937 | 2.720.226 | -4,79 | 8,19 | -1.121.514 | 22.278.651 | |
| 2015-10-06 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -403 | 27.439 | -1,45 | 10,34 | -4.167 | 283.719 | |
| 2015-10-06 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -47.497 | 2.857.163 | -1,64 | 10,34 | -491.119 | 29.543.065 | |
| 2015-10-01 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -400 | 27.842 | -1,42 | 10,34 | -4.136 | 287.886 | |
| 2015-10-01 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -47.100 | 2.904.660 | -1,60 | 10,34 | -487.014 | 30.034.184 | |
| 2015-10-01 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -369 | 28.242 | -1,29 | 10,17 | -3.753 | 287.221 | |
| 2015-10-01 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -43.471 | 2.951.760 | -1,45 | 10,17 | -442.100 | 30.019.399 | |
| 2015-10-01 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -89 | 28.611 | -0,31 | 10,08 | -897 | 288.399 | |
| 2015-10-01 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -10.469 | 2.995.231 | -0,35 | 10,08 | -105.528 | 30.191.928 | |
| 2015-09-28 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -89 | 28.700 | -0,31 | 10,30 | -917 | 295.610 | |
| 2015-09-28 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -10.513 | 3.005.700 | -0,35 | 10,30 | -108.284 | 30.958.710 | |
| 2015-09-28 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -311 | 28.789 | -1,07 | 11,07 | -3.443 | 318.694 | |
| 2015-09-28 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -66.489 | 3.016.213 | -2,16 | 11,07 | -736.033 | 33.389.478 | |
| 2015-09-28 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -800 | 29.100 | -2,68 | 10,07 | -8.056 | 293.037 | |
| 2015-09-28 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -64.400 | 3.082.702 | -2,05 | 10,07 | -648.508 | 31.042.809 | |
| 2015-09-28 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -8.152 | 3.147.102 | -0,26 | 11,00 | -89.672 | 34.618.122 | |
| 2015-09-28 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -148 | 29.900 | -0,49 | 11,00 | -1.628 | 328.900 | |
| 2015-09-28 |
|
4 | SIEN |
Sientra, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -6 | 3.155.254 | 0,00 | 9,78 | -59 | 30.858.384 | |
| 2015-07-21 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
A - Award | 285 | 1.120.609 | 0,03 | ||||
| 2015-07-21 |
|
4 | DNAI |
ProNAi Therapeutics Inc
Series D Preferred Stock |
C - Conversion | -1.725.790 | 0 | -100,00 | ||||
| 2015-07-21 |
|
4 | DNAI |
ProNAi Therapeutics Inc
Common Stock |
P - Purchase | 175.000 | 1.989.949 | 9,64 | 17,00 | 2.975.000 | 33.829.133 | |
| 2015-07-21 |
|
4 | DNAI |
ProNAi Therapeutics Inc
Common Stock |
J - Other | 89.159 | 1.814.949 | 5,17 | 5,22 | 464.964 | 9.464.959 | |
| 2015-07-21 |
|
4 | DNAI |
ProNAi Therapeutics Inc
Common Stock |
C - Conversion | 1.725.790 | 1.725.790 | |||||
| 2015-07-08 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 4.717 | 65.398 | 7,77 | 2,75 | 12.972 | 179.844 | |
| 2015-07-08 |
|
4 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
P - Purchase | 495.283 | 7.194.222 | 7,39 | 2,75 | 1.362.028 | 19.784.110 | |
| 2015-06-30 |
|
4 | GKOS |
GLAUKOS Corp
Series D Convertible Preferred Stock Warrant (right to buy) |
M - Exercise | -261 | 0 | -100,00 | ||||
| 2015-06-30 |
|
4 | GKOS |
GLAUKOS Corp
Series D Convertible Preferred Stock Warrant (right to buy) |
M - Exercise | -27.346 | 0 | -100,00 | ||||
| 2015-06-30 |
|
4 | GKOS |
GLAUKOS Corp
Series F Convertible Preferred Stock |
C - Conversion | -2.672 | 0 | -100,00 | ||||
| 2015-06-30 |
|
4 | GKOS |
GLAUKOS Corp
Series F Convertible Preferred Stock |
C - Conversion | -280.531 | 0 | -100,00 | ||||
| 2015-06-30 |
|
4 | GKOS |
GLAUKOS Corp
Series E Convertible Preferred Stock |
C - Conversion | -1.599 | 0 | -100,00 | ||||
| 2015-06-30 |
|
4 | GKOS |
GLAUKOS Corp
Series E Convertible Preferred Stock |
C - Conversion | -167.898 | 0 | -100,00 | ||||
| 2015-06-30 |
|
4 | GKOS |
GLAUKOS Corp
Series D Convertible Preferred Stock |
C - Conversion | -22.923 | 0 | -100,00 | ||||
| 2015-06-30 |
|
4 | GKOS |
GLAUKOS Corp
Series D Convertible Preferred Stock |
C - Conversion | -2.406.441 | 0 | -100,00 | ||||
| 2015-06-30 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
F - Taxes | -111 | 27.344 | -0,40 | 18,00 | -1.998 | 492.192 | |
| 2015-06-30 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
M - Exercise | 261 | 27.455 | 0,96 | ||||
| 2015-06-30 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
F - Taxes | -11.623 | 2.870.593 | -0,40 | 18,00 | -209.214 | 51.670.674 | |
| 2015-06-30 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
M - Exercise | 27.346 | 2.882.216 | 0,96 | ||||
| 2015-06-30 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
C - Conversion | 27.194 | 27.194 | |||||
| 2015-06-30 |
|
4 | GKOS |
GLAUKOS Corp
Common Stock |
C - Conversion | 2.854.870 | 2.854.870 | |||||
| 2015-06-29 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
13.458.559 | ||||||||
| 2015-06-29 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
6.820.301 | ||||||||
| 2015-06-29 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
13.458.559 | ||||||||
| 2015-06-29 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
6.820.301 | ||||||||
| 2015-06-29 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
13.458.559 | ||||||||
| 2015-06-29 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
6.820.301 | ||||||||
| 2015-06-29 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
13.458.559 | ||||||||
| 2015-06-29 | 3 | PIRS |
PIERIS PHARMACEUTICALS, INC.
Common Stock |
6.820.301 | ||||||||
| 2015-05-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -1.457.551 | 7.400.000 | -16,46 | 34,13 | -49.746.216 | 252.562.000 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -90 | 1.120.324 | -0,01 | 294,82 | -26.534 | 330.293.922 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -2.500 | 1.120.414 | -0,22 | 293,85 | -734.625 | 329.233.654 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -6.000 | 1.122.914 | -0,53 | 292,13 | -1.752.780 | 328.036.867 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -3.700 | 1.128.914 | -0,33 | 291,12 | -1.077.144 | 328.649.444 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -13.974 | 1.132.614 | -1,22 | 290,02 | -4.052.739 | 328.480.712 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -15.131 | 1.146.588 | -1,30 | 289,07 | -4.373.918 | 331.444.193 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -26.028 | 1.161.719 | -2,19 | 288,11 | -7.498.927 | 334.702.861 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -18.041 | 1.187.747 | -1,50 | 287,16 | -5.180.654 | 341.073.429 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -7.611 | 1.205.788 | -0,63 | 286,24 | -2.178.573 | 345.144.757 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -23.903 | 1.213.399 | -1,93 | 285,18 | -6.816.658 | 346.037.127 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -16.845 | 1.237.302 | -1,34 | 284,20 | -4.787.349 | 351.641.228 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -9.357 | 1.254.147 | -0,74 | 282,87 | -2.646.815 | 354.760.562 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -8.397 | 1.263.504 | -0,66 | 282,13 | -2.369.046 | 356.472.384 | |
| 2015-03-30 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -5.623 | 1.271.901 | -0,44 | 281,11 | -1.580.682 | 357.544.090 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -2.800 | 1.277.524 | -0,22 | 270,23 | -756.644 | 345.225.311 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -3.844 | 1.280.324 | -0,30 | 275,56 | -1.059.253 | 352.806.081 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -12.066 | 1.284.168 | -0,93 | 275,00 | -3.318.150 | 353.146.200 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -2.700 | 1.296.234 | -0,21 | 273,19 | -737.613 | 354.118.166 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -3.050 | 1.298.934 | -0,23 | 272,13 | -829.996 | 353.478.909 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -6.063 | 1.301.984 | -0,46 | 271,15 | -1.643.982 | 353.032.962 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -9.574 | 1.308.047 | -0,73 | 270,13 | -2.586.225 | 353.342.736 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -1.539 | 1.317.621 | -0,12 | 269,10 | -414.145 | 354.571.811 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -6.764 | 1.319.160 | -0,51 | 268,13 | -1.813.631 | 353.706.371 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -1.000 | 1.325.924 | -0,08 | 288,60 | -288.600 | 382.661.666 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -1.400 | 1.326.924 | -0,11 | 286,04 | -400.456 | 379.553.341 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -52 | 1.328.324 | 0,00 | 283,44 | -14.739 | 376.500.155 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -1.548 | 1.328.376 | -0,12 | 283,29 | -438.533 | 376.315.637 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -3.500 | 1.329.924 | -0,26 | 282,00 | -987.000 | 375.038.568 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -6.306 | 1.333.424 | -0,47 | 281,01 | -1.772.049 | 374.705.478 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -9.465 | 1.339.730 | -0,70 | 280,00 | -2.650.200 | 375.124.400 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -3.668 | 1.349.195 | -0,27 | 279,00 | -1.023.372 | 376.425.405 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -14.152 | 1.352.863 | -1,04 | 278,00 | -3.934.256 | 376.095.914 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -8.195 | 1.367.015 | -0,60 | 276,96 | -2.269.687 | 378.608.474 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -37.666 | 1.375.210 | -2,67 | 275,95 | -10.393.933 | 379.489.200 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -3.579 | 1.412.876 | -0,25 | 274,86 | -983.724 | 388.343.097 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -11.869 | 1.416.455 | -0,83 | 273,89 | -3.250.800 | 387.952.860 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -8.638 | 1.428.324 | -0,60 | 272,79 | -2.356.360 | 389.632.504 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -7.764 | 1.436.962 | -0,54 | 271,70 | -2.109.479 | 390.422.575 | |
| 2015-03-25 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -40.598 | 1.444.726 | -2,73 | 270,70 | -10.989.879 | 391.087.328 | |
| 2015-02-05 |
|
4 | MRTX |
Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share |
P - Purchase | 100.000 | 1.267.000 | 8,57 | 20,00 | 2.000.000 | 25.340.000 | |
| 2014-10-28 | 3 | SIEN |
Sientra, Inc.
Common Stock |
6.340.568 | ||||||||
| 2014-10-28 | 3 | SIEN |
Sientra, Inc.
Common Stock |
3.215.356 | ||||||||
| 2014-10-28 | 3 | SIEN |
Sientra, Inc.
Common Stock |
6.340.568 | ||||||||
| 2014-10-28 | 3 | SIEN |
Sientra, Inc.
Common Stock |
3.215.356 | ||||||||
| 2014-10-28 | 3 | SIEN |
Sientra, Inc.
Common Stock |
6.340.568 | ||||||||
| 2014-10-28 | 3 | SIEN |
Sientra, Inc.
Common Stock |
3.215.356 | ||||||||
| 2014-10-28 | 3 | SIEN |
Sientra, Inc.
Common Stock |
6.340.568 | ||||||||
| 2014-10-28 | 3 | SIEN |
Sientra, Inc.
Common Stock |
3.215.356 | ||||||||
| 2014-09-18 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -49.000 | 8.857.551 | -0,55 | 25,07 | -1.228.430 | 222.058.804 | |
| 2014-09-18 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -2.600 | 8.906.551 | -0,03 | 26,06 | -67.756 | 232.104.719 | |
| 2014-09-18 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -42.400 | 8.909.151 | -0,47 | 25,45 | -1.079.080 | 226.737.893 | |
| 2014-08-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -400 | 1.485.324 | -0,03 | 302,34 | -120.936 | 449.072.858 | |
| 2014-08-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -5.400 | 1.485.724 | -0,36 | 301,36 | -1.627.344 | 447.737.785 | |
| 2014-08-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -45.058 | 1.491.124 | -2,93 | 300,11 | -13.522.356 | 447.501.224 | |
| 2014-08-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -10.400 | 1.536.182 | -0,67 | 299,13 | -3.110.952 | 459.518.122 | |
| 2014-08-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -1.990 | 1.546.582 | -0,13 | 297,26 | -591.547 | 459.736.965 | |
| 2014-08-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -10.010 | 1.548.572 | -0,64 | 296,59 | -2.968.866 | 459.290.969 | |
| 2014-08-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -25.442 | 1.558.582 | -1,61 | 295,52 | -7.518.620 | 460.592.153 | |
| 2014-08-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -12.558 | 1.584.024 | -0,79 | 294,67 | -3.700.466 | 466.764.352 | |
| 2014-08-19 |
|
4 | OTIC |
Otonomy, Inc.
Series D Preferred Stock |
C - Conversion | -378.039 | 0 | -100,00 | ||||
| 2014-08-19 |
|
4 | OTIC |
Otonomy, Inc.
Series C Preferred Stock |
C - Conversion | -1.706.484 | 0 | -100,00 | ||||
| 2014-08-19 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
P - Purchase | 171.875 | 2.256.398 | 8,25 | 16,00 | 2.750.000 | 36.102.368 | |
| 2014-08-19 |
|
4 | OTIC |
Otonomy, Inc.
Common Stock |
C - Conversion | 2.084.523 | 2.084.523 | |||||
| 2014-08-19 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | -990.000 | 8.951.551 | -9,96 | 26,35 | -26.086.500 | 235.873.369 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -350 | 1.596.582 | -0,02 | 308,13 | -107.844 | 491.948.425 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -14.640 | 1.596.932 | -0,91 | 307,06 | -4.495.314 | 490.349.149 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -525 | 1.611.572 | -0,03 | 306,23 | -160.772 | 493.516.528 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -1.732 | 1.612.097 | -0,11 | 305,14 | -528.501 | 491.913.666 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -1.193 | 1.613.829 | -0,07 | 303,77 | -362.394 | 490.227.994 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -1.100 | 1.615.022 | -0,07 | 302,55 | -332.806 | 488.626.521 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -1.710 | 1.616.122 | -0,11 | 301,42 | -515.426 | 487.129.877 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -3.985 | 1.617.832 | -0,25 | 300,21 | -1.196.329 | 485.686.109 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -100 | 1.621.817 | -0,01 | 298,61 | -29.861 | 484.290.774 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -9.985 | 1.621.917 | -0,61 | 297,76 | -2.973.134 | 482.942.006 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -6.192 | 1.631.902 | -0,38 | 296,86 | -1.838.139 | 484.441.532 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -7.062 | 1.638.094 | -0,43 | 296,21 | -2.091.814 | 485.214.909 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -3.254 | 1.645.156 | -0,20 | 294,96 | -959.800 | 485.255.214 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -4.468 | 1.648.410 | -0,27 | 293,85 | -1.312.908 | 484.380.333 | |
| 2014-08-18 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -3.704 | 1.652.878 | -0,22 | 292,70 | -1.084.165 | 483.799.043 | |
| 2014-08-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | -324 | 0 | -100,00 | ||||
| 2014-08-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
M - Exercise | 324 | 1.656.582 | 0,02 | ||||
| 2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -337.973 | 0 | -100,00 | ||||
| 2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Series A Convertible Preferred Stock |
C - Conversion | -1.562.499 | 0 | -100,00 | ||||
| 2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
P - Purchase | 275.385 | 2.175.857 | 14,49 | 13,00 | 3.580.005 | 28.286.141 | |
| 2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
C - Conversion | 337.973 | 1.900.472 | 21,63 | ||||
| 2014-08-06 |
|
4 | LOXO |
Loxo Oncology, Inc.
Common Stock |
C - Conversion | 1.562.499 | 1.562.499 | |||||
| 2014-07-24 |
|
4 | ROKA |
Roka BioScience, Inc.
Series E Convertible Preferred Stock |
C - Conversion | -56.490 | 0 | -100,00 | ||||
| 2014-07-24 |
|
4 | ROKA |
Roka BioScience, Inc.
Series E Convertible Preferred Stock |
C - Conversion | -5.931.402 | 0 | -100,00 | ||||
| 2014-07-24 |
|
4 | ROKA |
Roka BioScience, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -80.715 | 0 | -100,00 | ||||
| 2014-07-24 |
|
4 | ROKA |
Roka BioScience, Inc.
Series D Convertible Preferred Stock |
C - Conversion | -8.475.069 | 0 | -100,00 | ||||
| 2014-07-24 |
|
4 | ROKA |
Roka BioScience, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -38.021 | 0 | -100,00 | ||||
| 2014-07-24 |
|
4 | ROKA |
Roka BioScience, Inc.
Series C Convertible Preferred Stock |
C - Conversion | -3.992.203 | 0 | -100,00 | ||||
| 2014-07-24 |
|
4 | ROKA |
Roka BioScience, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -116.981 | 0 | -100,00 | ||||
| 2014-07-24 |
|
4 | ROKA |
Roka BioScience, Inc.
Series B Convertible Preferred Stock |
C - Conversion | -12.238.019 | 0 | -100,00 | ||||
| 2014-07-24 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, $0.001 par value per share |
P - Purchase | 3.616 | 30.378 | 13,51 | 12,00 | 43.392 | 364.536 | |
| 2014-07-24 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, $0.001 par value per share |
P - Purchase | 379.717 | 3.190.051 | 13,51 | 12,00 | 4.556.604 | 38.280.612 | |
| 2014-07-24 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, $0.001 par value per share |
C - Conversion | 5.116 | 26.762 | 23,63 | ||||
| 2014-07-24 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, $0.001 par value per share |
C - Conversion | 537.264 | 2.810.334 | 23,64 | ||||
| 2014-07-24 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, $0.001 par value per share |
C - Conversion | 7.563 | 21.646 | 53,70 | ||||
| 2014-07-24 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, $0.001 par value per share |
C - Conversion | 794.178 | 2.273.070 | 53,70 | ||||
| 2014-07-24 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, $0.001 par value per share |
C - Conversion | 3.443 | 14.083 | 32,36 | ||||
| 2014-07-24 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, $0.001 par value per share |
C - Conversion | 361.612 | 1.478.892 | 32,37 | ||||
| 2014-07-24 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, $0.001 par value per share |
C - Conversion | 10.596 | 10.640 | 24.081,82 | ||||
| 2014-07-24 |
|
4 | ROKA |
Roka BioScience, Inc.
Common Stock, $0.001 par value per share |
C - Conversion | 1.112.592 | 1.117.280 | 23.732,76 | ||||
| 2014-07-16 | 3 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
9.420 | ||||||||
| 2014-07-16 | 3 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
4.776 | ||||||||
| 2014-07-16 | 3 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
9.420 | ||||||||
| 2014-07-16 | 3 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
4.776 | ||||||||
| 2014-07-16 | 3 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
9.420 | ||||||||
| 2014-07-16 | 3 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
4.776 | ||||||||
| 2014-07-16 | 3 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
9.420 | ||||||||
| 2014-07-16 | 3 | ROKA |
Roka BioScience, Inc.
Common Stock, par value $0.001 per share |
4.776 | ||||||||
| 2014-07-01 |
|
4 | MRTX |
Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -5.000 | 1.167.000 | -0,43 | 20,04 | -100.200 | 23.386.680 | |
| 2014-07-01 |
|
4 | MRTX |
Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -4.717 | 1.172.000 | -0,40 | 21,11 | -99.576 | 24.740.920 | |
| 2014-07-01 |
|
4 | MRTX |
Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -9.283 | 1.176.717 | -0,78 | 20,33 | -188.723 | 23.922.657 | |
| 2014-07-01 |
|
4 | MRTX |
Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -9.212 | 1.186.000 | -0,77 | 23,09 | -212.705 | 27.384.740 | |
| 2014-07-01 |
|
4 | MRTX |
Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share |
S - Sale | -79.120 | 1.195.212 | -6,21 | 21,79 | -1.724.025 | 26.043.669 | |
| 2014-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
M - Exercise | 325 | 1.656.258 | 0,02 | ||||
| 2014-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
M - Exercise | 1.330 | 1.655.933 | 0,08 | ||||
| 2014-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | -325 | 324 | -50,08 | ||||
| 2014-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | -1.330 | 0 | -100,00 | ||||
| 2014-04-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -81.305 | 1.654.603 | -4,68 | 320,00 | -26.017.600 | 529.472.960 | |
| 2014-02-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | -324 | 649 | -33,30 | ||||
| 2014-02-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
M - Exercise | 324 | 1.735.908 | 0,02 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Warrant to Purchase Common Stock |
M - Exercise | -327.133 | 0 | -100,00 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Warrant to Purchase Common Stock |
J - Other | 327.133 | 327.133 | |||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Warrant to Purchase Preferred Stock |
J - Other | -327.133 | 0 | -100,00 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Warrant to Purchase Common Stock |
M - Exercise | -1.417.578 | 0 | -100,00 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Warrant to Purchase Common Stock |
J - Other | 1.417.578 | 1.417.578 | |||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Warrant to Purchase Preferred Stock |
J - Other | -1.417.578 | 0 | -100,00 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Series C-2 Preferred Stock |
C - Conversion | -693.991 | 0 | -100,00 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Series C-1 Preferred Stock |
C - Conversion | -3.007.297 | 0 | -100,00 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Series B-2 Preferred Stock |
C - Conversion | -1.905.702 | 0 | -100,00 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Series B-1 Preferred Stock |
C - Conversion | -1.295.845 | 0 | -100,00 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
P - Purchase | 712.192 | 9.941.551 | 7,72 | 11,00 | 7.834.112 | 109.357.061 | |
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
F - Taxes | -5.116 | 9.229.359 | -0,06 | 11,00 | -56.276 | 101.522.949 | |
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
M - Exercise | 327.133 | 9.234.475 | 3,67 | 0,17 | 55.613 | 1.569.861 | |
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
F - Taxes | -22.166 | 8.907.342 | -0,25 | 11,00 | -243.826 | 97.980.762 | |
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
M - Exercise | 1.417.578 | 8.929.508 | 18,87 | 0,17 | 240.988 | 1.518.016 | |
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
C - Conversion | 693.991 | 7.511.930 | 10,18 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
C - Conversion | 3.007.297 | 6.817.939 | 78,92 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
C - Conversion | 1.905.702 | 3.810.642 | 100,04 | ||||
| 2013-11-20 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
C - Conversion | 1.904.940 | 1.904.940 | |||||
| 2013-11-12 |
|
4 | RBM |
RESPONSE BIOMEDICAL CORP
Warrant |
P - Purchase | 151.632 | 151.632 | |||||
| 2013-11-12 |
|
4 | RBM |
RESPONSE BIOMEDICAL CORP
Warrant |
P - Purchase | 2.408 | 2.408 | |||||
| 2013-11-12 |
|
4 | RBM |
RESPONSE BIOMEDICAL CORP
Warrant |
P - Purchase | 254.122 | 254.122 | |||||
| 2013-11-12 |
|
4 | RBM |
RESPONSE BIOMEDICAL CORP
Common Stock |
P - Purchase | 303.265 | 1.818.677 | 20,01 | 2,45 | 742.999 | 4.455.759 | |
| 2013-11-12 |
|
4 | RBM |
RESPONSE BIOMEDICAL CORP
Common Stock |
P - Purchase | 4.816 | 28.997 | 19,92 | 2,45 | 11.799 | 71.043 | |
| 2013-11-12 |
|
4 | RBM |
RESPONSE BIOMEDICAL CORP
Common Stock |
P - Purchase | 508.244 | 3.047.927 | 20,01 | 2,45 | 1.245.198 | 7.467.421 | |
| 2013-11-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | -325 | 973 | -25,04 | ||||
| 2013-11-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
M - Exercise | 325 | 1.735.584 | 0,02 | ||||
| 2013-10-31 |
|
4 | MRTX |
Mirati Therapeutics, Inc.
Common Stock, par value $0.001 per share |
P - Purchase | 125.000 | 1.274.332 | 10,88 | 17,50 | 2.187.500 | 22.300.810 | |
| 2013-10-23 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -40.088 | 1.735.259 | -2,26 | 62,50 | -2.505.500 | 108.453.688 | |
| 2013-10-17 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
S - Sale | -376.585 | 1.775.347 | -17,50 | 62,50 | -23.536.562 | 110.959.188 | |
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Series F Convertible Preferred |
C - Conversion | -14.574 | 0 | -100,00 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Series F Convertible Preferred |
C - Conversion | -38.924 | 0 | -100,00 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Series E Convertible Preferred |
C - Conversion | -8.466 | 0 | -100,00 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Series E Convertible Preferred |
C - Conversion | -22.612 | 0 | -100,00 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Series E Convertible Preferred Stock |
C - Conversion | -31.113 | 0 | -100,00 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Series E Convertible Preferred |
C - Conversion | -83.097 | 0 | -100,00 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Series D Convertible Preferred Stock |
C - Conversion | -8.777 | 0 | -100,00 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Series D Convertible Preferred |
C - Conversion | -23.442 | 0 | -100,00 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Series C Convertible Preferred Stock |
C - Conversion | -65.680 | 0 | -100,00 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Series C Convertible Preferred |
C - Conversion | -175.419 | 0 | -100,00 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Series B Convertible Preferred Stock |
C - Conversion | -422.101 | 0 | -100,00 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Series B Convertible Preferred Stock |
C - Conversion | -1.127.346 | 0 | -100,00 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Common Stock |
C - Conversion | 14.574 | 576.889 | 2,59 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Common Stock |
C - Conversion | 38.924 | 1.540.759 | 2,59 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Common Stock |
C - Conversion | 13.431 | 562.315 | 2,45 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Common Stock |
C - Conversion | 35.873 | 1.501.835 | 2,45 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Common Stock |
C - Conversion | 50.145 | 548.884 | 10,05 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Common Stock |
C - Conversion | 133.930 | 1.465.962 | 10,05 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Common Stock |
C - Conversion | 8.777 | 498.739 | 1,79 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Common Stock |
C - Conversion | 23.442 | 1.332.032 | 1,79 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Common Stock |
C - Conversion | 65.680 | 489.962 | 15,48 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Common Stock |
C - Conversion | 175.419 | 1.308.590 | 15,48 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Common Stock |
C - Conversion | 422.101 | 424.282 | 19.353,55 | ||||
| 2013-09-26 |
|
4 | XLRN |
ACCELERON PHARMA INC
Common Stock |
C - Conversion | 1.127.346 | 1.133.171 | 19.353,58 | ||||
| 2013-09-18 | 3 | XLRN |
ACCELERON PHARMA INC
Common Stock |
5.825 | ||||||||
| 2013-09-18 | 3 | XLRN |
ACCELERON PHARMA INC
Common Stock |
2.181 | ||||||||
| 2013-08-13 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | -325 | 1.298 | -20,02 | ||||
| 2013-08-13 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
M - Exercise | 325 | 2.151.932 | 0,02 | ||||
| 2013-07-16 | 3 | MRTX |
Mirati Therapeutics, Inc.
Common Stock |
1.149.332 | ||||||||
| 2013-05-24 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
P - Purchase | 120 | 14.067 | 0,86 | 6,99 | 839 | 98.318 | |
| 2013-05-24 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
P - Purchase | 12.380 | 1.476.702 | 0,85 | 6,99 | 86.528 | 10.321.113 | |
| 2013-05-24 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
P - Purchase | 200 | 13.947 | 1,45 | 6,86 | 1.372 | 95.690 | |
| 2013-05-24 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
P - Purchase | 21.100 | 1.464.322 | 1,46 | 6,86 | 144.767 | 10.046.713 | |
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Series D Convertible Preferred Stock |
C - Conversion | -18.795 | 0 | -100,00 | ||||
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Series D Convertible Preferred Stock |
C - Conversion | -1.973.439 | 0 | -100,00 | ||||
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Series D-2 Convertible Preferred Stock |
C - Conversion | -50.256 | 0 | -100,00 | ||||
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Series D-2 Convertible Preferred Stock |
C - Conversion | -5.276.702 | 0 | -100,00 | ||||
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Series E Convertible Preferred Stock |
C - Conversion | -83.959 | 0 | -100,00 | ||||
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Series E Convertible Preferred Stock |
C - Conversion | -8.815.565 | 0 | -100,00 | ||||
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
P - Purchase | 80 | 13.747 | 0,59 | 6,90 | 552 | 94.813 | |
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
P - Purchase | 8.020 | 1.443.222 | 0,56 | 6,90 | 55.314 | 9.953.902 | |
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
P - Purchase | 590 | 13.667 | 4,51 | 8,00 | 4.720 | 109.336 | |
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
P - Purchase | 61.910 | 1.435.202 | 4,51 | 8,00 | 495.280 | 11.481.616 | |
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
P - Purchase | 5.653 | 13.077 | 76,14 | 8,00 | 45.224 | 104.616 | |
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
P - Purchase | 593.618 | 1.373.292 | 76,14 | 8,00 | 4.748.944 | 10.986.336 | |
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
C - Conversion | 1.730 | 7.424 | 30,38 | ||||
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
C - Conversion | 181.689 | 779.674 | 30,38 | ||||
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
C - Conversion | 2.094 | 5.694 | 58,17 | ||||
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
C - Conversion | 219.863 | 597.985 | 58,15 | ||||
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
C - Conversion | 3.498 | 3.600 | 3.429,41 | ||||
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
C - Conversion | 367.315 | 378.122 | 3.398,86 | ||||
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
P - Purchase | 100 | 102 | 5.000,00 | 6,78 | 678 | 691 | |
| 2013-05-22 |
|
4 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
P - Purchase | 10.500 | 10.807 | 3.420,20 | 6,78 | 71.162 | 73.242 | |
| 2013-05-15 | 3 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
307 | ||||||||
| 2013-05-15 | 3 | AMBI |
AMBIT BIOSCIENCES CORP
Common Stock, $0.001 par value per share |
2 | ||||||||
| 2013-05-13 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | -324 | 1.623 | -16,64 | ||||
| 2013-05-13 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
M - Exercise | 324 | 2.151.607 | 0,02 | ||||
| 2013-04-15 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | -649 | 1.947 | -25,00 | ||||
| 2013-04-15 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
M - Exercise | 649 | 2.151.283 | 0,03 | ||||
| 2013-02-14 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -41.100 | 817.000 | -4,79 | 7,58 | -311.361 | 6.189.347 | |
| 2013-02-14 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -108.900 | 2.183.000 | -4,75 | 7,58 | -824.994 | 16.537.753 | |
| 2013-02-14 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -41.483 | 858.100 | -4,61 | 7,52 | -312.027 | 6.454.457 | |
| 2013-02-14 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -110.700 | 2.291.900 | -4,61 | 7,52 | -832.663 | 17.239.213 | |
| 2013-02-01 |
|
4 | ANTH |
Anthera Pharmaceuticals Inc
Common Stock |
P - Purchase | 5.700.000 | 7.462.000 | 323,50 | 0,66 | 3.762.000 | 4.924.920 | |
| 2013-01-29 |
|
4 | ANTH |
Anthera Pharmaceuticals Inc
Common Stock |
P - Purchase | 1.762.000 | 1.762.000 | 0,65 | 1.142.481 | 1.142.481 | ||
| 2012-12-19 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -100.000 | 0 | -100,00 | 7,08 | -707.670 | ||
| 2012-12-19 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
S - Sale | -197.815 | 100.000 | -66,42 | 6,85 | -1.354.617 | 684.790 | |
| 2012-10-16 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Series C Preferred Stock |
C - Conversion | -10.500.000 | 0 | -100,00 | ||||
| 2012-10-16 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
P - Purchase | 333.334 | 2.150.634 | 18,34 | 15,00 | 5.000.010 | 32.259.510 | |
| 2012-10-16 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock, par value $0.001 per share |
C - Conversion | 1.817.300 | 1.817.300 | |||||
| 2012-09-05 |
|
4 | AMRN |
AMARIN CORP PLC\UK
Ordinary Shares |
S - Sale | X | -2.244 | 5.700 | -28,25 | 14,43 | -32.388 | 82.268 |
| 2012-09-05 |
|
4 | AMRN |
AMARIN CORP PLC\UK
Ordinary Shares |
S - Sale | X | -231.456 | 594.300 | -28,03 | 14,43 | -3.340.604 | 8.577.532 |
| 2012-07-30 |
|
4 | AMRN |
AMARIN CORP PLC\UK
Ordinary Shares |
S - Sale | X | -3.456 | 7.944 | -30,32 | 14,61 | -50.483 | 116.041 |
| 2012-07-30 |
|
4 | AMRN |
AMARIN CORP PLC\UK
Ordinary Shares |
S - Sale | X | -362.844 | 825.756 | -30,53 | 14,61 | -5.300.207 | 12.062.148 |
| 2012-07-13 |
|
4 | GNOM |
COMPLETE GENOMICS INC
Common Stock |
S - Sale | -4.500 | 27.859 | -13,91 | 2,51 | -11.298 | 69.943 | |
| 2012-07-13 |
|
4 | GNOM |
COMPLETE GENOMICS INC
Common Stock |
S - Sale | -474.800 | 2.922.141 | -13,98 | 2,51 | -1.192.033 | 7.336.327 | |
| 2012-07-13 |
|
4 | GNOM |
COMPLETE GENOMICS INC
Common Stock |
S - Sale | -2.076 | 32.359 | -6,03 | 2,85 | -5.916 | 92.210 | |
| 2012-07-13 |
|
4 | GNOM |
COMPLETE GENOMICS INC
Common Stock |
S - Sale | -218.624 | 3.396.941 | -6,05 | 2,85 | -622.991 | 9.679.923 | |
| 2012-07-13 |
|
4 | GNOM |
COMPLETE GENOMICS INC
Common Stock |
S - Sale | -4.792 | 34.435 | -12,22 | 2,90 | -13.891 | 99.820 | |
| 2012-07-13 |
|
4 | GNOM |
COMPLETE GENOMICS INC
Common Stock |
S - Sale | -503.144 | 3.615.565 | -12,22 | 2,90 | -1.458.514 | 10.480.800 | |
| 2012-07-03 |
|
4 | ANTH |
Anthera Pharmaceuticals Inc
Common Stock |
S - Sale | -1.283.300 | 0 | -100,00 | 0,73 | -942.071 | ||
| 2012-06-19 |
|
4 | AMRN |
AMARIN CORP PLC\UK
Ordinary Shares |
S - Sale | -5.900 | 11.400 | -34,10 | 12,91 | -76.185 | 147.205 | |
| 2012-06-19 |
|
4 | AMRN |
AMARIN CORP PLC\UK
Ordinary Shares |
S - Sale | -611.200 | 1.188.600 | -33,96 | 12,91 | -7.892.242 | 15.348.035 | |
| 2012-05-08 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Series A Convertible Preferred Stock |
C - Conversion | -827.627 | 0 | -100,00 | ||||
| 2012-05-08 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Series A Convertible Preferred Stock |
C - Conversion | -2.498.842 | 0 | -100,00 | ||||
| 2012-05-08 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Series A Convertible Preferred Stock |
C - Conversion | -6.673.891 | 0 | -100,00 | ||||
| 2012-05-08 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
P - Purchase | 90.999 | 297.815 | 44,00 | 5,00 | 454.995 | 1.489.075 | |
| 2012-05-08 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
P - Purchase | 274.873 | 899.583 | 44,00 | 5,00 | 1.374.365 | 4.497.915 | |
| 2012-05-08 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
P - Purchase | 734.128 | 2.402.600 | 44,00 | 5,00 | 3.670.640 | 12.013.000 | |
| 2012-05-08 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 206.816 | 206.816 | |||||
| 2012-05-08 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 624.710 | 624.710 | |||||
| 2012-05-08 |
|
4 | SUPN |
SUPERNUS PHARMACEUTICALS INC
Common Stock |
C - Conversion | 1.668.472 | 1.668.472 | |||||
| 2012-03-22 |
|
4 | ANTH |
Anthera Pharmaceuticals Inc
Common Stock |
S - Sale | -1.306.700 | 1.283.300 | -50,45 | 2,40 | -3.140.131 | 3.083.898 | |
| 2012-03-22 |
|
4 | ANTH |
Anthera Pharmaceuticals Inc
Common Stock |
S - Sale | -125.000 | 2.590.000 | -4,60 | 2,87 | -358.312 | 7.424.235 | |
| 2012-03-22 |
|
4 | ANTH |
Anthera Pharmaceuticals Inc
Common Stock |
S - Sale | -116.800 | 2.715.000 | -4,12 | 2,90 | -338.638 | 7.871.600 | |
| 2012-03-13 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -700 | 2.446.000 | -0,03 | 11,03 | -7.722 | 26.983.783 | |
| 2012-03-13 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -62.400 | 2.446.700 | -2,49 | 11,03 | -688.384 | 26.991.505 | |
| 2012-03-13 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -300 | 2.509.100 | -0,01 | 11,25 | -3.374 | 28.216.335 | |
| 2012-03-13 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -36.700 | 2.509.400 | -1,44 | 11,25 | -412.714 | 28.219.709 | |
| 2012-02-29 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -3.000 | 2.546.100 | -0,12 | 10,86 | -32.584 | 27.654.211 | |
| 2012-02-29 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -100 | 2.549.100 | 0,00 | 11,12 | -1.112 | 28.347.012 | |
| 2012-02-29 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -10.000 | 2.549.200 | -0,39 | 11,12 | -111.204 | 28.348.124 | |
| 2012-02-29 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -300 | 2.559.200 | -0,01 | 11,05 | -3.314 | 28.271.994 | |
| 2012-02-29 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -28.700 | 2.559.500 | -1,11 | 11,05 | -317.055 | 28.275.308 | |
| 2012-02-15 |
|
4 | CCXI |
ChemoCentryx, Inc.
Series C Preferred Stock |
C - Conversion | -242.674 | 0 | -100,00 | ||||
| 2012-02-15 |
|
4 | CCXI |
ChemoCentryx, Inc.
Series B Preferred Stock |
C - Conversion | -1.574.345 | 0 | -100,00 | ||||
| 2012-02-15 |
|
4 | CCXI |
ChemoCentryx, Inc.
Series C Preferred Stock |
C - Conversion | -514.354 | 0 | -100,00 | ||||
| 2012-02-15 |
|
4 | CCXI |
ChemoCentryx, Inc.
Series B Preferred Stock |
C - Conversion | -3.888.423 | 0 | -100,00 | ||||
| 2012-02-15 |
|
4 | CCXI |
ChemoCentryx, Inc.
Series C Preferred Stock |
C - Conversion | -10.706 | 0 | -100,00 | ||||
| 2012-02-15 |
|
4 | CCXI |
ChemoCentryx, Inc.
Series B Preferred Stock |
C - Conversion | -78.928 | 0 | -100,00 | ||||
| 2012-02-15 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
C - Conversion | 908.509 | 908.509 | |||||
| 2012-02-15 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
C - Conversion | 2.201.388 | 2.201.388 | |||||
| 2012-02-15 |
|
4 | CCXI |
ChemoCentryx, Inc.
Common Stock |
C - Conversion | 44.817 | 44.817 | |||||
| 2012-02-03 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -500 | 2.588.200 | -0,02 | 10,79 | -5.395 | 27.927.713 | |
| 2012-02-03 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -49.500 | 2.588.700 | -1,88 | 10,79 | -534.125 | 27.933.108 | |
| 2012-02-03 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -200 | 2.638.200 | -0,01 | 10,85 | -2.171 | 28.637.133 | |
| 2012-02-03 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -23.100 | 2.638.400 | -0,87 | 10,85 | -250.746 | 28.639.304 | |
| 2012-02-03 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -700 | 2.661.500 | -0,03 | 11,01 | -7.704 | 29.291.937 | |
| 2012-02-03 |
|
4 | PCRX |
Pacira Pharmaceuticals, Inc.
Common Stock |
S - Sale | -69.300 | 2.662.200 | -2,54 | 11,01 | -762.702 | 29.299.641 |
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)
